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 Abbreviations 
 
Akt  V-akt murine thymoma viral oncogene homolog 1 protein kinase 
Atg  Autophagy protein 
Cbl  Casitas B-Lineage Lymphoma 
CBP   Calmodulin binding peptide 
CCP  Clathrin-coated pits 
CCV  Clathrin Coated Vesicles 
CIN85  Cbl-interacting protein of 85 kDa 
c-Met  Hepatocyte growth factor receptor tyrosine kinase 
CPS  Carboxy Peptidase S 
CP  Core particle 
CSK  Non receptor Tyrosine-protein kinase CSK (C-Src kinase) 
DUB  De-ubiquitination domain 
E1  Ubiquitin Activating Enzyme 
E2  Ubiquitin Conjugating Enzyme 
E3  Ubiquitin Ligase 
EGF  Epidermal Growth Factor 
EGFR   Epidermal Growth Factor Receptor 
Elk  Transcription factor 
ERAD  ER-Associated Degradation 
Eps15  Epidermal growth factor receptor Pathway Substrate 15 
Epsin  Eps15 interacting protein 
ESCRT  Endosomal protein Complex Required for Transport 
Fos  Proto-oncogene protein c-fos  
FTMS  Fourier Transform Mass Spectrometry 
FUR4  Uracil permease 
FYVE  Zinc finger present in Fab1, YOTB/ZK632.12, Vac1, and EEA1 
GAE  γ-adaptin ear 
GAMPO   Goat anti-mouse peroxidase 
GARPO   Goat anti-rabbit peroxidase 
GAT   GGA and TOM1 homology domain 
GFP   Green fluorescent protein 
GGA  Golgi associated, γ Adaptin ear containing 
GLUE  GRAM Like Ubiquitin binding in EAP45  
Grb2  Growth factor Receptor-Bound protein 2 
GST   Glutathion-S-transferase 
HECT   Homologous to the E6-AP COOH Terminus 
HPV  Human Papilloma Virus 
Hrs  Hepatocyte growth factor regulated tyrosine kinase substrate 
JAB1  Jun kinase activation domain binding protein 
JAMM  JAB1/MPN/Mov34 metalloenzyme 
LC   Liquid chromatography 
MAPK  Mitogen Activated Protein Kinase 
MCAC   Metal chelation affinity chromatography 
MEK  MAPK/Erk kinase 
MHCII  Major Histocompatibility Class II 
MS   Mass Spectrometry 
MVB   Multi-vesicular body 
Myc  Proto-oncogene protein (c-Myc) (Transcription factor p64) 
MyoD  Myoblast determination protein 
NEM   N-ethyl-maleimide 
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NZF  Npl4 zinc finger  
P21  Cyclin-dependent kinase inhibitor 1A 
PAGE   Polyacrylamide gel electrophoresis 
Pep4  Vacuolar aspartyl protease 
Phm5p  Vacuolar endopolyphosphatase  
PLC-γ  Phospholipase C-γ  
ProtA   Protein A 
PTB  Phospho Tyrosine Binding 
PtdIns  Phosphatidylinositol  
Rac  Rac GTPase 
Raf  Proto-oncogene serine/threonine-protein kinase 
Ras  Rat sarcoma virus oncogene 
RING   Really Interesting New Gene domain 
RP  Regulatory particle 
Rpn10/S5a  Non-ATPase proteasome regulatory particle subunit  
S6/Rpt5   Proteasome regulatory particle ATPase  
SDS   Sodium-dodecyl-sulphate 
SH2  Src Homology domain 2 
Shc  Src Homology 2 domain Containing  
Shp1  Non receptor protein tyrosine phosphatase 
Snf7  Vacuolar protein sorting-associated protein VPS32 
Sos  Son of sevenless  
Src   Proto-oncogene tyrosine-protein kinase 
STAT5  Signal transducer and activator of transcription 5 
Ste2p   Receptor for α-factor pheromone; seven transmembrane-domain  
TAP   Tandem Affinity Purification 
TCR  T-Cell Receptor 
TEV   Tobacco Etch virus 
TGF-α  Transforming Growth factor alpha 
TGN  Trans-Golgi Network 
Tsg101  Tumor suppressor protein 101 
UBA  Ubiquitin Associated  
UEV  Ubiquitin conjugating Enzyme Variant 
UIM  Ubiquitin Interacting Motif 
Usp   Ubiquitin specific protease 
Vcp  Valocin-Containing Protein 
VHS  Domain present in VPS-27, Hrs and STAM 
Vps  Vacular Protein Sorting 
WCL   Whole cell lysate 
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1) THE ERBB-1/EGFR PATHWAY 
 
1.1) The ErbB network 
 
Cells have evolved various signaling systems to perceive environmental cues and translate them into 
actions that are crucial for cellular homeostasis and proper development of multicellular organisms. 
One such signaling system is the ErbB signaling network. The ErbB network model is composed of 
three layers. The input layer is composed of a panel of EGF-domain containing growth factors. These 
growth factors exert their biological function through interaction with membrane-bound ErbB family 
of receptor tyrosine kinases. Ligand-induced activation of these receptors initiates downstream 
signaling events that form the signal-processing layer where signaling cascades undergo spatial and 
temporal co-ordination. Cellular responses constitute the output layer through execution of various 
fundamental cellular processes like cell cycle progression (1), cellular differentiation (2), rescue from 
apoptosis, cell migration (3), initiation of angiogenesis and development (2). 
 
1.2) Ligands of the ErbB receptor family 
 
Polypeptide growth factors of the epidermal growth factor family (EGF) play a critical role in cellular 
proliferation, differentiation, cell survival, migration, angiogenesis, and neoplasias (4). Members of 
this family include among others EGF (Epidermal Growth Factor), TGF-α (Transforming Growth 
Factor alpha), NRG (neuregulin), HB-EGF (Heparan-Binding Epidermal Growth Factor) and 
epiregulin (Figure-1). These growth factors exert their biological function through binding to members 
of the ErbB receptor tyrosine kinases (4). Interestingly, their tertiary structure encodes an EGF module 
(5, 6, 7, 8), which constitutes the receptor binding domain. It is defined by six cystein residues that 
form three intramolecular disulphide loops (4, 9, 10, 11). Different ligands exhibit differential 
affinities towards different members of the ErbB receptors despite the structural similarities of their 
EGF domains (12). Moreover, different ligands exhibit variable affinities towards the same receptor. 
For instance, although both EGF and TGF-α bind the EGFR/ErbB-1 receptor, the latter was found to 
be more potent than EGF (13, 14). In addition, domain-swap experiments revealed that replacing EGF 
amino acid sequence from the fourth cystein residue with the corresponding one from TGF-α confers 
the new chimeric molecule, called E4T, a superagonistic behavior (15), meaning that ten-fold lower 
concentration of E4T is needed to achieve similar mitogenic stimulation as EGF does. Although the 
molecular mechanism for this behavior is poorly understood, it is possible that this is at least in part 
due to (i) differences in association and dissociation constants, (ii) differences in pH-dependency of 
ligand binding to its receptor. Thus, in contrast to EGF, the superagonist E4T displays enhanced on/off 
rates. Like TGF-α, E4T binding to the EGFR is sensitive to low pH compared to EGF. It is therefore 
hypothesized that E4T and TGF-α might prematurely dissociate from their receptors in acidifying 
endosomes when compared to EGF, which may explain the enhanced recycling of EGF receptors that 
are activated by TGF-α or E4T (16). 
 
1.3) ErbB family of receptor tyrosine kinases 
 
The human ErbB family of receptor tyrosine kinases is composed of four members. The most studied 
one is the EGFR which is also known as HER-1 or hErbB-1. The other three members are called 
HER-2/hErbB-2, HER-3/hErbB-3, and HER-4/hErbB-4 (11). Specific activation of members of this 
family by EGF and EGF-like ligands is responsible for various fundamental cellular processes like cell 
cycle progression (1), rescues from apoptosis, cellular differentiation (2), cell migration (3), initiation 
of angiogenesis and development (2).  
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Figure-1:  
The binding of the shown ErbB ligands to various forms of ErbB dimers is color-coded according to their 
affinities. White color represent low affinity (IC50 >> 1uM) and black represent high affinity (IC50 >> 
1nM). IC50 represents IC50(EGF)/IC50(Ligand) x 100% as measured by displacement of 125I-EGF by the 
corresponding ligands. From thesis entitled: The role of EGF-like growth factors in selective ErbB receptor 
dimerization. By Stortelers C, (2003). 
 
ErbB receptors are type I transmembrane receptors that are synthesized with a short hydrophobic N-
terminal ER signal sequence that is removed in the ER. Mature ErbB receptors show a comparable 
domain organization (Figure-2), which includes a glycosylated extracellular ligand-binding domain, a 
hydrophobic transmembrane region, and a cytoplasmic domain containing a short membrane proximal 
region, the catalytic tyrosine kinase module followed by a C-terminal tail (17). The extracellular 
domain of the EGFR is composed of four subdomains designated as I, II, III, and IV. Domains I and 
III are globular immunoglobulin-like domains which are responsible for ligand binding. Domains II 
and IV are composed of cystein rich furin-like domains that interact with each other in the unliganded 
autoinhibitory state. In this state, the dimerization interface of domain II is unavailable as it is involved 
in intramolecular interactions with domain IV. Upon disruption of the autoinhibitory conformation, 
simultaneous ligand binding to both domains I and III is feasible, leading to exposure of the 
dimerization interface of domain II, which then results in intermolecular contacts with domain II of 
another ligand-bound receptor monomer (18). The ErbB-2 receptor has no known ligand, and 
therefore, it is often called an orphan receptor (17). In the absence of bound ligand, the ErbB-2 
extracellular domain is constitutively found in a dimerization-competent state due to the existence of 
specific intramolecular contacts between domains I and III, providing an explanation for the fact that 
ErbB-2 is the preferential dimerization partner for other ErbB receptors. The ErbB-3 receptor encodes 
a kinase-dead domain and cannot signal in the context of ErbB-3 homodimers, but can participate in 
downstream signaling when it forms a heterodimer with a kinase-active ErbB receptor. Importantly, 
homo- or hetero-dimer formation of ErbB receptors is believed to depend on the identity of the ligand 
(19) as well as on expression levels of various ErbB receptors.  
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Figure-2: 
Components of the ErbB system. Layered signaling has been proposed to govern the ErbB network. The input 
layer is composed of ErbB ligands and their cognate receptors. Signaling molecules downstream activated 
receptors form the signal processing layer and shape the final cellular response; the output layer. From 
reference (11). 
 
1.4) Signaling through ErbB receptor tyrosine kinases 
 
Ligand binding to the extracellular domain triggers receptor homo- or hetero-dimerization (17). 
Consequently, the intracellular tyrosine kinase becomes activated, which results in trans-
phosphorylation of tyrosine residues within the cytosolic tail of the receptors. Phosphorylated tyrosine 
residues serve as docking sites for cellular proteins that contain Src homology domain 2 (SH2) or 
phosphotyrosine binding (PTB) domains. Several cytosolic signaling enzymes and scaffolding 
proteins contain an SH2/PTB domain through which they bind to activated receptors leading to 
amplification and diversification of the signaling events (Figure-2). Many of these proteins are key 
components of distinct signaling pathways, the activation of which mediate the transmission of the 
signal to the nucleus leading eventually to the activation of nuclear transcription factors. 
Consequently, up-regulation of specific set of proteins takes place that are, at least in part, responsible 
for determining the cell response.  
Cellular proteins known to interact with activated EGFRs include members of the Cbl ubiquitin ligase 
family, Grb2, Shc, PLC-γ, Shp2, and cytosolic protein tyrosine kinases like Src and Csk. In contrast to 
ErbB-1 (EGFR), the kinase dead ErbB-3 receptor cannot bind Cbl, STAT5 and PLC-γ, but it 
preferentially binds Grb7 and signals through activation of phosphatidylinositol 3-kinase pathway (11, 
20, 21). However, the classical MAPK pathway is an invariable target for all ErbB receptor ligands, 
which is activated either directly or indirectly by various ErbB receptors (11). 
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Signaling through the MAPK pathway is initiated by recruitment of Grb2 in complex with the guanine 
nucleotide exchange factor Sos to activated receptors. Membrane recruitment of Sos induces the 
formation of the GTP-bound Ras. GTP-bound Ras constitutes the active form of Ras, the formation of 
which is a critical event in activation of Ras downstream effectors like the Ser/Thr Raf kinase. 
Raf kinase encodes a regulatory domain and a catalytic domain. Point mutations in the catalytic 
domain render Raf highly oncogenic (22). Once activated, Raf kinase directly phosphorylates MEK 
kinases at serine and threonine residues. Finally, MEK kinase phosphorylates MAPK (Erk1/Erk2) 
leading to its activation. Activated MAPK translocates to the nucleus and triggers phosphorylation of 
transcription factors such as Myc and Elk leading to upregulation of specific set of genes that 
determine cell responses. Activation of ErbB-1 (EGFR) homodimers by EGF also induces the 
activation of PLC-γ, which activates PKC that is responsible for the activation of the transcription 
factor Fos.  
Diversification, specificity and potency of the signaling events downstream activated receptors are 
thought to be determined by at least five mechanisms, i.e. (i) the identity of the ligand, (ii) the 
formation of specific homo- or hetero-dimers, (iii) the position of phosphorylated tyrosine residues at 
the C-terminal tail of the receptors, (iv) the activated signaling pathway downstream activated 
receptors, and (v) fine-tuning of activated pathways by regulatory factors (2, 11, 21, 23). 
 
1.5) ErbB receptors and human cancer 
 
Overexpression of one or more genes of the ErbB receptor tyrosine kinase protein family is frequently 
observed in a wide variety of human carcinomas (24, 25). For detailed insight into the role of ErbB 
receptors in clinical manifestations of cancers and genotype/phenotype correlation the reader is 
referred to several excellent reviews on these topics (2, 26, 27, 28, 29). ErbB-1 for instance exhibits 
high incidence in gliomas (30), and was detected in invasive ductal carcinomas (31). Its 
overexpression has been found to correlate with both resistance to chemotherapy (31) and poor 
prognosis (32, 33). Furthermore, a constitutively active mutant form of ErbB-1 lacking a portion of its 
extracellular domain is frequently detected in breast, lung, and ovary carcinomas (34, 35, 36, 37). In 
addition, co-expression of ErbB-1 and ErbB-2 family members may constitute a significant indicator 
of poor survival of patients (38, 39). ErbB ligands were also found over-expressed in human 
neoplasias like TGF-α in prostate cancer (40), pancreas, lung, ovary and colon cancers (11). In cases 
where TGF-α is co-expressed with ErbB-1 receptor it correlates with poor prognosis (24).  
Taken together, the frequent involvement of the ErbB receptor tyrosine kinases and their ligands in a 
variety of human cancers rationalize the elucidation of their basic biology. 
 
1.6) The ErbB family as target in cancer therapy 
 
Blockade of ErbB signaling with various therapeutic strategies proved to be useful in halting tumor 
growth and viability in in vitro and in vivo systems (41). Therefore, the role of ErbB signaling in the 
establishment of human cancers made the ErbB receptor tyrosine kinases the lead target for 
developing strategies aimed at combating cancer (26, 42, 43). For instance, it has been shown that 
small tyrosine kinase inhibitors that compete for the ATP binding site in the catalytic domain of ErbB-
1 and ErbB-2 tyrosine kinase domain effectively block the kinase activity and its downstream 
signaling events (44, 45). Various ErbB specific tyrosine kinase inhibitors have been developed 
including ATP analogs showing reversible or irreversible binding, or that display specificity for a 
single or multiple ErbB receptors. Thus, control of the kinase activity and downstream signaling 
provide an effective approach for developing anti-cancer agents.  
Inhibition ErbB downstream signaling was also achieved by designing specific antibodies directed 
against the extracellular domain of one of the ErbB receptors like anti-EGFR IgG2a monoclonal 
antibody (mab)  clone 528 (46) and mab 225 (47, 48). Based on cell biological assays, these antibodies 
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were shown to block binding of radio active labeled EGF and TGF-α to the EGFR in a highly efficient 
manner. Like EGF and TGF-α, these antibodies are capable of inducing receptor dimerization, but in 
contrast to EGF and TGF-α, they failed to induce phosphorylation of cellular proteins, clearly 
indicating that receptor engagement by these antibodies severely impairs downstream signaling 
cascades. This phenotype was further demonstrated to correlate with the capacity of these antibodies to 
inhibit the growth of a variety of tumor cell lines, which express EGF receptors. Interestingly, further 
analysis of the mechanism of growth inhibition revealed that following binding of radioactively 
labeled antibodies, the receptors undergo internalization and subsequent degradation. Taken together, 
these findings suggest that receptor degradation may, at least in part, underlie inhibition of growth of 
tumor cells by these antibodies (46, 47, 48). At the cellular level, the control of receptor tyrosine 
kinase signaling is primarily mediated by endocytosis of ligand-receptor complex and subsequent 
delivery to the lysosomes for degradation, a process that is often referred to as receptor 
downregulation (49, 50, 51). This leads to clearance of the receptors from the cell surface, which is 
expected to attenuate downstream signaling. Therefore, perturbation of receptor downregulation is 
predicted to contribute to hyperproliferative and invasive properties of cancerous cells (52). 
 
2) MECHANISM OF UBIQUITINATION-DEPENDENT EGFR DEGRADATION 
 
There are three major known cellular mechanisms that are responsible for the degradation of cellular 
proteins, namely (i) autophagy, (ii) the cytosolic ubiquitin-proteasome pathway (note that not all 
proteins have to be ubiquitinated in order to be degraded by proteasomes), (iii) lysosome-dependent 
degradation.  
 
2.1) Autophagy 
Autophagy is a process whereby membraneous vesicles emerge inside the cytosol. Such vesicles form 
to engulf substrates like invading pathogenes who had escaped lysosomal destruction following 
internalization through the endocytic pathway. These autophagosomes vesicles fuse ultimately with 
the lysosome to deliver their content for lysosomal destruction thereby providing a mechanism for 
cellular immunity against invading pathogens such as bacteria. Autophagy is also relevant for antigen 
presentation by Major Histocompatibility Class II (MHCII) molecules. Both processes are important 
for cellular and organismal immunity. Beside these functions, autophagy also contributes to cellular 
homeostasis by eliminating organelles at the end of their life time and elimination of misfolded 
proteins. At the organismal level, autophagy is induced by starvation (53). In the absence of apoptotic 
proteins like Bax and Bak, cells can survive for relatively long periods under conditions whereby 
uptake of nutrients is blocked a process that apparently requires autophagy protein Atg7 (54). 
Moreover, lack of Atg5 and Atg7 inhibits basal autophagy in the brain and causes neurodegeneration 
in neuronal cells due to accumulation of aggregated proteins in these cells (55). These findings raised 
the hypothesis that autophagy may contribute to clearance of misfolded proteins. Thus, by delivering 
cargo for lysosomal degradation, autophagy constitutes a degradation pathway that is important for 
cellular homeostasis. 
 
2.2) The ubiquitin proteasome pathway 
 
Pioneering studies in yeast uncovered a vital role for ubiquitin-dependent protein degradation in cell 
cycle control, DNA repair, protein synthesis, and regulation of transcription (56, 57, 58, 59, 60, 61). 
Ubiquitin is a 76 amino acid protein that is highly conserved in eukaryotes (62). The cellular pool of 
monomeric ubiquitin protein is derived from various sources. Thus, ubiquitin is produced (i) from a 
single open reading frame (63), (ii) by cleavage of a head-to-tail multiubiquitin fusion precursor 
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protein (64), and (iii) by cleavage of a N-terminal in-frame fusion of ubiquitin to ribosomal proteins 
like L40 and S27a (65, 66).  
 
2.2.1) The ubiquitination cascade 
 
The ubiquitination reaction begins with the formation of a high-energy thiol-ester bond between 
ubiquitin involving the very distal glycine residue with the so-called E1 ubiquitin activating enzyme in 
an ATP dependent manner (Figure-3). Subsequently, ubiquitin is transferred to the active site cystein 
of E2 ubiquitin conjugating enzymes involving a thiol-ester bond as well. The final step in the 
ubiquitination reaction involves the transfer of the ubiquitin moiety from ubiquitin-loaded E2s to the 
target substrate that is specifically bound to a member of the ubiquitin ligase E3 family (62). There are 
two different classes of the ubiquitin-ligases i.e. (i) HECT (Homologous to the E6-AP COOH 
Terminus) domain-containing E3s and (ii) Ring finger E3 adaptor proteins.  
 
 
 
 
 
 
 
 
 
 
 
Figure-3: 
The ubiquitination reaction is executed by the sequential action of E1, E2, and E3 enzyme leading eventually 
to substrate ubiquitination. The substrate is either degraded by the proteasome or rescued by deubiquitination 
enzymes or isopeptidases. From reference (67). 
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HECT domain E3 ligases are bonafide enzymes that bind ubiquitin covalently through a high energy 
thiol ester bond involving the catalytic site cystein and the C-terminus of ubiquitin. HECT domain E3 
ligases also interact with various substrate proteins leading to transfer of the ubiquitin moiety via an 
isopeptide bond to lysine side chains of the bound substrate (68). RING finger E3 ubiquitin ligases 
facilitate the attachment of ubiquitin to the substrate by acting as adaptor proteins. These E3s bind 
ubiquitin-loaded E2 ubiquitin conjugating enzymes by virtue of their RING finger domain. RING 
finger E3s also bind a substrate through their substrate-binding module thereby bringing ubiquitin-
loaded E2s in close contact with the target substrate (69, 70). In this case, E2s mediate the transfer of 
ubiquitin molecule to the epsilon NH2 group of a lysine residue in the substrate. Therefore, ubiquitin 
is linked to the substrate through a covalent isopeptide bond. Whereas there is only one E1 ubiquitin 
activating enzyme cells possess tens of E2s and hundreds of E3s that determine the ultimate substrate 
specificity. Ubiquitin itself may also act as a substrate for ubiquitination, as it contains various internal 
lysine residues (e.g. K29, K48, K63). This then results in the formation of poly-ubiquitin chains. In 
some cases, E4 ubiquitin chain elongation enzymes have been proposed to be involved in poly-
ubiquitin chain elongation of particular substrates (71). Finally, chain extension may be restricted by 
CDC48/p97 to prevent excessive lengthening and to provide optimal chain length for proteasomal 
recognition (72). Alternatively, deubiquitinating enzymes may also be involved in trimming poly-
ubiquitin chains to mono- or oligo-ubiquitin chains. 
Depending on the identity of the internal lysine of ubiquitin and the type of target substrate the mode 
of ubiquitination could be classified as (i) NH2-terminal ubiquitination, (ii) mono-ubiquitination, (iii) 
multi-ubiquitination, and (iv) poly-ubiquitination. In case of NH2-terminal ubiquitination, the 
ubiquitin C-terminus is covalently linked to the amino group of the first amino acid of the target 
protein. This type of ubiquitination has been shown for cell cycle negative regulator p21 (73), MyoD, 
and HPV (Human Papilloma Virus) E7 proteins. 
Mono-ubiquitination results in the attachment of a single ubiquitin moiety to target proteins. The yeast 
polyphosphatase Phm5p is a membrane protein that is targeted to the vacuole in a mono-ubiquitination 
dependent manner. Mutation of the ubiquitination site leads to missorting of Phm5p, whereas 
biosynthetic addition of a single ubiquitin chain was sufficient to restore its vacuolar targeting (74). 
Multi-ubiquitination of target proteins requires the attachment of single ubiquitin molecule to different 
lysine residues of the substrate protein. Genetic and biochemical studies suggested that receptor 
tyrosine kinases are multi-ubiquitinated with single ubiquitin molecule at different lysine residues 
(75). 
Poly-ubiquitination occurs by linking the ubiquitin carboxyl group of C-terminal glycine residue to the 
epsilon amino group of an internal lysine residue in target protein. Additional rounds of ubiquitination 
reaction may continue to iterate resulting in the attachment of a new ubiquitin molecule to an internal 
lysine residue of the previously attached ubiquitin, a process that is referred to as poly-ubiquitination. 
Thus, the ubiquitin molecule itself has lysine residues that are potential sites for ubiquitination. Site-
specific polyubiquitination of internal lysines in the ubiquitin moiety creates variable branches of the 
polyubiquitin chain. Ubiquitination of lysine 63 creates K63-linked poly-ubiquitination, which is 
implicated in endocytosis, DNA repair, and stress response (76, 77, 78). Alternative ubiquitin linkages 
like lysine K6, K11, K29, and K48 are thought to play critical role in proteasome-dependent 
degradation and other pathways (79, 80). K48 poly-ubiquitination in particular has been linked to 
proteasomal degradation.  
 
2.2.2)  The proteasome 
 
Polyubiquitinated substrates are recognized by the 26S proteasome followed by their proteasome-
dependent degradation into small peptides. The 26S proteasome is a multiprotein complex composed 
of barrel-like 20S catalytic core particle (CP) that is responsible for proteasomal catalytic activity 
represented by the trypsin, chymotrypsin and caspase-like endoproteases (also called XYZ peptidases) 
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(Figure-4). Both extremities of the barrel-like CP can be capped by a 19S multiprotein complex called 
regulatory particle (RP), which in turn is composed of the lid and the base multiprotein subunits (81). 
The current understanding of the function of the RP implicates a role for the RP in substrate 
recognition (82), deubiquitination (83, 84) and ATP-dependent unfolding (85). Two criteria have been 
proposed in order for the proteasome to recognize ubiquitinated substrates: First, the polyubiquitin 
chain has to be composed of at least four ubiquitin monomers. Second, the polyubiquitin chain should 
be of non K63-linkage type. The finding that components of the 19S proteasome regulatory particle 
like Rpn10/S5a and S6/Rpt5 are able to recognize and bind K48-linked ubiquitin chains provided an 
important insight into how proteasomes specifically recognize ubiquitinated substrate proteins (79, 82, 
86). The current hypothesis regarding proteasome dependent protein degradation implicates that, 
following substrate recognition the ubiquitinated substrates are first deubiquitinated and then unfolded 
in an ATP-dependent manner, which is mediated by the base-resident AAA-ATPase chaperone 
proteins. Subsequently, the polypeptide chain is extruded along the cylinder-shaped 20S CP of the 
proteasome, which leads to exposure of the substrate to CP peptidase activities. This leads to the ATP-
dependent digestion of the substrate protein into small peptides. 
 
 
 
 
Figure-4: 
Theoretical model of proteasome structure. The barrel-like catalytic core complex (CP) is harboring the 
XYZ peptidase activities and is capped by the regulatory particle (RP). This is composed of two 
subcomplexes the lid and the base complexes. From reference (62). 
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2.3) The lysosomal pathway 
 
Vesicular trafficking (which includes endocytosis) between various organelles is a fundamental 
characteristic of all eukaryotes and these pathways are well conserved among eukaryotes including 
fungi and metazoans (Figure-5). Historically, vesicular trafficking pathways have been initially 
elucidated in yeast through various genetic screens. Eukaryotic cells endocytose cargo-loaded 
membrane bound receptors either constitutively or in response to receptor engagement (51, 87). 
Internalization of cargo from the cell surface takes place either through clathrin-dependent or clathrin-
independent pathways. Clathrin-independent internalization pathways include (i) phagocytosis (which 
occurs only in phagocytic cells), (ii) internalization through caveolae, (iii) macropinocytosis, and (iv) 
constitutive clathrin-independent endocytosis. Clathrin-independent internalization has been 
implicated in mediating the internalization of ubiquitinated EGFR (88). Other cargo also internalize 
via this pathway like: CD59, a glycosylphosphatidyl inositol-anchored protein (GPI-AP), 
sphingolipids, GABA(A) receptor (89, 90), and the histocompatibility protein class I (MHCI) (89). 
The mechanisms that differentiate clathrin-dependent from clathrin-independent EGFR internalization 
pathways remains poorly understood (88). 
 
 
 
 
Figure-5: 
Model of the endocytic pathway highlighting the trafficking routes of clathrin-dependent and clathrin 
independent internalization of cargo vesicles. Endocytosed cargo, which is concentrated on endocytic vesic
translocates to the early endosomes. Cargo either recycles back to the cell surface or translocates again to la
endosomes. Late endosomes fuse with pre-existing lysosomes leading to the deposition of its content into th
lysosomes and ultimately resulting in its destruction. From reference (95). 
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To internalize cargo through clathrin-dependent pathway, cargo or activated receptors concentrate in 
clathrin-coated pits (CCP) on the plasma membrane. CCP emerge from inward invagination of the 
plasma membrane, which is enforced by the assembly of the triskelions clathrin lattice at the cytosolic 
side of the plasma membrane. Recruitment of cargo proteins into the CCP is thought to be mediated by 
heterotetrameric AP2 complex, which binds cargo through its µ2 subunit while interacting with 
clathrin through its ß2 subunit (91, 92). Subsequently, the adaptor GTPase protein dynamin mediates 
the pinch-off of the vesicle (87) since GTPase deficient dynamin blocks endocytosis. The resulting 
clathrin-coated vesicle (CCV) translocates down the endocytic pathway and fuses with early 
endosomes after removing the clathrin coat. The early endosomes are thought to function as a sorting 
station from which internalized receptors either recycle back to the cell surface, or are further 
transported to the surface of multivesicular bodies (MVBs)/late endosomes. Internalized receptors then 
undergo translocation into the internal vesicles of late endosomes. These vesicles emanate from 
inward invagination of the limiting membrane of late endosomes. Subsequently, late 
endosomes/MVBs fuse with pre-existing lysosomes causing the exposure of its content to lysosomal 
hydrolases. Biochemical and cell biological studies demonstrated that the internal pH of the endocytic 
vesicles declines gradually from 7.5 to 5.5 in the lysosomes, which is imputable to the action of the v-
type ATPase proton pomp. The acidification of endosomes is essential for the proteolytic maturation 
and activation of lysosomal hydrolases that are responsible for final degradation of internalized cargo 
proteins (93, 94). 
 
2.4) Lysosomal degradation of the EGFR controls EGFR-dependent mitogenic signaling 
 
Strong line of evidence has demonstrated that the EGFR undergoes clathrin-dependent endocytosis 
following its activation and subsequent delivery to the lysosomes for degradation (11). Impairment of 
EGFR endocytosis, for instance, has been shown to correlate strongly with sustained mitogenic 
signaling (51). In addition, perturbation of lysosomal targeting leads to receptor stabilization, which 
may result in enhanced receptor recycling either from the early endosomes or from the surface of late 
endosomes (11, 96). Therefore, correct trafficking of internalized activated receptors is crucial for 
receptor degradation and hence attenuation of mitogenic signaling. Moreover, the identity of the ligand 
plays an important role in determining the fate of activated receptors (15, 97). EGFR activation by 
transforming growth factor a (TGF-α) induces enhanced EGFR recycling and superior mitogenic 
signaling when compared to EGF treatment (98, 99), whereas EGF treatment leads to efficient EGFR 
targeting to the MVB pathway and subsequent receptor degradation. Accumulating evidence suggest 
that this ligand-dependent differential routing of internalized receptors is, at least in part, determined 
by the binding characteristics of the ligands (97). Specifically, binding of TGF-α to the EGFR is more 
sensitive to low pH environment when compared to EGF. Consequently, it has been proposed that 
TGF-α dissociates early during the process of receptor internalization. This may render receptor 
dimers unstable and may lead to enhanced receptor recycling. In contrast, EGF binding to the EGFR is 
resistant to low pH milieu and therefore it is possible that it remains bound to the EGFR along the 
endocytic pathway resulting in efficient receptor targeting to the lysosomes. Intriguingly, EGF-
induced EGFR hetero-dimerization with the orphan receptor ErbB-2/Neu-2 promotes enhanced EGFR 
recycling implicating an important role for the dimerization partner in trafficking of internalized 
EGFRs (16). Interestingly, several reports implicated the proteasomes in the breakdown of activated 
EGFR (100, 101). It has been shown that blocking the proteasomes with the peptide aldehyde MG132 
leads to stabilization of the EGFR and downstream signaling molecules like Grb2 and Shc. These 
findings led to the hypothesis that not only lysosomes, but also proteasomes are involved in EGFR 
breakdown. It should be noted however, that MG132 not only inhibits proteasome function, but also 
strongly blocks lysosomal hydrolases (100, 101). 
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2.5) Regulation of lysosomal targeting 
 
Targeting of receptor tyrosine kinases to the MVB pathway is a complex multi-factorial process, 
which depends on their kinase activity and interacting partner molecules. Moreover, sequence motifs, 
and receptor post-translational modification like phosphorylation and ubiquitination serve, at least in 
part, as a sorting signal of internalized receptors within the endocytic pathway. Sorting signals may 
function constitutively (e.g. YxxΦ (where Φ is any large hydrophobic residue) or dileucine signals) or 
they may be induced/regulated by receptor activation (e.g. ubiquitination). For instance, EGFR 
ubiquitination probably provides docking sites for Eps15 protein, which bind to the ubiquitin moiety 
through its UIM (Ubiquitin Interacting Motif). Such interaction is required to promote EGFR 
downregulation. Binding of Eps15 to ubiquitin is regulated by Eps15 ubiquitination, which depends on 
the ubiquitin ligase parkin. Parkin targets Eps15 UIM for ubiquitination, which sterically hinders 
Eps15 UIM from recognizing the ubiquitin moiety on the EGFR. These findings led to the hypothesis 
that parkin might negatively control EGFR downregulation by interfering with Eps15 recruitment to 
activated receptors (102, 103). Furthermore, different sorting signals known to affect trafficking of 
internalized receptors might act redundantly or might be recognized by sorting proteins at specific 
compartments of the endocytic pathway. In the case of the EGFR, a dileucine motif in the membrane 
proximal region of the EGFR has been proposed to regulate the lysosomal targeting of the EGFR (104, 
105). Site-directed mutagenesis of the di-leucine motif (Leu679 and Leu680) of the EGFR decreased 
the level of EGFR sorting to the lysosomal pathway. Consistent with this finding, EGFR Leu679Ala 
and Leu680Ala double mutant exhibits enhanced retention into the recycling pathway (106). In 
contrast to these findings, Morrison et al (107) reported that the dileucine motif at position 679/680 
served as a lysosomal sorting signal only in truncated EGFRs, and that mutation of the dileucine signal 
did not affect lysosomal targeting of full length EGFRs (107). More recently, Huang et al. implicated a 
dileucine motif in the EGFR C-terminal tail (Leu1010/1011) in lysosomal targeting of the EGFR 
(108). Moreover, a dileucine motif was also linked to lysosomal sorting of the human insulin receptor 
HIR (109, 110, 111), and the TCR complex (T-cell receptor accessory molecule CD3 (112). It is 
believed, based on in vitro and in vivo evidence, that the dileucine motif provides a docking site for the 
AP2 complex (113), which binds to clathrin through a separate interaction interface, thereby allowing 
local concentration of cargo in clathrin-coated pits. Similarly, the AP2 complex also recognizes YxxΦ 
motif located in the cytosolic tail of cargo proteins (e.g. EGFR Y974), an interaction event that 
mediate, in a similar manner as the dileucine signal, the selective recruitment of cargo to clathrin-
coated pits (114). 
 
The catalytic activity of the EGFR tyrosine kinase domain is hypothesized to promote sorting of 
activated receptors to non-recycling compartment MVBs/late endosomes, since point mutation 
catalytic defect receptor increases receptor stabilization by enhancing its recycling potency (115, 116). 
Indeed, electron microscopy studies indicate that a kinase-dead EGFR mutant remains on the limiting 
membrane of MVBs and is not incorporated into internal vesicles of late endosomes (116). The role of 
the kinase activity in lysosomal targeting is still an issue of debate (117) given the fact that the kinase 
dead mutant, like wild type EGFR, translocates to the MVB pathway when the recycling pathway is 
blocked by monensin suggesting that the kinase activity of the EGFR is required to prevent access of 
the recycling pathway to the EGFR (116). It may be worth noting in this regard that the naturally 
catalytic defect ErbB-3 neuregulin receptor exhibits enhanced recycling behaviour, and is defective in 
lysosomal targeting compared to ErbB-1 (99, 118). However, ErbB-3 also lacks various sorting signals 
that have been identified in the EGFR cytoplasmic tail such as consensus AP2 and Cbl binding sites. 
Indeed, replacement of the EGFR autophosphorylation C-terminal domain with the corresponding 
sequence of ErbB-3 resulted in shunting the chimeric EGF-receptor into the recycling pathway. These 
findings raised the question of how the C-terminal part of the EGFR regulates its trafficking following 
internalization. 
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2.5.1) Role of Cbl protein family in EGFR lysosomal targeting 
 
It has been shown that members of the proto-oncogene Cbl (Casitas B-lineage Lymphoma) (119) 
adapter protein family could negatively regulate the signaling of receptor tyrosine kinases (120, 121) 
by enhancing the sorting of activated receptors to the lysosomal/degradative pathway (120, 122).  
It has been shown that the C-terminal domain of the EGFR is essential for binding of the Cbl ubiquitin 
ligase adapter protein (120). Importantly, this interaction event is critical for efficient lysosomal 
sorting of activated EGFRs (120). Interestingly, Cbl is rapidly tyrosine phosphorylated in response to 
EGFR activation, whereas ligand binding to ErbB-3 has no effect on Cbl phosphorylation (123). 
Furthermore, Cbl binds activated EGFRs, but it cannot bind ErbB-3 neuregulin receptors which are 
defective in lysosomal targting (120).  
Cbl proteins including c-Cbl, Cbl-b and Cbl-3 belong to the RING finger class of the E3 ubiquitin 
ligase family (124, 125). The major structural elements of Cbl proteins include an N-terminal 
Phospho-Tyrosine Binding domain (PTB), RING finger domain, proline rich sequence, and a C-
terminal UBA domain (ubiquitin associated domain). Upon activation of the EGFR, Cbl proteins 
rapidly undergo tyrosine phosphorylation (126, 127). Cbl is recruited to EGFR by direct binding of its 
PTB domain to phosphorylated EGFR Tyr1045. Cbl proteins interact indirectly with the EGFR via 
Grb2, which interacts with the Cbl proline rich region through its SH3 domain and with the several 
EGFR major autophosphorylation sites through its SH2 domain (128). Cbl also interacts with Src-
family tyrosine kinases and phospholipase C-γ, both of which may simultaneously interact with the 
EGFR as well. It has been hypothesized that Cbl/EGFR interaction takes place at the cell surface and 
persists through the endocytic pathway at the level of early and late endosomes (120, 129).  
It has been postulated that Cbl regulates EGFR internalization by acting as a scaffolding protein 
through binding to ligand-induced phosphorylated EGFR tyrosine residue 1045 (128, 130, 131). This 
binding triggers the recruitment of the Cbl/CIN85/Endophilin protein complex to the activated EGFR, 
thereby facilitating the pinch-off of the clathrin-coated pits (130). Moreover, Cbl proteins induce 
downregulation of the EGFR, and other receptor tyrosine kinases, by virtue of their ubiquitin ligase 
activity (120, 122, 132), which is required to ubiquitinate activated receptors in a ligand-induced 
manner. EGFR ubiquitination is not affected when Cbl/CIN85 complex is disrupted (130) suggesting a 
dual role for Cbl in EGFR downregulation. To ubiquitinate the EGFR, Cbl protein is incorporated into 
a trimeric protein complex involving on one hand Cbl PTB domain-mediated interaction with the 
EGFR and on the other hand RING-finger mediated interaction of Cbl with the E2 conjugating 
enzyme hUbc7. Accordingly, Cbl acts as a scaffolding adapter by recruiting the E2 ubiquitin 
conjugating hUbc7 machinery to activated receptors (69, 70). Prevention of this interaction blocks 
EGFR ubiquitination leading to sustained EGFR expression and enhanced mitogenic signaling (70). 
This may, at least in part, provide the rationale for the proposed oncogenic behavior of Cbl ring finger 
deletion mutants (70, 120, 124). Thus, activated EGFR are subject to ubiquitination mediated by Cbl 
E3 ubiquitin ligases (124, 126). However, analysis of EGFR Y1045F mutant defective in Cbl binding 
revealed that receptor internalisation is unaffected (128). Consistently, studies in mouse c-Cbl -/- 
fibroblasts demonstrated that although EGFR ubiquitination was diminished, receptor internalisation 
remained unaffected when compared to cells expressing c-Cbl protein to physiological levels (133). 
Thus, it appears that c-Cbl protein is not absolutely required for EGFR internalisation. However, 
redundant regulatory pathways may exist. For instance, the EGFR may still be subject to low-level 
ubiquitination by Cbl-b (100, 134) or other ubiquitin ligases that may be sufficient to drive EGFR 
internalisation. Furthermore, although EGFR Y1045F mutant shows decreased Cbl binding, the 
receptor still undergoes residual ligand-induced ubiquitination. This was shown to be mediated by Cbl 
protein through interaction with Grb2 adaptor protein (128) independent of Cbl recruitment to 
phosphorylated tyrosine 1045.  
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2.6) Role of ubiquitin in the endocytic pathway 
 
Cbl-dependent EGFR ubiquitination shows temporal correlation with EGFR degradation. In addition, 
Cbl associates with the EGFR along the endocytic pathway (99, 120). These findings raised the 
possibility that EGFR trafficking along the endocytic pathway may at least in part be regulated 
through the ubiquitin moiety. The role of ubiquitin in trafficking of internalized receptors is best 
illustrated in yeast system. It has been found in yeast cells that ubiquitination of the G protein coupled 
a factor receptor Ste2p is an important step in triggering Ste2p internalization (135). In line with these 
findings, mutant yeast cells carrying chromosomal deletion of Ubc4 and Ubc5 ubiquitin conjugating 
enzymes fail to ubiquitinate Ste2p and these mutations led to inhibition of Ste2p internalization (135). 
In addition, the ubiquitin ligase Rsp5/Npi1 (the ortholog of mammalian Nedd4) is required for the 
ubiquitination and internalization of cell surface receptors, such as Ste2p, the general amino acid 
permease Gap1 and uracil permease Fur4 (136, 137, 138). Furthermore, analysis of ubiquitination of 
the ABC-transporter a-factor receptor Ste6p, which is required for the secretion of the yeast mating 
pheromone a-factor, indicates that yeast mutants defective in internalization accumulate Ste6p in a 
hyper-ubiquitinated form (139). Finally, depletion of cellular level of ubiquitin blocked Ste3p 
degradation, and interestingly, Ste3p was retained at the cell surface (140). This line of evidence has 
led to the hypothesis that ubiquitination of membrane bound receptors functions as a signal for their 
internalisation. 
In mammalian cells many membrane bound receptors are known to be ubiquitinated upon receptor 
activation. These include EGFR, TCR-ζ, growth hormone receptor, c-Met and many others (141). The 
growth hormone receptor accumulates in a non-ubiquitinated form in E1 ubiquitin conjugating enzyme 
temperature-sensitive mutant cells (142) thereby implicating a role for the ubiquitin conjugating 
system in GHR downregulation. However, mutating all ubiquitin-acceptor lysines at the cytosolic tail 
of the GHR did not affect receptor endocytosis (143). Surprisingly, biochemical analysis of the GHR 
endocytosis revealed that a ten amino acids long motif located at the cytosolic part of the receptor is 
essential for GHR internalisation (143) and may function as a recruitment site for a putative 
interacting protein that is ubiquitinated upon receptor engagement. 
The type or mode of ubiquitination of cell surface receptors varies depending on the identity of the 
receptor. Indeed, yeast Ste2p receptor undergoes mono-ubiquitination that is sufficient to drive 
receptor internalisation (144, 145). Di-ubiquitination was also observed for the yeast a-factor receptor 
(146). The Gap1 general amino acid permease has been reported to undergo both multiubiquitination 
and K63-linked polyubiquitination (137). Biochemical evidence has been presented showing that the 
EGFR and PDGFR undergo multiple mono-ubiquitination on different lysines (75). Moreover, recent 
evidence provided by mass spectrometry analysis of ubiquitinated EGFR demonstrated that the EGFR 
undergo K63-linked poly-ubiquitination (147). The TrkA neurotrophin receptor tyrosine kinase has 
also been reported to undergo K63-linked polyubiquitination (148). In the case of the EGFR, 
ubiquitinated receptors are recognized at various steps along the endocytic pathway by adapter 
proteins containing ubiquitin interacting domains. During receptor internalization, Eps15 and Epsins 
were implicated in regulation of ubiquitin-dependent sorting of cargo proteins. They do so by binding 
to the ubiquitin moiety of ubiquitinated receptors through their UIM motif, and at the same time they 
interact with clathrin thereby facilitating the physical coupling of ubiquitinated receptors to the 
clathrin machinery (149, 150).  
 
2.7) Role of ubiquitin in lysosomal targeting 
 
Analysis of yeast mutants defective in endocytosis indicated that Ste6 accumulates on plasma 
membranes in a hyper-ubiquitinated form (139). Current evidence suggests that ubiquitinated cell 
surface proteins are destined for vacuolar/lysosomal degradation since yeast mutants defective in 
vacuolar degradation accumulate cell surface receptors in hyper-ubiquitinated form as well (135, 140, 
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151). Furthermore, the uracil permease FUR4 is a membrane bound protein that is rapidly degraded 
under several physiological conditions. PEP4 (vacuolar protease) deletion mutants accumulates FUR4 
in the vacuole indicating that FUR4 is constitutively degraded in a vacuole-dependent manner (138, 
152). These findings prompted the speculation that ubiquitin may also function as a sorting signal in 
post-internalization sorting events of cargo proteins.  
 
2.7.1) ESCRT-0 complex 
 
Genetic screens in yeast have identified numerous proteins that are required for efficient vacuolar 
protein sorting (Vps). The class E Vps proteins are required for the formation of internal vesicles of 
MVBs. Deletion of Vps class E proteins leads to an enlarged multilamellar prevacuolar compartment 
lacking lumenal vesicles called the Vps class E compartment (153). As a result, Vps class E mutants 
are unable to sort endosomal cargo proteins into internal vesicles of MVBs, thereby failing to sort 
cargo proteins to the lumen of vacuoles/lysosomes. Genetic and biochemical analysis have led to the 
identification of various Vps class E protein complexes (Endosomal protein Complex Required for 
Transport) which have been denoted ESCRT-0, -I, -II, and -III.  
 
The ESCRT-0 complex is composed of Vps27, the yeast homologue of mammalian Vps27/Hrs 
(Hepatocyte growth-factor-Regulated tyrosine kinase Substrate) and Hse1, the yeast homologue of 
STAM/Hbp. Vps27/Hrs was found to play an important role in regulation trafficking of internalized 
receptors in yeast and animal cells (96, 154, 155). Vps27/Hrs encodes distinct structural domains 
including a FYVE domain (Zinc finger present in Fab1, YOTB/ZK632.12, Vac1, and EEA1) that 
interacts with phosphatidylinositol-3-phosphate localized on endosomal membranes, a UIM (Ubiquitin 
Interacting Motif) that can bind to ubiquitinated cargo proteins, a clathrin box that interacts with 
clathrin on the endosomal limiting membrane and a Pro-Ser-Ala-Pro (PSAP) motif that interacts with 
the ubiquitin conjugating enzyme variant (UEV) domain of TSG101, a component of the ESCRT-1 
complex. Thus, Hrs is possibly involved in concentrating ubiquitinated cargo proteins in flat clathrin 
coats on the limiting membrane of endosomes and recruitment of downstream ESCRT complexes, to 
initiate sorting of ubiquitinated cargo proteins to the MVB pathway.  
 
2.7.2) ESCRT I complex 
 
Vps23 together with Vps28 and Vps37 form a protein complex named ESCRT-I, for Endosomal-
associated Complex Required for Transport (156). Deletion of members of the ESCRT-I complex 
leads to an enlarged MVBs prevacuolar compartment lacking lumenal vesicles called Class E 
compartment (153). In addition, Vps27/Hrs interacts with Vps23 by virtue of its PSAP motif (96). 
Vps23 is the yeast homologue of the mammalian TSG101 (Tumor Susceptibility Gene 101), which 
encodes an ubiquitin-conjugating E2 enzyme variant UEV domain. The UEV domain lacks the active 
site cystein; therefore, it is defective in ubiquitin conjugating activity (157). The UEV domain of 
Vps23/Tsg101, as well as the Hrs ubiquitin-interaction motif (UIM), binds ubiquitin with low affinity 
(154, 158). Deletion of the yeast Vps23 compromises the canonical trafficking and vacuolar targeting 
of cargo proteins (156). Similarly, downregulation of Tsg101 impairs lysosomal targeting of the EGF 
receptors (96), probably due to defect in sorting events that are essential for EGFR entry into the 
MVB/late endosome pathway (159, 160). Taken together, these findings suggest that Vps27/Hrs and 
ESCRT-I protein complexes could act as endogenous molecular ubiquitin sensors that are able to 
discriminate between ubiquitinated versus non-ubiquitinated cargo proteins in the endocytic pathway 
(Figure-6). 
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2.7.3) ESCRT II complex 
 
Genetic and biochemical analysis in yeast revealed that ESCRT-II protein complex, composed of 
Vps22, Vps25, and Vps36 physically interacts with ESCRT-I protein complex, an event that is critical 
for activation of the MVB pathway (161). Interestingly, Vps36 binds ubiquitin with low affinity 
similar to Vps27 and ESCRT-I, which is mediated through its NZF (Npl4 zinc finger) domain (162). 
However, its mammalian orthologue Eap45 lacks the NZF domain, yet it is able to bind ubiquitin 
through its GLUE domain (GRAM Like Ubiquitin binding in EAP45) (163). The crystal structure of 
ESCRT-II complex shows that its components assemble into a trilobal 'T' shaped structure (164, 165), 
where two copies of Vps25 represent the branches, while Vps22 and Vps36 represent the stem. The 
latest is hypothesized to face the endosomal vesicles and directly interact with ubiquitinated cargo 
through its NZF domain (164). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: 
Theoretical model illustrating the sequential action of ESCRT-I, -II, and -III complexes in recognizing 
ubiquitinated cargo. Following concentration of cargo on late endosomes, Vps4 AAA-ATPase catalyzes the 
dissociation of ESCRT complexes allowing multiple rounds of cargo selection. A deubiquitination step mediated 
by Doa4 removes ubiquitin from cargo, which acts downstream ESCRT-III. From reference (166). CPS: 
Carboxy Peptidase S. 
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2.7.4) ESCRT III complex 
 
The assembly of ESCRT-II complex on endosomes provides a docking site for ESCRT-III protein 
complex, which is composed of Vps2, Vps20, Vps24, and Vps32/Snf7 proteins (165, 166, 167). 
Structural analysis of ESCRT-III complex revealed that its components assemble into two distinct 
subcomplexes. The first subcomplex is composed of Vps2 and Vps24, the second one comprises 
Vps20 and Vps32/Snf7. Recruitment of ESCRT-III to cargo endosomes is thought to be mediated by 
interaction of Vps20 with ESCRT-II Vps25 protein (165), and in part by myristoylation of Vps20 
(166, 168). Based on electron microscopy experiments ESCRT-III complex is implicated in 
concentrating cargo proteins into the MVB vesicles (166).  
 
Finally, it has been established that the AAA-type ATPase Vps4 protein is essential for maintaining 
the MVB pathway (169, 170). The role of Vps4 in the MVB pathway is that it mediates the 
dissociation of the ESCRT protein complexes from the surface of the endosomes in a manner that is 
dependent on its ATPase activity to further allow multiple rounds of cargo recognition by the ESCRT 
machinery (156, 161, 166, 169, 170). Most importantly, Vps4 AAA ATPase activity triggers internal 
vesicle formation. 
 
2.7.5) GGA proteins 
 
Apart from components of the ESCRT machinery, clathrin associated GGA proteins (Golgi associated, 
γ Adaptin ear containing) have also been implicated in recognition of ubiquitinated cargo proteins in 
the endosomal system. More specifically, GGA proteins have been proposed to be involved in 
ubiquitin-dependent sorting of (biosynthetic) cargo proteins from the TGN (Trans-Golgi Network) to 
endosomes. Biosynthetic cargo proteins that are destined for the vacuolar lumen like carboxypeptidase 
S and the polyphosphatase Phm5p that contain polar residues in their transmembrane domains are 
ubiquitinated at the TGN or en route to endosomes, and sorted via the MVB pathway to internal 
vesicles of MVBs (74, 171, 172). Similarly, cell surface expression of biosynthetic Tat2, Fur4 and 
Gap1 amino acid permeases is regulated by their ubiquitination at the TGN or en route to endosomes, 
after which they are sorted into internal vesicles of MVBs leading to their vacuolar degradation (157, 
173). In contrast, Pep12/syntaxin is normally transported from the TGN to the limiting membrane of 
prevacuolar endosomes, from where it can reach the vacuolar membrane (174). Interestingly, 
introduction of polar residues in the transmembrane domain of Pep12 leads to ubiquitination-
dependent targeting to internal vesicles of the prevacuolar compartment through the MVB pathway 
(175, 176). 
The tertiary structure of GGA proteins folds into four distinct domains: VHS (Domain present in 
Vps27, Hrs, and STAM), GAT, Hinge, and GAE (γ-adaptin ear) domain. The hinge region binds 
clathrin whereas GAE recruits additional proteins. The three-helix bundle (135) GAT domain (GGA 
and TOM1 homology domain) binds Arf:GTP, but interestingly, it also binds ubiquitin through two 
redundant sites (177, 178, 179). Indeed, only when both sites are mutated GGA proteins become 
defective in ubiquitin binding. Importantly, these mutations compromised dramatically the sorting of 
the yeast Gap1 amino acid transporter from the TGN to the endosomes (177). Three GGA proteins are 
expressed in mammalian cells and found to associate with clathrin coated TGN carriers (180). In 
addition, GGA proteins were also found to localize to early endosomes and play an important role in 
sorting of internalized receptor in a non-redundant manner. RNA interference experiments directed 
against the individual GGA genes/proteins revealed that only GGA3 was required for canonical 
sorting of internalized EGFRs in mammalian cells (178). The EGFR accumulated in enlarged early 
endosomes in GGA3 depleted cells indicating that GGA proteins are essential for early to late 
endosome transport and for lysosomal targeting in yeast and in mammalian cells. Interestingly, yeast-
two-hybrid experiments revealed that GGA proteins bind TSG101 through their VHS-GAT domain 
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(178), which may indicate that GGA proteins and ESCRT complexes could act in concert to regulate 
the sorting of ubiquitinated cargo proteins.  
Altogether, these findings strongly demonstrate a central role for ESCRT and GGA proteins in the 
process of cargo selection based on ubiquitin recognition. The current hypothesis states that Vps27, 
ESCRT-I, II and III sequentially recognize ubiquitinated cargo proteins through their various ubiquitin 
interacting domains. It has been proposed that Vps27 and ESCRT proteins devolve ubiquitinated cargo 
to each other in a sequential manner, which is mechanistically permitted by the low affinity ubiquitin-
binding characteristics of these proteins. Following cargo selection, ESCRT proteins facilitate 
substrate concentration on the surface of MVB/late endosomes. Dissociation of ESCRT complex, 
which is catalyzed by Vps4 activity, triggers cargo incorporation into internal vesicles of late 
endosomes. Dissociation of ESCRT proteins would allow their use in successive rounds of cargo 
selection.  
 
3) ROLE OF DEUBIQUITINATION ENZYMES IN PROTEIN DEGRADATION. 
 
De-ubiquitination enzymes play an important role in the ubiquitination system in a similar manner as 
the role of dephosphorylation enzymes play in the protein phosphorylation system. Since the discovery 
of the ubiquitin proteasome system much of the research was focused on the analysis of the E2s and 
E3s ubiquitination enzymes, while the deubiquitination enzymes remained largely uncharacterized. 
Historically, deubiquitination enzymes were identified as hydrolases that are able to maintain the 
cellular level of free ubiquitin monomers (Figure-7) either by cleaving off an N-terminally fused 
ubiquitin to ribosomal proteins (65, 66), by disassembly of head-to-tail precursor multi-ubiquitin 
protein (64) or by removal of the ubiquitin moiety from post-translationally ubiquitinated proteins 
(181). Recent advances unleashed the significance of deubiquitination enzymes in regulation of 
various cellular processes like cell cycle/cell growth, DNA damage response, development, gene 
transcription and endosomal trafficking.  
 
3.1) Function of deubiquitination enzymes 
 
The sequence of events of proteasome-dependent degradation of ubiquitinated substrates provoked the 
question of what is the fate of poly-ubiquitin chain and what is its role in protein degradation. Purified 
proteasomes from different organisms revealed the association of de-ubiquitination enzymes like 
UCH-37 (83), USP14 (182), and the yeast Doa4 (183) with the proteasomes. In addition and in a series 
of elegant experiments, it has been shown that the regulatory particle of the proteasome harbors 
Jab/MPN metalloproteinase motif-containing protein Rpn11 that is essential for the removal of the 
ubiquitin chain from ubiquitinated substrates, thereby facilitating substrate entry into the cylinder-
shaped catalytic core of the proteasome (84). Subsequent genetic analysis in yeast demonstrated that 
Rpn11 gene is essential for cell viability (84) thereby underscoring the relevance of de-ubiquitination 
enzymes for protein degradation and cellular homeostasis. 
 
The family of deubiquitination enzymes constitutes a large number of proteins, which based on 
sequence similarity are divided into five classes, as described in the following sections. 
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Figure-7: 
Summary of various fuctions of deubiquitination enzymes showing their role in cleavage of ubiquitin fusion 
from ribosomal protein L40, salvage of ubiquitinated adducts, and isassembly of degradation intermediates. All 
pathways lead to production of free ubiquitin. From reference (184). 
 
3.1.1) The JAB/JAMM MPN metalloprotease deubiquitination enzymes 
 
Members of the JAMM (JAB1/MPN/Mov34 metalloenzyme) family encode a JAB1/MPN 
metalloprotease (MPN) motif that is responsible for the deubiquitination activity of this family. The 
MPN motif is characterized by the presence of a conserved histidine, aspartic acid and a glutamic acid 
residue that together form the catalytic triad (185, 186). Further analysis of the primary sequence of 
the JAMM family by iterative profile alignment identified additional conserved residues embedded 
within the MPN motif in a subset of the JAMM family members (186). This extended novel MPN 
motif was designated as MPN+ and exhibits a defined pattern of His-X-His-X[7]-Ser-X[2]-Asp, where 
X is any given amino acid. Rpn11, a member of the JAMM family, is a component of the proteasomal 
lid (84) and its deubiquitination activity has been implicated in the removal of the ubiquitin tag from 
the proximal region of the polyubiquitin chain of ubiquitinated substrates prior to their proteasomal 
degradation (84). Interestingly, mutational analysis of the MPN+ motif in yeast Rpn11 protein 
revealed defects in deubiquitination of ubiquitinated cellular proteins, which correlate with severe 
slow growth phenotype of mutant yeast cells (186). Furthermore, Rpn11 requires additional factors for 
its deubiquitination activity (84). In contrast, purified AMSH protein, an endosome associated 
mammalian JAMM family member, has been shown to be fully competent in disassembly of K63-
branched ubiquitin chains in vitro to generate free ubiquitin (185). However, AMSH failed to process 
K48-branched ubiquitin chains (185). Interestingly, AMSH associates with ubiquitinated cargo on the 
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endosomal membranes, which suggests a requirement for a deubiquitination activity along the 
endocytic pathway (185). Indeed, catalytically inactive AMSH perturbs the morphology of the 
endosomal vesicles that originate from the cell surface. However, siRNA-mediated downregulation of 
endogenous AMSH had only a minor effect on the kinetics of EGFR degradation (185). Therefore, 
additional deubiquitination proteins were hypothesized to participate in EGFR deubiquitination (185). 
 
3.1.2) Ubiquitin C-terminal Hydrolases (UCHs) 
 
UCH enzymes are in general smaller in size than UBPs. Members of the UCH family show variable 
tissue-specific expression patterns. For example, UCH-L3 is found primarily in hematopoietic cells, 
whereas UCH-L1 was found more abundant in neuronal tissues (187, 188). Mice mutated in either of 
these genes grow normally, while double mutant mice show severe neurodegenerative phenotypes 
suggesting functional overlap between UCH-L1 and UCH-L3 (189). In contrast to the JAMM family, 
the active site of the UCH proteins contains a highly conserved cystein instead of glutamate residue. 
Structural analysis of the UCHs active site indicates strong similarity to the structural configuration of 
the active site of papain/cathepsin B protease. Comparison of the ubiquitin aldehyde-bound and 
ubiquitin aldehyde-free UCH-L3 structures has shown that the active site is masked in the ubiquitin-
free state. Ubiquitin binding is thought to induce conformational changes in the active site that is 
hypothesized to promote unmasking of the active site and thereby contributing to the enzymatic 
specificity towards ubiquitin (190, 191). UCHs are catalytically capable of hydrolyzing small amides 
and esters attached to the C-terminus of ubiquitin (192). An example of UCH family is the 
proteasome-associated deubiquitination enzyme UCH-37. It has been demonstrated that UCH-37 
removes ubiquitin monomers one at a time from the distal region of the polyubiquitin chain. Since 
UCH-37 is a component of the proteasomal regulatory particle it suggests that UCH-37 mediated 
deubiquitination take place after substrate-proteasome engagement (83, 193). The finding that both 
UCH-37 and Rpn11 reside in the regulatory particle of the proteasome raises the possibility that both 
proteins may cooperate to deubiquitinate substrates that are destined for proteasomal degradation. 
However, the molecular mode of such cooperative action of these deubiquitination enzymes remains 
unknown. 
 
3.1.3) Otubain-1/2 ovarian tumour deubiquitiantion enzymes 
 
Bioinformatics approach identified Otu deubiquitination enzymes (DUBs) that belong to the ovarian 
tumour superfamily of proteases (194). They show weak sequence similarity to known DUBs, which 
is further reflected in the unique topological orientation of the active site triad observed in its crystal 
structure (195). Two proteins otu-1 and -2 were identified by affinity purification (196) and found to 
exhibit cystein protease activity. It has been reported that otu-1 and -2 regulate CD4 T-cell anergy 
through binding to GRAIL an E3 ubiquitin ligase that is crucial for induction of T-cell anergy (197). 
However the physiological function of otu-1/2 in other biological processes remains largely unknown.  
 
3.1.4) Ataxin-3 and ataxin-3 like deubiquitination enzymes 
 
Mutation in ataxin-3 in humans causes spinocerebellar ataxia type 3, a neurodegenerative disorder. It 
has been found that the disease making mutation leads to expansion of polyglutamine tract in ataxin-3 
protein. Consequently, the protein tends to form pathological aggregates. It has been suggested that 
ataxin-3 binding to VCP (Valocin-Containing Protein) reduces its fibrillogene formation potency 
(198). These findings also linked ataxin-3 to the ER-associated degradation known as the ERAD 
pathway. The ERAD pathway is responsible for the retro-translocation of misfolded proteins that 
accumulate in the ER back to the cytosol (199, 200), where they are subsequently ubiquitinated and 
targeted for proteasomal degradation. p97 interacts with ataxin-3 and transiently recruits ataxin-3 to 
 28
ER membranes. Its deubiquitination activity was found to facilitate the passage of p97-bound substrate 
to the proteasome for final destruction (199).  
 
3.1.5) Ubiquitin Specific Proteases (USPs) 
 
In the human genome, more than 50 genes encode for USP family of deubiquitination enzmyes 
(DUBs) (201). Members of this family share structural similarities in their core DUB domain. This is 
composed of two regions that are variably interspaced and named the Cys-box and His-box according 
to the highly conserved catalytic active site cystein and histidine residues (202). The DUB domain is 
usually flanked by additional structural motifs that may determine the subcellular localization (203), or 
substrate specificity of these enzymes (204). Common structural motifs encountered in USPs include 
the ubiquitin-binding module Zf-UBP, DUSP and Rhodanese domains. A Rhodanese homology 
domain is only present in a single metazoan Usp enzyme, namely Usp8 and orthologs. In yeast, Usp8 
orthologs include the two paralogs Ubp4 en Ubp5, both of which contain a rhodanese domain. Also 
yeast Ubp7, which is closely related to Ubp4/5 contains a rhodanese homology domain, but this 
enzyme has no counterpart in metazoans. The functional role of these accessory domains remains 
largely unknown except for few proteins. Example is the N-terminal divergent sequence of the germ 
cell specific USPs UBP-t1 and UBP-t2. Both enzymes share identical DUB domains but they encode 
divergent N-terminal sequences. Comparative analysis led to the finding that the N-termini modulate 
the enzymatic activity of these proteins since overexpression of the core DUB domain removes 
ubiquitin from ubiquitinated proteins more rapidly than holoenzymes UBP-t1 and UBP-t2 (204). 
 
3.2) Role of deubiquitination enzymes in the endocytic pathway 
 
Ubiquitination of membrane-bound cell surface receptors strongly enhances their degradation by the 
MVB degradative pathway. Deubiquitination enzymes were shown to act along the endocytic pathway 
on internalized ubiquitinated cargo proteins. However, the consequence of such an event in terms of 
cargo trafficking along the endocytic pathway is poorly understood. Evidence presented by 
accumulating reports favor a model that describe a positive role for deubiquitination enzymes in 
targeting of cargo proteins to the degradative pathway of MVBs/late endosomes, which function at a 
late step of the endocytic pathway. For instance, the degradation of the yeast membrane-bound 
receptors requires Vps class E Vps31/Bro1 protein (205), which associates with endocytic vesicles in a 
ESCRT-III/Vps4 dependent manner (206, 207). Bro1 null mutant cells show severe defects in the 
degradation of membrane-bound receptors including the yeast general amino acid permease Gap1, and 
these cells exhibit aberrant morphology of the endosomes (205). Deletion of Bro1 does not affect 
Gap1 ubiquitination nor does it affect its internalization (208). In these mutant cells, Gap1 recycles 
back to the cell surface, which strongly correlates with its deubiquitination (208).  
It has been shown that loss of Bro1 function could be suppressed by overexpression of the 
deubiquitination enzyme Doa4 (206). Doa4 overexpression restored endosome morphology and 
deubiquitination of carboxypeptidase S (CPS), a vacuolar hydrolase that is sorted in a ubiquitin-
dependent manner to the MVB pathway during its transport from the Golgi to the vacuole (206). Bro1 
also binds Doa4, albeit this binding is independent of Vps4 (206), yet both proteins are recruited to the 
endosomes in a Vps4 dependent manner. Bro1 association with the endosomes requires interaction 
with ESCRT-III component Snf7 (207). This led to the suggestion that Bro1 may act as a coordinator 
of cargo deubiquitination along the endocytic pathway (206). Consistently, deletion of Doa4 blocks 
Ste3 and Ste6 degradation (209, 210). This phenotype is reversed by supplementing free ubiquitin 
exogenously (210) suggesting that lack of free ubiquitin, which is required to ubiquitinate membrane-
bound receptors, in Doa4 mutants may account for defects in Ste3 and Ste6 degradation. Furthermore, 
the breakdown of ubiquitinated Fur4p uracil permease proceeds normally in cells lacking Doa4, which 
was suggested to be degraded by the vacuole still covalently linked to the ubiquitin moiety. However, 
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this degradation process was completely blocked in cells that are deficient in the vacuolar protease 
Pep4. Interestingly, and in this genetic background of these double mutant cells, deubiquitination of 
Fur4p was completely blocked clearly indicating that Fur4p is subject to Doa4-dependent 
deubiquitination prior to its vacuolar degradation (151). In the same genetic background, the 
internalized a-factor transporter Ste6 was found to accumulate at the surface of the vacuole suggesting 
that Doa4-mediated deubiquitination of Ste6 may be important for translocation of Ste6 protein into 
the internal vesicles of the MVBs (210). Interestingly, deletion of Vps27 in Doa4/Pep12 mutant cells 
restores deubiquitination of Fur4p, suggesting the involvement of an additional deubiquitination 
enzyme in the endocytic pathway, the identity of which is still unknown (151).  
Taken all together, these findings strongly indicate that the deubiquitination enzyme Doa4 is involved 
in the process of break down of membrane-bound receptors and that its function is regulated by 
members of the class E Vps proteins. The current hypothesis states that ESCRT-III associated Snf7 
recruits Doa4-bound Bro1 protein to the surface of endosomes that carry ubiquitinated cargo. Doa4 
then executes the removal of the ubiquitin tag from cargo proteins prior to their translocation into the 
internal vesicles of MVBs/late endosomes, thereby recycling ubiquitin proteins and replenishing the 
cellular ubiquitin pool for subsequent ubiquitination reactions. 
 
3.3) Deubiquitinaiton enzyme UBPY 
 
UBPY is likely to represent the mammalian orthologue of yeast deubiquitination enzyme Doa4 due to 
the structural similarities among them. Like Doa4, the N-terminal half of UBPY encodes a Rohdanese-
like (Rhod) domain that is often detected in dual specificity phosphatases and a C-terminal 
deubiquitination domain (Dub). Interestingly, UBPY was found to be essential for G1 to S-phase 
transition of the cell cycle. However the mechanism underlying UBPY function in cell cycle 
progression remained unknown (211). One possibility is that UBPY might, at least in part, augment 
Ras activation through direct interaction with Ras-GRF1, which is a Ras nucleotide exchange factor 
that stimulates Ras activity (212). Consequently, this interaction was found to be responsible for 
UBPY-dependent Ras-GRF1 deubiquitination and stability.  
Kato et al (213) reported that UBPY interact in vitro and in vivo with Hrs binding protein Hbp. The 
SH3 motif of Hbp is sufficient for UBPY interaction. Mutagenic analysis of UBPY sequence 
identified a consensus sequence PX(V/I)(D/N)RXXKP as the Hbp-SH3 domain binding motif. UBPY 
encodes two copies of this motif located at amino acid position: 405-413 and 699-708. Therefore, it is 
possible that two Hbp molecules could engage one UBPY molecule at the same time. However, the 
topology and stoicheometry of UBPY/Hbp complex as well as the functional relevance of this 
interaction remain undefined. 
Like UBPY, AMSH binds to Hbp through a similar Hbp-SH3 motif. Since both Hrs and Hbp are 
known to be involved in trafficking of internalized ubiquitinated cargo, Kato and colleagues (213) 
implicated UBPY and AMSH in trafficking of receptor tyrosine kinases like the EGFR and PDGFR.  
In line with this hypothesis, McCullough et. al. found that knockdown of AMSH accelerates ligand-
induced EGFR down regulation (185). In addition, Wu et. al. reported that the deubiquitination 
activity of UBPY is essential for stabilization of Nrd1 ubiquitin ligase, which is responsible for 
ubiquitination of ErbB-3 and ErbB-4 (214).  
Collectively, these findings suggest a functional link between the deubiquitination enzymes UBPY 
and AMSH in deubiquitination of internalized ubiquitinated receptor tyrosine kinases. However, the 
functional coupling of UBPY and AMSH to receptor down regulation remains poorly understood due 
to lack of a testable model that can explain their involvement in trafficking of internalized 
ubiquitinated cargo proteins. 
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4) AIM OF THE CURRENT STUDY 
 
It has been shown that blocking the proteasomes with the peptide aldehyde MG132 leads to 
stabilization of the EGFR and downstream signaling molecules like Grb2 and Shc. These findings led 
to hypothesize that both lysosomes and proteasomes are involved in EGFR breakdown. However, the 
role of the proteasomes in EGFR degradation remained unknown (100, 101). To address this issue, 
this work was partly aimed at dissecting the degradation mechanism of the EGFR. As described in 
chapter II, to evaluate the individual contribution of the lysosome and the proteasome in EGFR 
degradation both mechanisms were blocked by specific small drug inhibitors and analyzed for 
ubiquitination and degradation of stimulated EGFRs.  
Based on genetic and biochemical evidence, the vacuolar/lysosomal degradation mechanism of 
membrane-bound receptors is conserved in yeast and animal cells. As mentioned before, 
ubiquitination of cell surface receptors plays a central role in targeting of activated receptors to the 
vacuolar/lysosomal pathway. In yeast cells, deubiquitination of ubiquitinated receptors mediated by 
the deubiquitination enzyme Doa4 is a key step in regulating their entry into the MVB pathway and 
their ultimate degradation. In animal cells however, many receptor tyrosine kinases are known to be 
ubiquitinated following activation, yet the role of deubiquitination enzymes in receptor degradation is 
largely unknown. Therefore and based on the role of Doa4 in receptor deubiquitination in yeast, this 
work tested the role of the mammalian orthologue of Doa4 called UBPY. As shown in chapter III, the 
role of UBPY in the process of EGFR deubiquitination, degradation and downstream signaling was 
analysed. 
Finally, Doa4-dependent deubiquitination of internalized receptors is strongly regulated by additional 
proteins and protein complexes. Therefore, this work also aimed at purifying the endogenous protein 
complex of UBPY in order to gain detailed insight into the molecular function of UBPY in 
mammalian cells. For this goal, the Tandem-Affinity-Purification (TAP-tagging) technique has been 
used. The TAP-tagging method revolutionized proteomics analysis in yeast due to its rapidness and 
cost-effectiveness. The aim of TAP-tagging is to identify specific interacting partners for a protein of 
interest in a specific physiological condition. These properties made TAP-tagging the method of 
choice for systematic genome-wide proteomics analysis in yeast. However, the utilization of TAP-
tagging in mammalian cells has lagged behind its application in yeast due to various technical 
disadvantages (discussed in chapter IV). In this work a novel modification of the TAP-tagging 
technique is presented, which allow efficient and convenient purification of protein complexes in 
animal cells. 
Collectively, data presented in this work uncover a novel regulatory link between deubiquitination 
activity represented by UBPY and the EGFR pathway. 
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ABSTRACT   
 
 Studies on the differential routing of internalized epidermal growth factor receptors (EGFRs) 
induced by EGF, TGFα, and the superagonist EGF-TGFα chimera E4T suggested a correlation 
between receptor recycling and their mitogenic potency. EGFR sorting to lysosomes depends on its 
kinase domain and its ubiquitination by Cbl proteins. Proteasomes have also been proposed to regulate 
EGFR degradation, but the underlying mechanism remains obscure. Here we evaluated EGFR 
activation, Cbl recruitment, EGFR ubiquitination and degradation in response to EGF, TGFα, and 
E4T. We also determined the fate of activated EGFRs and Cbl proteins by using v-ATPase 
(bafilomycin A1) and proteasome (lactacystin) inhibitors. Our results demonstrate that E4T and TGFα 
provoke decreased Cbl recruitment, EGFR ubiquitination and EGFR degradation compared with EGF. 
Furthermore, bafilomycin treatment blocks EGFR but not c-Cbl degradation. In contrast, lactacystin 
treatment blocks EGF-induced c-Cbl degradation but does not block EGFR degradation, even though 
lactacystin causes a minor delay in EGFR degradation. Surprisingly, even though bafilomycin 
completely blocks EGFR degradation, it does not prevent EGFR de-ubiquitination upon prolonged 
EGF stimulation. Strikingly, when combined with bafilomycin, lactacystin treatment stabilizes the 
ubiquitinated EGFR and prevents its de-ubiquitination. We conclude that the enhanced EGFR 
recycling that has been observed in HER-14 cells following TGFα or E4T stimulation correlates with 
decreased EGFR ubiquitination and EGFR degradation, and that proteasomal activity is required for 
de-ubiquitination of the EGFR prior to its lysosomal degradation.  
 
INTRODUCTION   
  
 Polypeptide growth factors play an important role in the regulation of cell division. In various 
types of epithelial carcinomas the overexpression of human transforming growth factor α (TGFα)1 is 
frequently observed. This is often accompanied by overexpression of ErbB receptors (ErbB1 also 
called the EGFR, ErbB2) and has been associated with poor prognosis and poor response to 
chemotherapy (1, 2).  
 EGF and TGFα are highly homologous molecules; both are members of the epidermal growth 
factor family (3) and exert their biological function through binding to the EGFR, a member of the 
ErbB receptor family. Ligand-induced receptor dimerization is a prerequisite for receptor activation, 
which triggers the intrinsic kinase activity resulting in the phosphorylation of several tyrosine residues 
at the C-terminal region of the receptor (4). The phosphorylated tyrosine residues serve as docking 
sites for several SH2 domain-containing proteins thereby conveying the biological signal from outside 
to the inner side of the cell. Multiple protein-protein interaction cascades follow, resulting in the 
activation of MAPK and eventually in cell division. Ligand binding to the EGFR also triggers the 
internalization and subsequent degradation of the activated receptor (4). This process leads to clearing 
of activated receptors from the cell surface thereby desensitizing the cells for mitogenic signals (5–7). 
Recruitment of active receptors to clathrin-coated pits forms the first step in the internalization 
process. Clathrin-coated pits maturate into clathrin-coated vesicles, which subsequently fuse with the 
early endosome. From the early endosome, free EGFRs recycle back to the cell surface, whereas 
ligand-bound receptors undergo receptor kinase-dependent sorting into the internal vesicles of the 
multivesicular bodies (MVBs) (8). The maturation of early endosome to late endosome is 
accompanied by accumulation of EGF-EGFR complexes in the internal vesicles of MVBs (9) resulting 
in sequestration of the cytoplasmic domain, thereby preventing it from interacting with cytoplasmic 
target molecules. Subsequently, the late endosome fuses with pre-existing lysosomes leading to 
lysosomal degradation of ligand-receptor complexes by the lysosomal proteases (10). The pH of the 
lumen of the endocytic compartments decreases along the endocytic route due to the action of the 
vacuolar ATPase. The EGF-EGFR complex is resistant to the mildly acidic pH of early and late 
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endosomes and remains intact along the endocytic route (5). Upon reaching the lysosome, both ligand 
and receptor are degraded by the lysosomal proteases (9, 10).  
 Ligand-induced polyubiquitination of the EGFR (11) is an essential factor in the down-regulation 
of activated EGFRs (12–16). Ubiquitination of cargo proteins requires the ATP-dependent activation 
and covalent binding of the 76 amino acids ubiquitin molecule by the ubiquitin-activating enzyme 
(designated E1), after which ubiquitin is transferred to an E2 ubiquitin-conjugating enzyme. E2 
enzymes ubiquitinate target substrate proteins in concert with either E3 ubiquitin ligase enzymes or 
with E3 RING finger adapter proteins. This results in the covalent attachment of ubiquitin molecules 
to a lysine residue on a substrate protein. This process is often iterated resulting in multiple 
attachments of ubiquitin molecules to either a different lysine residue on a substrate protein or to a 
lysine residue on previously attached ubiquitin (17).  
 Ubiquitination of the EGFR is critically dependent on the activity of Cbl adapter proteins (18, 19). 
Cbl-b and c-Cbl are members of the Cbl adapter family that constitute an important part of the 
ubiquitination machinery. Both undergo tyrosine phosphorylation in response to EGFR activation (20, 
21). Negative regulation of activated EGFRs requires an intact SH2 variant N-terminal region (19), 
through which Cbl interacts with phosphotyrosine 1045 in the C-terminal tail of the EGFR (13) and 
intact linker and RING finger domains to which ubiquitin-conjugating enzymes (E2s) bind (22, 23). 
This dual binding property of Cbl proteins facilitates recruitment of the ubiquitination machinery to 
activated EGFRs, an event that results in polyubiquitination of the EGFRs. Interestingly, Levkowitz et 
al. (12) demonstrated that oncogenic Cbl proteins inhibit down-regulation and enhance recycling of 
internalized EGFRs.  
 In general, polyubiquitin serves as a signal for degradation by the 26S proteasome. Thus, even 
though degradation of activated EGFRs can be mediated by lysosomal proteases (5, 10, 24), it has 
been reported that proteasomes also play an important role in the ligand-induced degradation of 
ubiquitinated EGFRs. Indeed, blocking proteasomal activity with the non-proteasome-specific peptide 
aldehyde MG132 resulted in accumulation of full length EGFR and prevention of receptor degradation 
(16, 25). Therefore, the exact mechanism responsible for the degradation of the EGFR remains 
obscure and in particular the role of the proteasome in the degradation process of the EGFR is an issue 
of debate.  
 Multiple EGFR ligands are known to differ in their mitogenic activity. For example in various 
model systems, TGFα is a more potent mitogen than EGF (26–29). Moreover, several chimeric EGF-
TGFα growth factors that were generated in our department, show superagonist activity in both 32D1 
and HER-14 model systems and are able to induce similar mitogenic responses as EGF but at 10-fold 
lower concentrations (29, 30). One such superagonist ligand is E4T, in which EGF sequences after the 
fourth cysteine of the EGF module have been replaced by the corresponding residues of TGFα. In 
addition, similar to TGFα, EGFR binding capacity of these superagonists was found to be more 
sensitive to low pH compared with EGF (30). Consequently, TGFα and the superagonists might 
dissociate earlier in the endosomal system than EGF leading to enhanced recycling of the EGFR. 
Indeed, while EGFR internalization kinetics are similar in response to EGF, TGFα, or E4T (29, 30), 
recycling assays suggested a correlation between superagonist-induced receptor recycling and 
enhanced mitogenic activity in both HER-14 (30) and 32D1 (29) model systems. In addition, 
superagonist ligands, including E4T, show enhanced on/off rates as measured by Biacore experiments 
(31) as well as decreased ligand depletion from the medium (29).  
 To study the enhanced receptor recycling induced by TGFα and EGF/TGFα chimeric superagonist 
ligands we hypothesized that Cbl proteins are inefficiently "coupled" to these growth factors. In the 
present study the functional coupling of Cbl adapter proteins to EGF, TGFα and superagonist ligand 
E4T was investigated. The degradation process of the EGFR was further analyzed by studying the 
differential effects of lysosomal and proteasomal inhibitors on the degradation of the EGFR. We have 
found that the lysosomal degradation of the EGFR is preceded by its de-ubiquitination.  
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EXPERIMENTAL PROCEDURES   
  
 Cell Culture—NIH 3T3 cells stably transfected with human EGFR (HER-14) (32) were used 
throughout this study. Cells were cultured on flasks coated with 0.1% gelatin and grown at 37 °C in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum. Cells 
were trypsinized when confluent and seeded in flasks for regular maintenance.  
 Antibodies and Materials—anti-c-Cbl (clone R2) was a generous gift from W. Langdon. Anti-c-
Cbl (clone C15), anti-Cbl-b (clone H121), and anti-EGFR antibodies (mAb 528 and polyclonal 
antibody 1005) were obtained from Santa Cruz Biotechnology. Anti-phosphotyrosine (4G10) and anti-
EGFR mAb LA22 were obtained from Upstate Biotechnology, and anti-ubiquitin antibody from 
Sigma (pr. no. U5379). Anti-EGFR (clone13), as well as goat anti-rabbit (GARPO) and goat anti-
mouse (GAMPO) antibodies linked to horseradish peroxidase were purchased from Signal 
Transduction Laboratories. Anti-EGFR antibody Ab12 was obtained from Neomarkers. Recombinant 
growth factors were produced and quantified as previously described (30). Sepharose beads coupled to 
protein A were obtained from Amersham Biosciences. Bafilomycin A1 and lactacystin were obtained 
from Calbiochem.  
 Cell Stimulation and Pretreatment with Inhibitors—Near confluent HER-14 cells were first 
washed twice with phosphate-buffered saline and incubated with serum-free medium for 24 h. Growth 
factors were then resuspended in DMEM containing 50 mM BES (N,N-bis-(2-hydroxyethyl)-2-
aminoethanesulfonic acid), pH 6.8. Then, growth factors were added to a final concentration of 100 
ng/ml. Lactacystin and bafilomycin A1 were dissolved in Me2SO and further diluted in serum-free 
DMEM (final concentration of lactacystin is 10 µM and bafilomycin is 0.25 µM) and added to cells 
one hour prior to stimulation.  
 Cell Lysis—Cells were washed twice with ice-cold PBS and adherent cells were lysed during a 20-
min incubation at 4 °C in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% Brij97, 5 mM EDTA 
pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml 
aprotinin, 1 µg/ml pepstatin). The lysis buffer did not contain inhibitors of de-ubiquitinating enzymes. 
Cell lysates were subsequently transferred to Eppendorf tubes and centrifuged for 10 min at 4 °C at 
1.104 x g in an Eppendorf centrifuge to remove nuclei and cell debris. Samples were prepared for 
SDS-PAGE analysis by adding Laemmli sample buffer to cleared whole cell lysates and then heated 
for 5 min at 95 °C prior to loading SDS-PAGE gels under reducing conditions.  
 Immunoprecipitation, Recapture, and Immunoblotting—Anti-c-Cbl clone C15 or anti-c-Cbl R2 
antiserum were used to immunoprecipitate c-Cbl protein. Anti-EGFR clone 528 was used throughout 
this study to immunoprecipitate EGFR. Antibodies used in the immunoprecipitation were first coupled 
to protein A-Sepharose beads for 30–60 min at 4 °C. Cleared cell lysates were then added to the 
antibody-absorbed beads and incubated for at least 2 h at 4 °C. Unbound cellular proteins were then 
removed by washing 3 times with ice-cold lysis buffer and once with ice-cold phosphate-buffered 
saline. Immunocomplexes were then resuspended in 2x Laemmli sample buffer. Samples were heated 
for 5 min at 95 °C and kept at –20 °C or loaded directly onto 8% SDS-PAGE gels. Immunocomplexes 
separated by SDS-PAGE were transferred to nitrocellulose filters. Blots were first blocked with 5% 
bovine serum albumin, except for ubiquitin blots, which were blocked with 5% milk in TBST (Tris-
buffered saline-Tween). After incubation with primary antibody, filters were washed in TBST, 
incubated with appropriate HRP-linked secondary antibodies, and washed again with TBST prior to 
visualization of proteins with enhanced chemiluminescence. For recapture experiments, primary anti-
EGFR (clone 528) precipitates were split in two equal parts during the phosphate-buffered saline 
wash, of which one part was processed as detailed above. 50 µl of 1% SDS was added to the other part 
of the primary immunoprecipitate and subsequently incubated for 5 min at 95 °C to denature all 
proteins in the immunoprecipitate. After boiling, samples were allowed to cool to room temperature 
and 950 µl of lysis buffer was added to dilute the SDS, after which samples were centrifuged briefly. 
The resulting supernatants were transferred to beads coated with 2 µg of anti-EGFR recapture 
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antibodies (LA22 or clone13) for 16 h at 4 °C. Samples were washed and prepared for SDS-PAGE as 
described above. Image analysis was performed using the NIH-Image software program available 
from rsb.info.nih.gov/nih-image. Briefly, signals of interest were overlaid by a defined rectangle and 
the mean pixel value (MPV) of these boxed areas was calculated. In addition, the background MPV 
values was determined in areas not containing any specific signal. The background MPV value was 
then subtracted from experimental (including experimental control) MPV values. The resulting values 
were then normalized relative to the appropriate and similarly calculated control bands, or they were 
expressed as a percentage of time 0, and plotted as shown in the figures. All experiments shown are 
representative of at least two, and mostly three or more independent experiments (data not shown).  
 
RESULTS   
  
 Inefficient EGFR Ubiquitination following Superagonist Stimulation—Although EGF, TGFα, and 
the superagonist E4T induce similar initial EGFR kinase activation and EGFR internalization, TGFα 
and E4T differ markedly from EGF in their mitogenic potency (29–31). Moreover, E4T requires 10-
fold lower concentration to induce similar MAPK and mitogenic signaling as EGF and TGFα (29–31). 
However, the kinetics of EGFR activation in response to these growth factors has not been studied in 
detail. To investigate this issue, HER-14 cells were serum-starved and treated with saturating 
concentrations of EGF, TGFα, or E4T for various periods of time followed by evaluation of the 
tyrosine phosphorylation status of the EGFR. As seen in Fig. 1A (and data not shown), the tyrosine 
phosphorylation of the 180-kDa species of the EGFR is comparable for all growth factors, consistent 
with the use of saturating ligand concentrations which lead to similar cell surface receptor occupancy 
levels. In addition, Fig. 1, A and B show that in response to EGF stimulation the anti-phosphotyrosine 
antibody immunoreacted with high molecular weight species of the EGFR, represented by the smear 
above the 180-kDa band. The high molecular weight smear is markedly decreased in TGFα- and E4T-
treated cells compared with EGF. This decrease is already visible after 5 min of EGFR activation (see 
Fig. 1B) and becomes more prominent after 15 min of receptor stimulation. 
 It is well established that ligand-dependent EGFR activation induces receptor polyubiquitination 
(12), which leads to a variable increase in the molecular weight of the EGFR according to the number 
of ubiquitin molecules that are covalently attached to the receptor. This influences the electrophoretic 
mobility of ubiquitinated EGFR on a SDS-PAGE gel and as a result ubiquitinated EGFRs appear as a 
smear above the 180-kDa positions that corresponds with the non-ubiquitinated EGFR. To determine 
whether the phosphorylated high molecular weight smear corresponds with polyubiquitinated species 
of the EGFR, HER-14 cells were stimulated with EGF, TGFα, and E4T for the indicated period of 
time. The EGFR was immunoprecipitated and immunoblotting was performed with anti-ubiquitin 
antibody. As shown in Fig. 1C and quantitatively evaluated in Fig. 1D all growth factors induced 
receptor ubiquitination. However, there is a marked difference in the kinetics of EGFR ubiquitination. 
EGF induced peak EGFR ubiquitination at 15-min post-receptor activation, whereas TGFα and E4T 
induced peak receptor ubiquitination at 5 min, when a large fraction of stimulated EGFRs is already 
internalized, as previously demonstrated (30). Furthermore, and in contrast to the prolonged presence 
of the tyrosine phosphorylated 180-kDa EGFR species (Fig. 1A), the ubiquitinated EGFR rapidly 
declined upon prolonged stimulation.  
 As it is formally possible that the ubiquitinated proteins observed in anti-EGFR (528) 
immunoprecipitates are derived from proteins that coprecipitate with the EGFR, we further denatured 
primary anti-EGFR immunoprecipitates by boiling in 1% SDS. Denatured proteins that were released 
into the supernatant were then used for recapture experiments with anti-EGFR (LA22 and clone 13) 
antibodies that recognize EGFR proteins under denaturing conditions (e.g. during immunoblotting). 
The anti-EGFR mAb 528 cannot be used for recapture experiments (data not shown) as it recognizes a 
conformational epitope in the extracellular domain of the EGFR that is destroyed upon denaturation. 
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Figure 1. Inefficient EGFR ubiquitination following superagonist stimulation.  
A and B, HER-14 cells were starved 24 h prior to stimulation with 100 ng/ml EGF, TGFα, and E4T for the 
indicated periods. Cells were kept at 37 °C during the experiment. Cells were then lysed and whole cell lysates 
were subjected to immunoprecipitation with monoclonal anti-EGFR (528) antibody. The recovered 
immunocomplexes were then separated by SDS-PAGE and immunoblotted with monoclonal anti-
phosphotyrosine antibody (A and B). Subsequently, sequential immunoblot was performed with polyclonal anti-
EGFR (1005) antibody (lower panel). The autoradiograph in B is overexposed to visualize the tyrosine-
phosphorylated high molecular weight species of the EGFR. C, HER-14 cells were starved for 24 h prior to 
stimulation with 100 ng/ml EGF, TGFα, and E4T for the indicated time intervals. After stimulation, cells were 
lysed on ice and cleared whole cell lysates were subjected to immunoprecipitation against the EGFR followed by 
immunoblotting with anti-ubiquitin antibody. The blot was then stripped and immunoblotted with anti-EGFR 
(1005) antibody (lower panel). D, graph resulting from densitometric scanning of the ubiquitin signal (in MPV) 
relative to the EGFR signal (in MPV) as shown in C in response to EGF (solid line, diamonds), TGFα (dashed 
line, squares), and E4T (dotted line, triangles). E, primary (1st) anti-EGFR (528) immunoprecipitates from 
unstimulated HER-14 cells (–) or cells stimulated with EGF for 15 min (+) were denatured by boiling in 1% 
SDS and used for recapture experiments with secondary (2nd) anti-EGFR mAbs (either clone13 or LA22), as 
detailed in materials and methods. Immunoprecipitates were separated by SDS-PAGE, transferred to 
nitrocellulose and immunoblotted with anti-ubiquitin antibodies (upper panel) and, subsequently, reprobed with 
anti-EGFR (Ab12) antibodies (lower panel). 
   
As illustrated in Fig. 1E, after stimulation of HER-14 cells with EGF, ubiquitinated species were still 
observed in anti-EGFR recapture experiments of denatured primary anti-EGFR immunoprecipitates, 
demonstrating that the >180 kDa ubiquitinated proteins indeed represent ubiquitinated EGFRs, 
consistent with earlier studies (11). It is important to note that the decreased ubiquitin signal observed 
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in the secondary recapture (LA22 or c13) immunoprecipitates relative to the primary anti-EGFR (528) 
immunoprecipitates (Fig. 1E, upper panel) correlates with a decreased 180-kDa EGFR signal (Fig. 1E, 
lower panel), indicating that recapture of the EGFR is not quantitative. As excess amounts of antibody 
were used during the recapture (data not shown), we suggest that inefficient recapture of the denatured 
EGFR is due to poor recognition of the denatured EGFR by these antibodies. It is also noteworthy 
that, although Eps15 and Cbl can associate with the EGFR, the ubiquitinated species of these proteins 
run well below the 180-kDa mark, indicating that it is highly unlikely that ubiquitinated forms of these 
proteins contribute significantly to the observed ubiquitin signal in EGFR precipitates.  
 The data presented in Fig. 1 suggest that although EGF, TGFα, and E4T do not differ in the 
phosphorylation of the 180-kDa species of the EGFR, they differ markedly in inducing 
phosphorylation of the high molecular weight smear of the EGFR. The data also demonstrate that the 
superagonist E4T and TGFα induce markedly decreased EGFR polyubiquitination compared with 
EGF. These findings are consistent with the model that TGFα and E4T rapidly dissociate from 
internalized EGFRs due to acidification of endosomal vesicles, leading to a very transient EGFR 
ubiquitination, whereas EGF, which remains bound to the EGFR along the endocytic route, leads to 
more prolonged and enhanced EGFR ubiquitination.  
 
 E4T and TGFα Induce Diminished Cbl Recruitment to Activated EGFR—Efficient ubiquitination 
of the EGFR requires the recruitment of Cbl adapter proteins to phosphorylated tyrosine 1045 in the 
C-terminal tail of the EGFRs (13) and Cbl interaction with E2 ubiquitin-conjugating enzymes (22, 23). 
To demonstrate EGFR/Cbl interaction in HER-14 cell system, cells were treated with EGF for 5 min 
or left untreated. Fig. 2A shows that the addition of EGF resulted in co-precipitation of c-Cbl with the 
EGFR. To demonstrate Cbl-b interaction with activated EGFR, HER-14 cells were stimulated with 
EGF or left unstimulated. Fig. 2A shows that the EGFR coprecipitates with Cbl-b and with c-Cbl only 
in EGF-stimulated cells. Since TGFα and E4T induced decreased EGFR ubiquitination compared with 
EGF, we argued that this might be a direct result of poor recruitment of Cbl adapter proteins to TGFα- 
and E4T-stimulated EGFRs. In order to test this hypothesis, HER-14 cells were stimulated with either 
EGF, TGFα or E4T for the indicated period of time, followed by immunoprecipitation of c-Cbl 
proteins and subsequently immunoblotted with anti-phosphotyrosine antibody. Fig. 2B shows that in 
unstimulated cells no tyrosine phosphorylated EGFRs coprecipitate with c-Cbl proteins. However, 
addition of EGF, TGFα, and E4T resulted in ligand-dependent co-precipitation of tyrosine-
phosphorylated 180-kDa protein, which corresponds with activated EGFR. Interestingly, as shown in 
Fig. 2B and quantified in Fig. 2C, TGFα and E4T were less efficient in inducing EGFR-c-Cbl complex 
formation because stimulation with TGFα and, in particular, E4T resulted in reduced co-precipitation 
of activated EGFR compared with EGF, especially upon prolonged (more than 5 min) incubation. This 
despite the fact that EGF, TGFα, and E4T are comparable with respect to tyrosine phosphorylation of 
the 180-kDa EGFR band (Fig. 1). Similar results were obtained for Cbl-b (data not shown). As seen 
for the 180-kDa tyrosine-phosphorylated EGFR, no significant difference in the phosphorylation of 
the 120-kDa Cbl protein was observed between EGF, TGFα, or E4T. The data presented in Fig. 2 
indicate that Cbl adapter proteins interact with the activated EGFR in response to EGF, TGFα, and 
E4T and that these ligands induce similar levels of tyrosine phosphorylation of Cbl adapter proteins. In 
addition, the data also show that Cbl recruitment to the activated EGFR is less efficient in TGFα and, 
in particular, E4T-stimulated cells compared with EGF, which correlates with decreased EGFR 
ubiquitination levels induced by these growth factors.  
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Figure 2. E4T and TGFα induce diminished Cbl recruitment to activated EGFR. A, HER-14 cells were starved 
overnight prior to stimulation with 100 ng/ml EGF for 5 min at 37 °C, or they were left unstimulated. 
Subsequently, immunoprecipitation against the EGFR was performed followed by immunoblotting with anti-c-
Cbl antibody (left panel). Whole cell lysates prepared on ice were used to immunoprecipitate c-Cbl or Cbl-b. 
Subsequently, the immunocomplexes were separated by SDS-PAGE and immunoblotted with anti-EGFR (1005) 
antibody (right panel). B, starved HER-14 cells were stimulated with 100 ng/ml EGF, TGFα, or E4T at 37 °C for 
the indicated time intervals or left unstimulated. Subsequently, c-Cbl proteins were immunoprecipitated and 
immunoblotted with anti-phosphotyrosine antibody. The same blot was then re-probed with anti-c-Cbl antibody 
(lower panel). C, graph resulting from densitometric scanning of the phospho-EGFR signal (in MPV) relative to 
the c-Cbl signal (in MPV) as shown in Fig. 1B in response to EGF (solid line, diamonds), TGFα (dashed line, 
squares), and E4T (dotted line, triangles). 
  
 E4T and TGFα Provoke Decreased EGFR Degradation—It has been shown that TGFα and E4T 
binding to the EGFR is more susceptible to the low pH environment of the endosomal system when 
compared with EGF (30). Consistently, at saturating concentrations, E4T and TGFα promote enhanced 
receptor recycling compared with EGF, which can be blocked by the carboxylic ionophore monensin 
(30). Because E4T and TGFα stimulation resulted in decreased receptor ubiquitination and Cbl 
recruitment when compared with EGF (see Figs. 1 and 2), the possibility arises that TGFα and E4T 
might provoke lower rates of receptor degradation. To determine the kinetics of EGFR degradation 
induced by EGF, TGFα, and E4T, the expression level of EGFR in HER-14 cells was analyzed after 
stimulation with these growth factors for the indicated period of time (Fig. 3). EGF stimulation for 5 h 
resulted in significant loss of the EGFR compared with unstimulated cells. The decline in the intensity 
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of the 180-kDa band was paralleled by the appearance of antibody-reactive low molecular weight 
fragments at 3- and 5-h post-EGF treatment, which likely represent intermediate proteolytic EGFR 
products. In contrast, TGFα and E4T provoked low rates of receptor turnover at the same time points 
as EGF (shown in Fig. 3A and quantified in Fig. 3B), and intermediate proteolytic products were 
hardly seen (Fig. 3A). These findings demonstrate that decreased EGFR ubiquitination (Fig. 1), and 
decreased Cbl recruitment (Fig. 2) in response to TGFα and E4T is associated with decreased EGFR 
degradation, when compared with EGF. These results are also in accordance with our previous studies 
that TGFα and E4T induce enhanced EGFR recycling compared with EGF, which efficiently targets 
the EGFR for degradation (30).  
  
 
  
Figure 3. E4T and TGFα provoke decreased EGFR degradation compared with EGF. A, HER-14 cells were 
starved overnight prior to stimulation with 100 ng/ml EGF, TGFα, or E4T at 37 °C for the indicated time 
intervals or they were left unstimulated. Whole cell lysates were prepared on ice followed by separation of 
cellular proteins by SDS-PAGE and immunoblotting with anti-EGFR (1005) antibody (upper panel). The same 
blot was stripped and reprobed against an irrelevant protein as a loading control (lower panel). B, graph resulting 
from densitometric scanning of the 180 kDa EGFR signal (in MPV) relative to a loading control (in MPV) as 
shown in A. The value obtained at time = 0 was taken as 100%. 
  
 Proteasome Inhibitor Lactacystin Fails to Block EGFR Degradation—Several studies have 
demonstrated that degradation of the EGFR is mediated by lysosomal proteases (5, 10, 24). However, 
accumulating evidence indicates that the degradation of the EGFR can be blocked by the proteasome 
inhibitor MG132 (16, 25), (data not shown). However, MG132 is not a specific inhibitor of 
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proteasomal proteases. Thus, the involvement of proteasomes in EGFR degradation is still an issue of 
debate. To investigate this issue, bafilomycin A1 and lactacystin were used as lysosomal and 
proteasomal inhibitors respectively. Bafilomycin A1 is a specific inhibitor of the proton pomp V-type 
ATPase, which prevents the acidification of the endosomal compartments required for the maturation 
of lysosomal proteases. In addition, bafilomycin treatment entraps internalized surface molecules in 
late endosome MVBs, which precludes their transport to the lysosome, but it does not interfere with 
the localization of these molecules to early endosomes or late MVBs (33, 34). In contrast to MG132, 
lactacystin is a specific inhibitor of mammalian proteasomes (35, 36). As a result of lactacystin 
treatment, chymotrypsin-like, trypsin-like, and caspase-like peptidase activities are inhibited.  
 To study the mechanism of EGFR degradation, HER-14 cells were pre-treated with lactacystin or 
bafilomycin prior to stimulation with either EGF, TGFα or E4T for 6 h. The level of EGFR expression 
was analyzed by Western blotting. As seen in Fig. 4A, EGF stimulation in the absence of any inhibitor 
resulted in the degradation of the EGFR as expected. When lactacystin was added to the cells, a 
relatively small stabilizing effect on the EGFR was observed relative to unstimulated control cells 
(compare 2nd and 6th lanes). Increasing the concentration of lactacystin in the medium up to four times 
had no additional effects on the protection of full length EGFR (data not shown). Lactacystin 
treatment was effective, however, as it resulted in markedly increased accumulation of ubiquitinated 
cellular proteins (Fig. 4B), indicating that lactacystin treatment did interfere with proteasomal activity 
in HER-14 cells. In contrast to lactacystin, bafilomycin treatment prevented the degradation of the 
EGFR completely (compare lanes 2 and 4). Consistent with Fig. 3, EGFR degradation in response to 
either TGFα or E4T in the absence of any inhibitor was markedly reduced compared with EGF (Fig. 
4A). Lactacystin treatment of TGFα and E4T-stimulated cells resulted in a relatively limited 
accumulation of full-length EGFR, when compared with EGF. In contrast to lactacystin, bafilomycin 
efficiently protected full-length EGFR in TGFα and E4T-stimulated cells (compare lanes 2 and 4). As 
the kinetics of EGFR degradation is somewhat delayed in the presence of lactacystin, these data 
indicate that proteasome activity may facilitate EGFR degradation, but clearly demonstrate that 
proteasome activity is not required for EGFR degradation.  
 
 Lactacystin Blocks Ligand-induced c-Cbl Degradation—It has been reported that Cbl adapter 
proteins undergo ligand-dependent ubiquitination and subsequent degradation, which can be blocked 
by lactacystin or MG132 (16). However, on the basis of electron microscopic co-localization studies, 
it has also been suggested that c-Cbl proteins remain associated with the EGFR in internal vesicles of 
MVBs (37). To determine the kinetics and underlying mechanism of c-Cbl degradation in response to 
EGF treatment, HER-14 cells were treated with EGF for various time intervals and the level of c-Cbl 
expression was analyzed by means of immunoblotting with a polyclonal anti-c-Cbl antibody. As seen 
in Fig. 5A (middle panel), the addition of EGF resulted in a gradual decrease in the tyrosine 
phosphorylation of c-Cbl protein, which was paralleled by decrease of the immunoprecipitated c-Cbl 
(upper panel) (see also Fig. 2). The decrease in the c-Cbl expression level was also observed in total 
cell lysates (Fig. 5A, lower panel). Cbl expression levels remained low for 1–2 h of EGF stimulation, 
after which Cbl expression levels gradually recovered after 5 h when Cbl expression levels reach base 
line levels and nearly all EGFRs are degraded (Fig. 5B). To determine the mechanism responsible for 
c-Cbl degradation, HER-14 cells were pretreated with lactacystin or bafilomycin, followed by 
stimulation with EGF for various times. Fig. 5C shows that bafilomycin treatment has no effect on the 
degradation of c-Cbl. In contrast, when lactacystin was added to the cells, full-length c-Cbl was 
completely protected from degradation. In addition, lactacystin treatment markedly stabilized the 120-
kDa phosphorylated species of c-Cbl protein up to 4 h of EGF stimulation (Fig. 5D), whereas in 
bafilomycin-treated cells Cbl phosphorylation was comparable to mock-treated (Me2SO-treated) cells. 
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Figure 4. Proteasome inhibitor lactacystin fails to block EGFR degradation. A, HER-14 cells were starved 
overnight followed by pretreatment for 1 h with either Me2SO, 0.25 µM bafilomycin A1, or 10 µM lactacystin. 
Subsequently, cells were either left unstimulated or stimulated for 6 h at 37 °C with 100 ng/ml EGF (upper 
panel), TGFα (middle panel), and E4T (lower panel). Whole cell lysates were prepared on ice and cleared by 
centrifugation. Samples were run on SDS-PAGE and cellular proteins were transferred to nitrocellulose filter 
followed by immunoblotting with anti-EGFR (1005) antibody. B, postnuclear fractions taken from EGF 
stimulated cells were also immunoblotted with anti-ubiquitin antibody. 
  
Surprisingly, lactacystin treatment also resulted in transient stabilization of the c-Cbl-EGFR complex 
compared with lactacystin-free cells (Fig. 5D). As lactacystin treatment does not block EGFR 
degradation (Fig. 4), the enhanced c-Cbl-EGFR co-precipitation seen is most likely due to lactacystin 
induced c-Cbl stabilization. Indeed, the tyrosine-phosphorylated 180-kDa EGFR band eventually 
disappeared from c-Cbl immunoprecipitates, consistent with the inability of lactacystin to prevent 
EGFR degradation. Even though bafilomycin treatment protects the EGFR from degradation, it does 
not lead to enhanced co-precipitation of the EGFR in Cbl immunoprecipitates, most likely because it 
does not protect c-Cbl from degradation. Indeed, when cells are treated with lactacystin and 
bafilomycin, co-precipitation of the phosphorylated EGFR with Cbl is enhanced related to either 
treatment alone, especially at 4 h, when significant EGFR degradation occurs. Even in the presence of 
bafilomycin alone or bafilomycin with lactacystin, phosphorylation of c-Cbl and EGFR is decreased at 
4 h, relative to 1 h, which may be due to dephosphorylation. These data demonstrate that c-Cbl adapter 
proteins undergo ligand-induced degradation that is dependent on proteasomal but not v-ATPase 
activity.  
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Figure 5. Lactacystin blocks ligand dependent c-Cbl degradation. A, HER-14 cells were starved overnight prior 
to stimulation with 100 ng/ml EGF at 37 °C. Whole cell lysates were prepared on ice and subjected to 
immunoprecipitation against the endogenous c-Cbl protein. Immunocomplexes were then separated by SDS-
PAGE followed by immunoblotting with anti-c-Cbl antibody (upper panel), or with anti-phosphotyrosine 
antibody (middle panel). Samples taken from the postnuclear fractions were immunoblotted with anti-c-Cbl 
antibody (lower panel). B, HER-14 cells were starved overnight and subsequently stimulated with 100 ng/ml 
EGF for the indicated period of time. Cells were lysed on ice and postnuclear fractions were loaded on 8% SDS-
PAGE gel. Cellular proteins were then transferred to nitrocellulose filter followed by immunoblotting with anti-
c-Cbl antibody. C, HER-14 cells were starved overnight followed by either treatment with 10 µM lactacystin or 
with 0.25 µM bafilomycin A1 prior to stimulation with 100 ng/ml EGF at 37 °C. Whole cell lysates were 
prepared on ice and the expression of c-Cbl was visualized by immunoblotting with anti-c-Cbl antibody. D, 
HER-14 cells were starved overnight and pretreated with Me2SO, 10 µM lactacystin, or 0.25 µM bafilomycin for 
1 h prior to stimulation with 100 ng/ml EGF. Cleared whole cell lysates were subjected to immunoprecipitation 
against c-Cbl protein with anti-c-Cbl antibody and the recovered immunocomplexes were separated by SDS-
PAGE followed by immunoblotting with antiphosphotyrosine antibody (upper panel). The same blot was then 
re-probed with anti-c-Cbl antibody (lower panel). 
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 Bafilomycin A1 Fails to Protect the Ubiquitinated EGFR from De-ubiquitination—Having 
determined the effect of lactacystin and bafilomycin on EGFR and Cbl expression levels, we next 
evaluated the effect of these inhibitors on ligand-induced EGFR post-translational modifications 
including tyrosine phosphorylation and ubiquitination. For this purpose, HER-14 cells were treated 
with lactacystin or left untreated prior to stimulation with EGF. The EGFR was then 
immunoprecipitated and, subsequently, immunoblotting was performed with anti-phosphotyrosine 
antibody. Fig. 6A (top panel) shows that lactacystin induces limited accumulation of the 180-kDa 
tyrosine-phosphorylated EGFR when compared with lactacystin-free cells, reminiscent of the effect of 
lactacystin treatment on EGFR expression levels (Fig. 6A, lower panel). Indeed, lactacystin treatment 
did not prevent the appearance of EGFR degradation products (Fig. 6A, middle panel). Next, the effect 
of bafilomycin treatment on the level of the tyrosine phosphorylated EGFR was studied by incubating 
HER-14 cells with bafilomycin prior to stimulation with EGF. As seen in Fig. 6B (top panel), in the 
absence of bafilomycin the level of tyrosine-phosphorylated EGFR returned to the initial level after 4 
h of stimulation with EGF, which is accompanied by the appearance of intermediate EGFR 
degradative products (Fig. 6B, middle panel) and decreased EGFR expression levels in total cell 
lysates (Fig. 6B, lower panel). In contrast, the addition of bafilomycin resulted in marked stabilization 
of the tyrosine phosphorylation of the 180-kDa species of the EGFR up to 4 h of EGF stimulation 
when compared with bafilomycin-free cells (Fig. 6B, top panel). We also noticed a more intense anti-
phosphotyrosine staining of the high molecular weight smear in the EGFR immunoprecipitates. 
Nevertheless, even in bafilomycin-treated cells the EGFR phosphotyrosine content decreased slowly, 
suggesting that the EGFR is, at least in part, dephosphorylated by tyrosine phosphatases prior to its 
lysosomal degradation. Interestingly, during the early stages of EGFR activation, the apparent 
expression level of the 180-kDa EGFR band in whole cell lysates decreased similarly in both 
bafilomycin-treated and bafilomycin-free cells (Fig. 6B, lower panel). However, the apparent 
expression level of the EGFR recovered gradually in bafilomycin-treated cells but not in control cells. 
In theory, the decrease in the 180-kDa band of the EGFR during initial stages of receptor activation 
could be due to either degradation or ubiquitination. Because bafilomycin completely blocks the 
degradation of the EGFR we conclude that the transient decrease in the 180-kDa band is not due to 
receptor degradation, but to polyubiquitination, which shifts the EGFR to high molecular weight 
positions on the blot.  
 To directly assess the effect of lactacystin and bafilomycin on EGFR ubiquitination, HER-14 cells 
were preincubated with either Me2SO, lactacystin, or bafilomycin prior to stimulation with EGF. The 
EGFR was then immunoprecipitated and the ubiquitinated species were visualized by immunoblotting 
with polyclonal anti-ubiquitin antibody. Fig. 6C shows that in the absence of lactacystin, the 
ubiquitinated species of the EGFR have disappeared after 4 h of stimulation. This decrease in the 
ubiquitination coincides with EGFR degradation (lower panel). When HER-14 cells were pre-
incubated with lactacystin, a transient stabilization of the ubiquitinated EGFR was observed (top 
panel). The decline in the ubiquitination of the EGFR in the presence of lactacystin is ultimately 
associated with EGFR degradation (lower panel). Next, the effect of bafilomycin treatment was 
analyzed by performing the same experiment as described above, except that bafilomycin was used 
instead of lactacystin. As shown in Fig. 6D, without bafilomycin, the level of the ubiquitinated species 
of the EGFR declined after 15 min of stimulation and reached its minimum after 4 h. This is paralleled 
by EGFR degradation, as seen in whole cell lysates (data not shown). In contrast to lactacystin, 
bafilomycin treatment resulted in marked accumulation and prolonged ubiquitination of the EGFR 
(Fig. 6D). Surprisingly, and in sharp contrast to the effect of bafilomycin on EGFR expression levels, 
accumulation of the ubiquitinated EGFR in the presence of bafilomycin was not sustained, but 
transient. As bafilomycin treatment completely blocks EGFR degradation we conclude that the 
 50
gradual disappearance of ubiquitinated EGFRs observed upon prolonged EGF stimulation of 
bafilomycin-treated cells is due to de-ubiquitination of the EGFR. The EGFR deubiquitination in 
bafilomycin-treated cells is accompanied by a molecular weight decrease that leads to the 
reappearance of the 180-kDa EGFR at levels found in unstimulated total cell lysates (Fig. 6B, lower 
panel).  
 
 
Figure 6. Bafilomycin A1 fails to protect the ubiquitinated EGFR from de-ubiquitination. A, HER-14 cells were 
starved overnight followed by Me2SO or 10 µM lactacystin treatment for 1 h prior to stimulation with 100 ng/ml 
EGF at 37 °C for the indicated time intervals. Whole cell lysates were then subjected to immunoprecipitation 
against the EGFR and immunoblotted with anti-phosphotyrosine antibody (upper panel). The same blot was then 
re-probed with anti-EGFR (1005) antibody (middle panel); whole cell lysates were immunoblotted with anti-
EGFR (1005) antibody (lower panel). B, the same experimental setting was used except that cells were treated 
with 0.25 µM bafilomycin instead of lactacystin. It is important to note that the sequential blot of the IPs (middle 
panel) was deliberately overexposed to show the degradation products of the EGFR in Me2SO-treated cells, 
whereas the WCL blot (lower panel) was deliberately underexposed to show the reappearance of the 180-kDa 
band of the EGFR in bafilomycin-treated cells due to the deubiquitination activity. C and D, experiments were 
performed as mentioned in A and B except that the blots were immunoblotted with anti-ubiquitin antibody. 
  
 Inhibition of EGFR De-ubiquitination by Simultaneous Bafilomycin and Lactacystin Treatment—
Proteasome inhibitors lead to the accumulation of ubiquitinated cellular proteins (see also Fig. 4B). 
This well known finding suggests a functional coupling between proteasomal activity and de-
ubiquitination of substrate proteins. Indeed, de-ubiquitination enzymes are known to associate with the 
regulatory subunit of the 26S proteasome (38). Under conditions of lactacystin treatment, 
ubiquitinated cargo proteins may remain bound to the 19S regulatory complex and clog up the de-
ubiquitination and proteasomal degradation pathway. To investigate the dependence of EGFR de-
ubiquitination on proteasomal activity, HER-14 cells were pretreated with either Me2SO, lactacystin, 
bafilomycin, or lactacystin plus bafilomycin prior to stimulation with EGF. The EGFR was then 
immunoprecipitated and immunoblotting was performed with anti-ubiquitin antibody. As seen in Fig. 
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7, lactacystin had little effect on the ubiquitinated status of the EGFR at 1 and 4 h of stimulation when 
compared with Me2SO-treated cells. Similar to previous results, bafilomycin treatment resulted in 
marked accumulation of ubiquitinated EGFRs when compared with Me2SO and lactacystin-treated 
cells. Strikingly, pretreatment with bafilomycin plus lactacystin resulted in almost complete inhibition 
of the decline in the level of ubiquitinated EGFR demonstrating that inhibition of proteasome activity 
blocked EGFR de-ubiquitination in bafilomycin-treated cells. Thus, we conclude that proteasome 
activity is required for de-ubiquitination of the EGFR prior to its degradation in the lysosomes. 
However, as the specific proteasome inhibitor lactacystin does not block EGFR degradation, we 
further conclude that EGFR de-ubiquitination is not required for EGFR degradation.  
 
 
 
Figure 7. Inhibition of EGFR de-ubiquitination by simultaneous bafilomycin and lactacystin treatment.  
HER-14 cells were starved overnight followed by pre-treatment with either Me2SO, 10 µM lactacystin, 0.25 µM 
bafilomycin A1, or with 10 µM lactacystin plus 0.25 µM bafilomycin A1 for 1 h. Following stimulation with 
100 ng/ml EGF for either 1 or 4 h, cells were lysed on ice and whole cell lysates were subjected to 
immunoprecipitation against the EGFR followed by immunoblotting with anti-ubiquitin antibody (upper panel). 
The same blot was then stripped and re-probed with anti-EGFR (1005) antibody (middle panel). Post-nuclear 
fractions (WCLs) were immunoblotted with anti EGFR (1005) antibody (lower panel). 
 
DISCUSSION   
 
The results presented here show that TGFα and the superagonist ligand E4T are poorly coupled to Cbl-
mediated EGFR ubiquitination because (i) E4T and, to a lesser extent, TGFα, induce decreased co-
precipitation of the tyrosine phosphorylated EGFR with Cbl when compared with EGF, (ii) E4T, and 
to a lesser extent, TGFα, induce weak EGFR ubiquitination when compared with EGF, and (iii) E4T 
and TGFα, induce a slow rate of EGFR turnover. As E4T and TGFα are known to enhance EGFR 
recycling in NIH3T3 cells overexpressing the EGFR (30), these findings are consistent with the model 
that Cbl recruitment to and subsequent ubiquitination of activated EGFRs correlates inversely with the 
ability of EGF, TGFα, and E4T to induce receptor recycling. Nevertheless, in accordance with 
observation that EGF, TGFα, and E4T share similar Kd values (31), the tested growth factors induced 
comparable tyrosine phosphorylation of the 180-kDa EGFR species at saturating ligand 
concentrations.  
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 We envision two mechanisms that might explain the poor recruitment of Cbl proteins to the 
activated EGFR. First, the enhanced pH sensitivity of TGFα and E4T binding to the EGFR might 
promote early dissociation of these growth factors from the EGFR within early endocytic 
compartments when endosomal pH values gradually decrease. As a result, proteins such as Cbl that 
are bound to the EGFR might disassemble and/or may not be recruited to the EGFR anymore. Indeed, 
Madshus and co-workers (25) recently reported that TGFα induces markedly reduced EGFR tyrosine 
phosphorylation at acidic pH, and poor recruitment of Cbl to endosomes when compared with EGF. 
Second, the enhanced association/dissociation rate constants of superagonist ligands such as E4T (31) 
might also contribute to disassembly of the ligand-receptor complex and its associated cytoplasmic 
signaling molecules. At present, we cannot determine the relative contribution of pH dependence of 
receptor binding versus enhanced association/dissociation rate constants for the observed decrease in 
Cbl recruitment, EGFR ubiquitination and EGFR degradation (this study) or for the increased EGFR 
recycling (29, 30) observed in response to E4T stimulation. Both mechanisms probably contribute, 
although enhanced association and dissociation of superagonist ligands from cell surface expressed 
EGFRs might be extremely important to limit ligand depletion at low ligand concentrations (29), and 
therefore explain the markedly enhanced mitogenic activity of the superagonist ligands under these 
conditions (29, 30).  
 The early dissociation of the ligand-receptor complex after EGFR internalization may limit post-
translational modification and could lead to a reduced steady-state EGFR tyrosine phosphorylation 
and/or Cbl-mediated EGFR ubiquitination, particularly when such modifications have not yet reached 
their maximum levels shortly after internalization. Thus, our finding that EGF, TGFα, and E4T induce 
similar levels of tyrosine phosphorylation of the 180-kDa EGFR could be explained if maximal 
ligand-induced EGFR tyrosine phosphorylation occurs on the plasma membrane or shortly after 
internalization, when TGFα or E4T have not yet dissociated from the EGFR in acidifying endosomes. 
However, EGF-induced EGFR ubiquitination clearly continues to increase for at least 15 min, when a 
large fraction of EGFRs has already been internalized (30). Indeed, based on the finding that Cbl is 
recruited to EGFR containing endosomes, Levkowitz et al. (12) suggested that Cbl-mediated 
ubiquitination occurs predominantly in early endosomes, although additional studies have revealed 
that Cbl-mediated EGFR ubiquitination also occurs in cells that fail to internalize the EGFR due to 
overexpression of a dominant negative dynamin mutant (39). Thus, the decreased EGFR 
ubiquitination and Cbl recruitment observed in response to TGFα and E4T stimulation, likely results 
from early pH-dependent dissociation of TGFα and E4T in acidifying endosomes. This model is 
further supported by the finding that Cbl is not efficiently recruited to endosomes in response to TGFα 
(25). In addition, the dissociated EGFR receptor chains might be particularly vulnerable for attack by 
constitutively active tyrosine phosphatases and deubiquitinating enzymes leading to a further decrease 
in EGFR post-transcriptional modification. Indeed, even though bafilomycin fully protects the EGFR 
from degradation (Figs. 4, 6, and 7), we found that EGFR tyrosine phosphorylation and ubiquitination 
are, at least in part, transient in the presence of bafilomycin (Figs. 6 and 7). A similar observation was 
previously made for the FcεRI receptor where ligand dissociation resulted in a rapid receptor de-
phosphorylation and de-ubiquitination (40).  
 As ubiquitination appears to act as a sorting signal on endosomal cargo proteins for targeting to the 
MVB pathway, we hypothesize that the decreased EGFR ubiquitination we observed in HER-14 cells 
in response to saturating doses of TGFα or superagonist ligands, leads to the enhanced EGFR 
recycling that has been documented under these assay conditions (30). When EGFR cell surface levels 
are limiting in the presence of excess growth factor, decreased degradation and enhanced recycling of 
internalized EGFRs may lead to enhanced mitogenic signaling. It should be noted however, that HER-
14 cells that overexpress the human EGFR show similar mitogenic responses to the saturating doses of 
growth factors that we have used throughout this study (30). Differences in the mitogenic potency of 
EGF, TGFα, and E4T on HER-14 or 32D1 cells are detected only at very low non-saturating doses of 
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growth factor (0.1–1.0 ng/ml range) (29, 30), conditions that do not allow evaluation of the EGFR 
ubiquitination status.  
 The role of proteasomes in the degradation of internalized plasma membrane receptors is an issue 
of debate. Indeed, several studies have demonstrated that the peptide aldehyde proteasome inhibitor 
MG132 blocks EGFR degradation (16, 25) (data not shown). Cbl proteins have also been reported to 
be degraded in an MG132 sensitive pathway (16). However, MG132 is not a specific proteasomal 
inhibitor: MG132 efficiently inhibits cathepsin B (25), which is a lysosomal proteinase of the papain 
family (41) that selectively catalyzes the degradation of the EGFR in the lysosome (10). Here we 
demonstrate that lactacystin, a specific inhibitor of the proteasome, fails to block EGFR degradation, 
although we consistently observed that lactacystin treatment leads to a minor and transient protection 
of the tyrosine phosphorylated and/or ubiquitinated EGFR (Figs. 4, 6, and 7). Lactacystin treatment 
effectively blocked proteasome function, however, as (i) it caused a marked accumulation of 
ubiquitinated cellular proteins (Fig. 4), (ii) it caused marked stabilization of tyrosine phosphorylated c-
Cbl proteins (which may still undergo dephosphorylation under these conditions) (Fig. 5), (iii) it 
rescued c-Cbl proteins from proteasomal degradation (Fig. 5), and (iv) it blocked EGFR de-
ubiquitination in the presence of bafilomycin (Fig. 7; see below). Moreover, increasing the dose of 
lactacystin failed to protect the EGFR from degradation (data not shown). Consistent with these 
findings, Madshus and co-workers (25) failed to prevent 125I-EGF degradation with lactacystin 
treatment. Thus, our findings indicate that proteasome activity facilitates EGFR degradation, even 
though it is not absolutely required for EGFR degradation.  
 Although we cannot exclude the possibility that proteasome activity is required for degradation of 
a hypothetical protein to facilitate lysosomal degradation, our experiments suggest an alternative 
explanation for the role of proteasomes in the lysosomal degradation of internalized plasma membrane 
receptors. When lysosomal proteases are blocked by bafilomycin treatment, EGFR ubiquitination is 
transient even though EGFR degradation is completely blocked. Most importantly, when the 
proteasome was inhibited under these circumstances by simultaneous lactacystin treatment, the 
ubiquitinated species of the EGFR was stabilized for prolonged periods of time and no EGFR de-
ubiquitination could be detected in our experiments (Fig. 7). Interestingly, Longva et al. (25) reported 
that lactacystin treatment decreased the translocation efficiency of the EGFR from the outer limiting 
membrane to internal vesicles of MVBs. Although the possibility exists that prolonged lactacystin pre-
treatment leads to depletion of the cellular free ubiquitin pool and consequently reduced EGFR 
ubiquitination and lysosomal targeting, this is clearly not the case in our study (Figs. 6 and 7). This 
leads us to propose a working model in which the EGFR is subject to de-ubiquitination reaction that 
may facilitate the sorting of EGFRs into internal vesicles of MVBs. As depicted in Fig. 8, the model 
presented in this work illustrates the role of proteasomes in the EGFR degradation pathway. EGFR 
activation triggers the recruitment of Cbl adapter proteins, which promote EGFR ubiquitination. After 
internalization, EGFR containing endocytic vesicles fuse with early endosomes. Prior to incorporation 
of EGFRs into internal vesicles of MVBs/late endosomes, proteasomes mediate the removal of 
ubiquitin chains from the EGFR. Fusion of MVBs with pre-existing lysosomes ultimately leads to 
EGFR degradation. This de-ubiquitination process might be required for maintaining the level of free 
ubiquitin and may also enhance the entrance of the EGFRs into the internal vesicles of the MVBs. The 
proteasomes also catalyze the degradation of c-Cbl adapter proteins, an event that could be blocked by 
lactacystin treatment. Testing this working hypothesis will require the identification of the 
deubiquitinating enzyme(s) that is (are) responsible for EGFR de-ubiquitination.  
 Intriguingly, this working model is surprisingly similar to the vacuolar targeting of ubiquitinated 
cargo proteins in yeast, whereby the proteasome-associated deubiquitinating enzyme Doa4 removes 
ubiquitin from cargo proteins prior to their entry into internal vesicles of MVBs (42–45). Thus, in 
yeast, the Fur4 plasma membrane receptor accumulates in a non-ubiquitinated form in a pep4 (a 
vacuolar protease) deletion strain and in a ubiquitinated form in a pep4 doa4 double mutant (45).  
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Figure 8. De-ubiquitination of the EGFR prior to its lysosomal degradation. See "Discussion" for explanation of 
figure. 
  
Because doa4 deletion strains display decreased levels of free ubiquitin (44), resulting in decreased 
ubiquitination and vacuolar targeting of cargo proteins (43), removal of ubiquitin from lysosomal 
cargo proteins is in part responsible for maintaining cellular free ubiquitin pools. Importantly, in doa4 
mutant cells that overexpress ubiquitin to supplement the decreased cellular pool of free ubiquitin, the 
Fur4 plasma membrane receptor is degraded (45), indicating that Doa4-mediated de-ubiquitination is 
not required for degradation of vacuolar cargo proteins. This is consistent with the fact that doa4 
deletion strains do not display the characteristic Vps class E phenotype (44). In this study, we have 
demonstrated that the ubiquitination status of the EGFR exactly parallels that of the yeast Fur4 plasma 
membrane receptor under conditions where lysosomal/vacuolar degradation (compare bafilomycin 
treatment with pep4 strains) and/or de-ubiquitination (compare lactacystin treatment with doa4 strains) 
is blocked. Obviously, intricate regulatory mechanisms must exist to ascertain correct 
vacuolar/lysosomal targeting of ubiquitinated cargo proteins while simultaneously ensuring that 
ubiquitin moieties are recycled from cargo proteins for future use prior to their complete destruction in 
vacuoles/lysosomes. It is presently unclear, however, how proteasomes contribute to the de-
ubiquitination of the EGFR without its concomitant proteasomal destruction. In this context it is 
intriguing to note that EGFR polyubiquitination appears to involve attachment of multiple mono-
ubiquitin chains rather than (multiple) polyubiquitin chains (46, 47), which are normally required for 
proteasomal destruction.  
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ABSTRACT 
 
 Whereas poly-ubiquitination targets protein substrates for proteasomal degradation, mono-
ubiquitination is known to regulate protein trafficking in the endosomal system and to target cargo 
proteins for lysosomal degradation. The role of the deubiquitinating enzymes AMSH and UBPY in 
endosomal trafficking of cargo proteins such as the EGFR has only very recently been the subject of 
study and is already a matter of debate. Whilst one report (Mizuno et al., 2005, Mol. Biol. Cell 16, 
5163) concludes that UBPY negatively regulates EGFR degradation by deubiquitinating the EGFR on 
endosomes, another report (Row et al., 2006, J.Biol.Chem 281, 12618) concludes that UBPY 
mediated EGFR deubiquitination is essential for EGFR degradation. Here, we demonstrate that 
Usp8/UBPY, the mammalian ortholog of budding yeast Ubp4/Doa4, constitutively co-precipitates in 
a bivalent manner with the EGFR. Moreover, UBPY is a substrate for Src-family tyrosine kinases that 
are activated following ligand-induced EGFR activation. Using overexpression of three different 
recombinant dominant negative UBPY mutants (UBPY C748A mutant, UBPY 1-505, and UBPY 
640-1080)  in NIH3T3 and HEK293 cells, we demonstrate that UBPY affects both constitutive and 
ligand-induced (i) EGFR ubiquitination, (ii) EGFR expression levels, (iii) the appearance of 
intermediate EGFR degradation products as well as (iv) downstream MAPK signal transduction. Our 
findings provide further evidence in favor of the model that UBPY mediated EGFR deubiquitination 
promotes EGFR degradation.  
 
INTRODUCTION 
 
 The EGFR (or ErbB1) is a member of the ErbB growth factor receptor tyrosine kinase family that 
is involved in the genesis of many human solid tumors (reviewed in (1,2)). EGFR activation leads to 
multiple downstream signalling events that control various cellular processes such as mitogenesis, cell 
survival, differentiation and cell migration. These processes must be tightly regulated to prevent 
uncontrolled mitogenic signaling, cell survival and cell migration which may lead to tumor formation. 
The principal mechanism by which cells downregulate activated receptors is by ligand-mediated 
endocytosis and subsequent delivery of the activated ligand-receptor complex to the lysosome for 
degradation (3,4).  
 Targeting of cell-surface receptors to the lumen of the lysosome is a complex process which is 
tightly regulated by several protein complexes along distinct steps of the endocytic pathway (3,5). 
Following ligand-induced dimerization of the EGFR, phosphorylated tyrosine residues in the C-
terminal tail serve as docking sites for SH2 or PTB domain containing proteins. The Cbl family of E3 
ubiquitin ligases (6) is recruited to EGFR pTyr1045 through its variant SH2 domain (7). The activated 
EGFR is then internalized through clathrin-coated pits and transported to early endosomes after which 
cargo is sorted either to the recycling pathway or to the lysosome for degradation (reviewed in (8)). 
Lysosomal targeting involves the delivery of cargo proteins to internal vesicles of late 
endosomes/multi-vesicular bodies (MVBs), which subsequently fuse with pre-existing lysosomes for 
subsequent degradation (5). Formation of MVBs is dependent on the evolutionary conserved vacuolar 
protein sorting (Vps) class E proteins including Hrs/Vps27, ESCRT-I, -II, and -III complexes, 
Vps31/Bro1/Alix, and the AAA-ATPase Vps4/SKD1 (5).  
 Several lines of evidence strongly support involvement of ubiquitin in the endosomal trafficking 
of cargo proteins, including sorting of cargo proteins at the trans-Golgi network, internalisation of 
cargo proteins at the plasma-membrane, sorting of cargo proteins to the MVB pathway and budding 
of retroviral particles at the plasma-membrane (9). Indeed, many of the key players (e.g. Eps15, 
GGA’s, Hrs, Vps23/TSG101, Vps36, Vps9 proteins) in the endocytic pathway contain ubiquitin-
interacting domains which assist them in recognizing ubiquitinated -cargo and/or -endosomal adapter 
proteins (e.g. Eps15, CIN85) (9).   
 Following agonist stimulation various activated protein tyrosine kinases, including receptor 
tyrosine kinases and Src- family kinases are rapidly ubiquitinated by Cbl E3 ubiquitin ligases (6). 
Recruitment of Cbl to EGFR pTyr1045 leads to EGFR mono-ubiquitination on multiple lysines 
(referred to as multi-ubiquitination) (10,11) as opposed to poly-ubiquitination, which targets cargo 
proteins for proteasomal degradation. Recent data obtained with mass spectrometry suggest, however, 
that a significant fraction of the EGFR is modified with K63-linked poly-ubiquitin chains within the 
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kinase domain (12). The role of EGFR ubiquitination during the internalization phase is debated (see 
for instance (13)). This controversy may be due to redundancy of ubiquitin-dependent and -
independent (e.g. clathrin AP2-mediated) internalization signals (14), multivalent recruitment of Cbl 
to the EGFR resulting in low level ubiquitination of the EGFR Y1045F mutant (15), and perhaps 
other factors. Accumulating evidence suggests, however, a role of EGFR ubiquitination in lysosomal 
targeting (13). Here, binding of Hrs to ubiquitinated cargo proteins through its UIM (Ubiquitin 
Interacting Motif) (16) and recruitment of the ESCRT-I complex to the surface of endosomes (17) 
initiates the lysosomal targeting of EGFR proteins. Ubiquitinated cargo is then transferred to the 
ESCRT-I protein TSG101/Vps23 which interacts with ubiquitin through its catalytically inactive 
ubiquitin conjugating enzyme variant (UEV) domain (18). Binding of the ESCRT-I complex to the 
surface of endosomes leads to the sequential recruitment of ESCRT-II, Vps31/Alix and ESCRT-III 
complexes. In budding yeast, this supra-molecular assemblage facilitates the recruitment of the 
deubiquitinating enzyme Ubp4/Doa4 (19) in an ESCRT-III- and Vps31/Bro1-dependent manner (20-
22). Doa4 action allows the recycling of ubiquitin from cargo proteins (23), prior to the translocation 
of cargo proteins into internal vesicles of MVBs (20,24). The evolutionary conserved Vps4/SKD1 
AAA-ATPase activity is required to release the endosomal protein complex from the membrane, 
thereby triggering MVB formation and incorporation of cargo into internal vesicles of MVBs (5). 
 We have previously shown that ubiquitinated EGFRs undergo deubiquitination prior to their 
delivery to lysosomes (4).  While our studies were considered elsewhere, several groups have recently 
implicated the JAMM/MPN+ family member AMSH and the ubiquitin specific protease (Usp) family 
member Usp8/UBPY in regulation of EGFR ubiquitination and degradation, with conflicting 
conclusions. Whilst one report (25) concludes that UBPY negatively regulates EGFR degradation by 
deubiquitinating the EGFR on endosomes, another report (26) concludes that UBPY mediated EGFR 
deubiquitination is essential for EGFR degradation. Here, using overexpression of three different 
recombinant dominant negative UBPY mutants in NIH3T3 and HEK293 cells, we investigate the role 
of UBPY in EGFR ubiquitination and downstream signaling.  
 
EXPERIMENTAL PROCEDURES 
 
 Reagents 
The following monoclonal (mAb) and polyclonal (pAb) antibodies were used in this study: anti-
EGFR 528 mAb (used for immunoprecipitation (IP)) and anti-EGFR 1005 pAb (used for 
immunoblotting (IB) except when indicated) (Santa Cruz), anti-EGFR Ab-12 pAb (Neomarkers), anti-
phosphotyrosine 4G10 mAb (Upstate Biotechnology), anti-ubiquitin pAb and anti-flag M2 mAb 
(Sigma), anti-active (phospho-p44/p42) MAPK mAb (Cell Signalling), anti-GFP antibody (Santa 
Cruz), anti-GAPDH antibody (Abcam), as well as goat anti-rabbit (GARPO) and goat anti-mouse 
(GAMPO) mAbs linked to horseradish peroxidase (Signal Transduction Laboratories). Other reagents 
that were used in this study included protein-A and protein-G sepharose beads (Amersham 
Biosciences), PP2 src kinase inhibitor, PD153035 EGFR tyrosine kinase inhibitor (Calbiochem), 
lipofectamine 2000 (Invitrogen), and mouse EGF (BD Bioscience). Anti-UBPY polyclonal antibodies 
(W39) were kindly provided by Dr. E. Martegani (27). The following expression vectors were used: 
pEGFP vector (Clonetech), pZome-1N retroviral vector (Cellzome), pLZRS-IRES-GFP (kindly 
provided by Dr. J.Jansen Department of Haematology, UMCN, Radboud University Nijmegen), 
pcDNA3-EGFR wild-type and Y1045F (kindly provided by Dr. Y.Yarden), pME18s-Flag UBPY 
wild-type and dSB constructs (kindly provided by Dr. N. Kitamura) (28). The Phoenix ecotrophic 
packaging cell line was obtained from Dr. G.P. Nolan (Stanford University Medical Center) through 
the American Type Culture Collection (ATCC). 
 DNA manipulation and plasmid construction 
pMe18s-flag-UBPY (corresponding to wild type (wt) full length mouse UBPY amino acids (aa) 1-
1080) and pMe18s-flag-UBPY-dSB (UBPY lacking both N-terminal and C-terminal Hbp SH3 binding 
(SB) motifs) were kindly provided by Dr. N. Kitamura (28). These constructs were used as template to 
generate catalytically inactive flag-UBPY-C748A and flag-UBPY-dSB-C748A. Wild-type and mutant 
UBPY cDNAs were then cloned into EcoR1 and SmaI sites of pEGFP-c2 vector to generate EGFP- 
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Figure 1.  Domain structure UBPY and mutants used in this study.  
Amino acid boundaries of individual domains are indicated on top of the figure. NTR = N-Terminal Region; 
Rhod = Rhodanese domain; DUB = catalytic deubiquitination domain; CA= C748A catalytically inactive 
mutant; dSB = deletion mutant lacking the SH3-binding motif(s); delta-140= deletion mutant lacking amino 
acids 1-140.  
 
 
UBPY-wt, EGFP-UBPY-dSB, EGFP-UBPY-CA, and EGFP-UBPY-dSB-CA (Figure 1). N-terminal 
and C-terminal deletion mutants were generated by amplifying individual domains of UBPY and 
subsequent cloning into EcoRI and SmaI sites of pEGFP-c2, which resulted in the following 
constructs: EGFP-Rhod (amino acids (aa) 1-504); EGFP-Rhod-dSB (aa 1-504 lacking the N-terminal 
SB motif); EGFP-Rhod-D140 (aa 140-504); EGFP-Rhod-dSB-D140 (aa 140-504 lacking the N-
terminal SB motif);  EGFP-Dub (aa 640-1080); EGFP-Dub-dSB (aa 640-1080 lacking the C-terminal 
SB motif); EGFP-Dub-CA (aa 640-1080 carrying the C748A mutation); and EGFP-Dub-dSB-CA 
(double mutant carrying both C-terminal dSB motif deletion and C748A mutation) (Figure 1). The 
wild type and C748A mutant of the Dub domain were also cloned into EcoRI and HindII sites of 
pZome-1N retroviral vector to generate ProtA-tagged Dub domains. Finally, pMe18s-Flag-UBPY 
constructs were digested with XhoI and SmaI to release UBPY sequence carrying the flag tag 
sequence and subsequently cloned into XhoI and SnaBI sites of pLZRS-IRES-GFP-PURO retroviral 
vector to create pLZRS-Flag-UBPY-IRES-GFP constructs. All constructs and mutations were verified 
by nucleotide sequencing. Additional cloning strategies and primer sequences are available upon 
request.
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 Cell culture and generation of stable cell lines 
HER-14 (NIH3T3 cells stably transfected with the human EGFR), Human Embryonic Kidney Cells 
(HEK293), and Phoenix cell lines were grown at 37°C in Dulbecco's Modified Eagle's medium 
(DMEM) supplemented with 10% newborn calf serum (NCS). Transient transfection was performed 
using either calcium phosphate precipitation or lipofectamine 2000 according to 
standard/manufacturer instructions. HER-14 cells stably expressing Flag-UBPY (w.t. & dSB) or 
vector control were generated by lipofectamine transfection with pLZRS-Flag-UBPY-IRES-GFP 
constructs followed by puromycin selection. Stable HER-14 cell lines expressing protein A (protA) 
tagged DUB domains or vector control were generated by transfection of Phoenix cells with pZome-
1N-Dub-wt, -Dub-CA constructs, isolation of recombinant retrovirus, and viral infection of HER-14 
cells followed by puromycin selection according to standard protocols.  
 Analysis of proteins and Data Quantification 
Cells were serum starved twenty four hours post-transfection in DMEM containing 0.1% NCS plus 
0.1% BSA for 18 hours prior to stimulation. Cells were stimulated with EGF (100 ng/ml) for 60 
minutes unless specified otherwise. Cell lysis, immuno-precipitation, SDS-PAGE electrophoresis and 
Western blotting was carried out as described previously (4). Signal quantification was performed 
with Photoshop software (Adobe systems). Briefly, mean pixel value (MPV) was calculated for a 
predefined rectangle encompassing signal of interest (SOI) after subtracting the background signal. 
Similar data calculation was carried out for loading control samples (e.g. GAPDH) as indicated in 
figure legends. The data plotted in the graphs represent MPV of SOI divided by the MPV of the 
loading control. 
 In Vitro deubiquitination assay 
Flag-UBPY wt, and flag-UBPY Cys748-Ala mutant were each transfected in two 10 cm plates of 
NIH3T3 by means of lipofectamine. Cells were harvested 24 hours post-transfection. Flag-UBPY was 
immuno-precipitated with M2 anti-Flag antibody coupled to Prot-G beads for 1.5 hours at 4 °C. After 
extensive washing, beads were then split into two fractions. One was treated with NEM (N-
ethylmaleimide) and the other with carrier ethanol at room temperature and their concentrations were 
kept constant throughout the experiment.  Four 10 cm dishes of HER-14 cells were serum starved 
overnight. To induce ubiquitination of EGFR, cells were stimulated with 100 ng/ml EGF for 15 
minutes. Cells were then lysed on ice and immunoprecipitation of ubiquitinated EGFR was performed 
with anti-EGFR (clone 528) coupled to Prot-A beads at 4 °C for 1.5 hours. Beads were then washed 
extensively in lysis buffer and split into two fractions. EGFR beads were then reconstituted in DUB-
buffer (10 mM Tris-HCl, pH 8.0, 1 mM DTT, 1 mM EDTA). EGFR immunoprecipitates were then 
combined with UBPY immunoprecipitates in a 100 μl final volume of DUB-buffer. Deubiquitination 
reaction was initiated by incubating the bead mixtures at 37 °C for 90 minutes with regular mixing. 
Beads were then washed three times with TBST and twice with PBS. Then, LSB (Laemmli Sample 
Buffer) was added to the mixture and incubated at 100 °C for 3 minutes prior to loading on SDS-
PAGE and western blotting. 
 
RESULTS 
 
 Tyrosine phosphorylation of UBPY following EGFR activation 
Based on the function of the yeast deubiquitinating enzyme Doa4/Ubp4, we hypothesized that 
Usp8/UBPY, the mammalian ortholog of Doa4, might be involved in deubiquitination of the EGFR. 
UBPY is the only mammalian DUB enzyme that, like Doa4, contains a catalytically inactive 
rhodanese-like homology domain (29). In addition, phylogenetic analysis of fungal and metazoan 
ubiquitin specific protease (Usp) enzymes reveals that fungal Ubp4/Ubp5 paralogs form a single clade 
with metazoan Usp8 orthologs (unpublished results). To assess the role of UBPY in EGFR signaling 
and turnover, we first asked whether UBPY is tyrosine phosphorylated in response to EGF treatment. 
As seen in Figure 2A, a clear EGF-induced tyrosine phosphorylation of flag-tagged UBPY was 
observed in NIH3T3 cells co-transfected with UBPY and EGFR, demonstrating that transfected  
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Figure 2. Tyrosine phosphorylation of UBPY following EGFR activation 
(A) NIH-3T3 cells were transfected with flag-tagged UBPY constructs, EGFR or control vector (pME18s, 
pcDNA3.1) as indicated. Serum starved cells were EGF-stimulated for 1 hour, lysed and WCL’s were used for 
IP and IB with anti-flag, anti-phosphotyrosine (pTyr) and anti-EGFR antibodies as indicated. (B) NIH-3T3 cells 
were co-transfected with EGFR and either wild type UBPY or catalytically inactive C748A mutant. Serum 
starved cells were EGF-stimulated for 1 hour and WCLs used for IP and IB as indicated. (C) HEK293 cells were 
transfected with EGFR, EGFP-tagged UBPY constructs or vector control as indicated. Serum starved cells were 
EGF-stimulated, and WCLs used for IP and IB as indicated. (D) Serum starved HER-14 cells were EGF-
stimulated for various periods of time as indicated. WCLs were used for IP and IB with anti-UBPY and anti-
phosphotyrosine as indicated. (E) Densitometric analysis of the phospho-signal of UBPY. Phospho-signal of the 
IPs in (D) was related to the amount of precipitated UBPY in the sequential blot and plotted as a function of 
time. Representative of 2-4 experiments. 
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UBPY is a substrate for EGF-activated protein tyrosine kinases. It should be noted that EGFR 
activation is associated with a characteristic mobility shift, as seen in Figure 2A (3rd panel). UBPY is 
known to interact with Hrs binding protein (Hbp) through the Hbp SH3-binding motifs of UBPY (at 
amino acid positions 405-413 (SB-N) and at amino acids 700-708 (SB-C)) (28). However, as shown 
in Figure 2A, EGF-induced tyrosine phosphorylation of Flag-UBPY-dSB was similar compared to 
wild-type flag-UBPY, demonstrating that the Hbp SH3 binding motifs in UBPY are dispensable for 
UBPY tyrosine phosphorylation. UBPY contains a highly conserved active site cysteine (Cys748) that 
is required for its enzymatic activity (30). As shown in Figure 2B, UBPY-C748A contained similar 
levels of phospho-tyrosine compared to wild type UBPY, demonstrating that UBPY’s 
deubiquitination activity is also not required for its tyrosine phosphorylation. To unequivocally 
demonstrate that the tyrosine phosphorylated protein detected in UBPY precipitates is UBPY itself 
and not a co-migrating protein, we generated EGFP fusion constructs of wild type, N-terminally 
truncated, and C-terminally truncated UBPY proteins. HEK293 cells were co-transfected with UBPY-
wt, UBPY 1-504 (which will be referred to as the Rhod (rhodanese) construct) or UBPY 640-1080 
(which will be referred to as the 'dub' construct). As shown in Figure 2C, EGF stimulation induced an 
EGFR-dependent tyrosine phosphorylation of GFP-UBPY-wt (155 kDa) and GFP-Rhod (85 kDa) but 
not of GFP-Dub, even though it was efficiently expressed (middle panel) and its deubiquitinating 
enzyme activity was still intact (data not shown). These findings demonstrate that transfected UBPY 
itself is undergoing tyrosine phosphorylation in response to EGFR activation and that the N-terminal 
Rhod but not the C-terminal Dub construct is sufficient for EGF-induced UBPY tyrosine 
phosphorylation. Moreover, as shown in Figure 2D, we could also detect EGF-induced tyrosine 
phosphorylation of endogenous UBPY (130 kDa), which was precipitated from HER-14 cells and 
detected by Western blot using the anti-UBPY W39 polyclonal antiserum (27). Quantification of the 
UBPY phospho-tyrosine signal showed that UBPY phosphorylation reached a maximum at 60 
minutes after stimulation followed by a gradual decline until it reached near basal levels after 4 hours 
of stimulation (Figure 2E). Interestingly, a tyrosine phosphorylated protein that co-migrates with the 
EGFR co-precipitated with endogenous UBPY (Figure 2D, lanes 1-6) suggesting that UBPY 
associates with the EGFR. Collectively, these data demonstrate that (i) EGF induces UBPY tyrosine 
phosphorylation in an EGFR-dependent manner. (ii) UBPY is tyrosine phosphorylated in its N-
terminal half, (iii) neither the Hbp SH3 binding motifs in the proline rich domain of UBPY nor the 
deubiquitination activity of UBPY is required for UBPY tyrosine phosphorylation.  
 
 Inhibition of src kinases with PP2 blocks UBPY tyrosine phosphorylation 
To further test whether the kinase activity of the EGFR is required for UBPY tyrosine 
phosphorylation, we used the specific EGFR kinase inhibitor PD153035. The EGFR kinase inhibitor 
effectively blocked EGF-induced tyrosine phosphorylation of the EGFR and other downstream 
signaling molecules as seen on WCL’s (Figure 3A, lower panel). Importantly, EGF-induced tyrosine 
phosphorylation of the immunoprecipitated EGFP-Rhod construct was completely blocked in the 
presence of PD153035 (Figure 3A, top panel). A tyrosine phosphorylated band of around 180 kDa, 
most probably the EGFR, co-precipitated with EGFP-Rhod and disappeared (as expected) upon  
PD153035 treatment. It is well known that Src-family tyrosine kinases are activated following EGFR 
activation (1,31). To test whether Src-family tyrosine kinases may be responsible for UBPY tyrosine 
phosphorylation, we used the specific Src-family kinase inhibitor PP2. Significantly, EGF-induced 
GFP-Rhod tyrosine phosphorylation was reduced in a concentration dependent manner by PP2 
(Figure 3B, top panel & Figure 3C). Complete inhibition of GFP-Rhod tyrosine phosphorylation was 
achieved with 5 μM of PP2 (Figure 3B & 3C), even though tyrosine phosphorylation of the EGFR 
remained relatively unaffected (Figure 3B, 3rd panel). It should be noted that a slight decrease in 
EGFR tyrosine phosphorylation upon PP2 treatment is expected because the EGFR itself is a substrate 
for Src-family tyrosine kinases (31). These data demonstrate that UBPY is a substrate for Src-family 
tyrosine kinases, and indicate that direct phosphorylation of UBPY by the EGFR kinase domain does 
not occur to a significant extent. 
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Figure 3. Inhibition of Src kinases with PP2 blocks UBPY phosphorylation 
(A) HEK293 cells were co-transfected with EGFR or pcDNA3.1 and GFP-Rhod or control pEGFP-c2 vector 
(GFP). Serum starved cells were pre-treated for 60 minutes with either 10 μM EGFR tyrosine kinase inhibitor 
PD153035 or carrier DMSO, and EGF-stimulated for 1 hour. WCL’s were used for IP and IB as indicated. (B) 
HEK293 cells were co-transfected with GFP-Rhod and EGFR. Serum starved cells were pre-treated for 60 
minutes with increasing amounts of PP2 Src kinase inhibitor and EGF-stimulated for 1 hour as indicated. 
WCL’s were used for IP and IB as indicated. (C) Densitometric analysis of phosphorylated GFP-Rhodanese 
signal in resting and EGF-stimulated cells as shown in (B), top panel. Specific GFP-Rhod phospho-signal was 
related to the amount of precipitated GFP-Rhod as shown in (B), (2nd panel from top) and plotted as a function 
of PP2 concentration. Representative of 2-3 experiments. 
 
 UBPY is found in a complex with the EGFR 
The data illustrated in Figures 2 & 3 suggest that the tyrosine phosphorylated EGFR co-precipitates 
with transfected as well as endogenous UBPY proteins. Indeed, as shown by direct co-precipitation 
(Figure 4A), flag-UBPY co-precipitated with the EGFR. Flag-UBPY-dSB bound the EGFR to similar 
levels as the wild type UBPY (Figure 4A), demonstrating that the Hbp SH3 binding motifs are not 
required for formation of a complex between UBPY and EGFR in vivo. Interestingly, flag-UBPY-
C748A showed four-fold enhanced binding to the EGFR compared to wild type UBPY (Figure 4A).  
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Figure 4. UBPY constitutively associates with the EGFR in a kinase activity-independent manner 
(A) HEK293 cells were co-transfected with EGFR, flag-tagged UBPY or control vectors as indicated. Serum 
starved (0.1% NCS) cells were lysed and WCL’s used for anti-EGFR IP and IB with anti-flag and anti-EGFR as 
indicated. The association between the EGFR and various UBPY constructs was quantified by means of 
densitometric analysis of flag signal in EGFR IPs (upper panel) relative to flag signal in WCL’s (lower panel). 
(B) HEK293 cells were co-transfected with flag-UBPY-C748A and EGFR or control pcDNA31. Serum starved 
(0.1% NCS) cells were treated for 90 minutes with either 10 μM EGFR tyrosine kinase inhibitor or carrier 
DMSO. WCL’s were used for anti-EGFR IP and IB with anti-flag, anti-phosphotyrosine and anti-EGFR as 
indicated. Representative of 2-3 experiments. 
 
The enhanced binding of the UBPY-C748A mutant to the EGFR suggests that the stability of the 
UBPY-EGFR complex is enhanced when the catalytic activity of UBPY is abolished, indicating 
substrate trapping characteristics of the UBPY C748A mutant. Similar results were obtained with 
GFP-tagged mutants of UBPY (data not shown). To determine whether complex formation of UBPY  
with the EGFR is dependent on its kinase activity, we transfected flag-UBPY-C748A (because of its 
enhanced binding to the EGFR) together with EGFR in the presence or absence of the EGFR kinase 
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inhibitor PD153035. UBPY binding to the EGFR remained unaffected when cells cultured in low 
serum were treated with PD153035 (Figure 4B, top panel) despite the fact that the kinase inhibitor 
dramatically decreased the activation state of the EGFR (Figure 4B, pTyr blot). We conclude that 
UBPY constitutively forms a complex with the EGFR in vivo through a mechanism that is 
independent of the Hbp SH3 binding motifs and independent of EGFR kinase activity. Furthermore, 
the enhanced binding of the catalytically inactive C748A mutant of UBPY to the EGFR suggests that 
this mutant shows a substrate trap phenotype. 
 
 The EGFR is a substrate for UBPY deubiquitination activity In Vitro 
Having shown that UBPY is tyrosine phosphorylated in response to EGFR activation and is 
constitutively associated with EGFR, we tested the impact of this interaction on the ubiquitination 
status of the EGFR. Initially, we tested whether the EGFR is a substrate for UBPY in vitro. Towards 
this goal, an in vitro EGFR deubiqutination assay was developed (see materials and methods). Thus, 
flag-UBPY, and flag-UBPY-C748A were immuno-purified and tested for their ability to 
deubiquitinate immuno-purified ubiquitinated EGFRs. To measure the deubiquitination activity we 
used N-ethylmaleimide (NEM) an alkylating agent that is highly potent in blocking deubiquitinating 
enzymes by covalent alkylation of their active site cysteine as a control. The difference in EGFR 
ubiquitination seen in NEM treated versus untreated samples provides a measure for the 
deubiquitination activity during incubation of the samples at 37 °C. Following the de-ubiquitination 
assay, samples were run on SDS-PAGE for a relatively short time in order to narrow the smear of 
ubiquitinated EGFRs to a relatively compact region, allowing better quantification. Untreated wild 
type flag-UPBY was able to deubiquitinate the EGFR (Figure 5A, lanes 1-2; Figure 5B). In contrast, 
flag-UBPY-C748A failed to deubiquitinate the EGFR in the absence of NEM (Figure 5A, lanes 3-4; 
Figure 5B).  
 
 The EGFR is a substrate for UBPY deubiquitination activity In Vivo 
To determine whether the EGFR is a substrate for UBPY’s deubiquitination activity in vivo,  HER-14 
cells stably expressing human EGFR were transfected with wild type and catalytically inactive 
UBPY, transfectants were enriched by puromycin selection, and resistant cells assayed for EGFR 
ubiquitination (Figure 6A). Even though the expression of the C748A mutant was significantly less 
than wild type UBPY (Figure 6A, bottom panel), the UBPY C748A mutant markedly enhanced 
accumulation of ubiquitinated EGFRs following EGF stimulation (Figure 6A, top panel). In our 
previous study, we used IP-recapture procedures to demonstrate that the high molecular weight 
ubiquitinated species seen in EGFR IP’s represent ubiquitinated EGFRs (4).  To further analyse the 
effect of UBPY C748A expression on EGFR steady state ubiquitination (i.e. in the absence of EGF), 
we co-transfected the EGFR with either UBPY wild type or C748A mutant into HEK293 cells (Figure 
6B). Overexpression of wild type UBPY did not markedly affect EGFR ubiquitination relative to 
vector control, but overexpression of the C748A mutant strongly enhanced accumulation of 
ubiquitinated EGFRs (Figure 6B). Moreover, introduction of the dSB mutation in UBPY C748A 
mutant did not abolish the dominant interfering activity of the catalytically inactive UBPY (data not 
shown), indicating that the effect of C748A is not mediated through competition with AMSH for the 
Hbp SH3 domain. We conclude that overexpression of the full length C748A catalytically inactive 
UBPY mutant leads to enhanced accumulation of ubiquitinated EGFRs in both ligand-independent as 
well as ligand-dependent model systems.  
 Ligand-induced EGFR multi-ubiquitination is critically dependent on the Cbl-family of E3 
ubiquitin ligase adapter proteins which is recruited to tyrosine phosphorylated EGFR pY1045 (6). The 
ability of the enzymatically inactive UBPY C748A mutant to up-regulate EGFR ubiquitination under 
steady state conditions in HEK293 cells (i.e. in the absence of ligand), prompted us to investigate the 
effect of wild type and C748A mutant UBPY on the ubiquitination of the EGFR Y1045F mutant, 
which shows a profound block in EGF-induced EGFR ubiquitination (7) (and data not shown). Most 
interestingly, the UBPY C748A mutant markedly enhanced steady state ubiquitination of both EGFR 
wt and EGFR Y1045F mutant constructs, whereas wild-type UBPY did not affect their ubiquitination 
status relative to vector control (Figure 6C, top panel). These findings indicate that the steady state  
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Figure 5. UBPY deubiquitinates the EGFR in vitro 
(A) For a detailed description of the procedure, see the Materials and Methods section. (B) Band intensities of 
the ubiquitin signal were calculated relative to the EGFR signal according to methods described in the Materials 
and Methods section. Representative of 2 experiments. 
 
 
EGFR ubiquitination is determined by the balance between ubiquitination and deubiquitination. 
Consistent with our previous data, GFP-UBPY C748A mutant also showed enhanced binding to the 
EGFR Y1045F mutant when compared to GFP-UBPY-wt. Collectively, the data in Figure 6 
demonstrate that UBPY modulates the EGFR ubiquitination status in vivo in both ligand-dependent 
and ligand-independent model systems. We further conclude that the recruitment of UBPY to the 
EGFR does not require phosphorylation of EGFR Tyr1045, consistent with our experiments using 
EGFR kinase inhibitors (Figure 4B). Moreover, these data demonstrate that the EGFR undergoes 
constitutive ubiquitination in a pTyr1045-independent manner, which is counteracted by UBPY-
mediated deubiquitination.  
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Figure 6.UBPY de-ubiquitinates the EGFR In Vivo  
(A) HER-14 cells were transfected with flag-UBPY w.t., C748A, or vector control (pLZRS-IRES-GFP) carrying 
the puromycin resistance gene and subjected to 5 days of puromycin selection. Serum starved cells were 
stimulated with EGF for 20 minutes, lysed and WCL’s used for IP with anti-EGFR and IB with anti-ubiquitin, 
anti-EGFR (Ab12), and anti-flag as indicated. (B) HEK293 cells were co-transfected with EGFR and flag-
UBPY w.t., C748A, or control vector as indicated. Serum starved cells were lysed and WCL’s used for anti-
EGFR IP and anti-ubiquitin, anti-EGFR (Ab12) and anti-flag IB as indicated. (C) HEK293 cells were co-
transfected with EGFR w.t., Y1045F or control vector and either GFP-UBPY-wt or GFP-UBPY-C748A as 
indicated. Serum starved cells were lysed and WCL’s used for anti-EGFR IP and anti-ubiquitin, anti-EGFR 
(Ab12), and anti-GFP IB as indicated. Representative of 2 experiments. 
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Figure 7. UBPY affects  constitutive EGFR turnover and downstream signalling to MAPK.  
HEK293 cells were co-transfected with EGFR and GFP-tagged UBPY deletion constructs or pEGFP-c2 vector 
control (GFP) as indicated (see also Figure 1). Serum starved cells were lysed, and WCL’s were used for anti-
EGFR IP and IB with anti-ubiquitin, anti-EGFR (Ab12), anti-GFP, anti-GAPDH, and anti-active MAPK as 
indicated. Representative of 2 experiments. 
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 Overexpression of enzymatically active UBPY Dub domain controls EGFR degradation and 
downstream signalling to MAPK 
To further define the requirements for complex formation of UBPY with the EGFR and UBPY-
mediated regulation of EGFR ubiquitination, we made non-overlapping N-terminal (‘Dub’) and C-
terminal ('Rhodanese') UBPY deletion mutants (Figure 1). In these mutants, the catalytic activity is 
disconnected from the remainder of the molecule, which often leads to dominant negative behaviour 
upon overexpression. Interestingly, overexpression of GFP-Dub and GFP-Dub-dSB in HEK293 cells 
induced an EGFR mobility shift that is typical for activated EGFRs (Figure 7, 5th panel, lane 1 & 3).  
 This shift was not seen when catalytically inactive GFP-Dub-C748A and GFP-Dub-dSB-C748A 
(lane 2 & 4) or when GFP alone (lane 10) was expressed. Partial EGFR activation correlated with the 
ability of the catalytically active GFP-Dub and GFP-Dub-dSB constructs to strongly coprecipitate 
with the EGFR (Figure 7, 3rd panel), while their C748A mutant counterparts poorly associated with 
the EGFR. Most strikingly, overexpression of the GFP-Dub and GFP-Dub-dSB mutants was 
associated with disappearance of intermediate EGFR proteolytic degradation products, and 
moderately enhanced expression of the 180 kD EGFR band compared to cells transfected with 
catalytic inactive C748A Dub mutants (Figure 7, 2nd panel). It is important to note that intermediate 
EGFR degradation products and decreased 180 kD EGFR bands were also observed in EGFR 
expressing cells containing GFP alone (Figure 7, lane 10). When analysing the ubiquitination status of 
the EGFR in cells co-expressing the Dub constructs, we found that EGFR ubiquitination was not 
significantly affected relative to GFP control (Figure 7, top panel). Consistent with the (partial) 
activation of the EGFR, enhanced EGFR expression levels and disappearance of intermediate EGFR 
degradation products, expression of catalytically active but not inactive GFP-Dub domains was 
associated with activation of both Erk2 (p42) and Erk1 (p44) MAPK proteins under steady state 
conditions, i.e. in the absence of EGF (Figure 7, bottom panel, compare lane 1-4, 10).  
 To provide further evidence for the effect of the Dub domain on ligand-induced EGFR signaling 
and EGFR turn-over, we generated three cell lines stably expressing protein-A-tagged wild type Dub 
(HER14-Dubwt), catalytically inactive Dub-C748A (HER14-Dubca), and control empty vector 
(HER14-Vec). Consistent with the results obtained in HEK293 cells, the expression level of the EGFR 
in serum-starved HER14-Dubwt is already elevated compared to HER14-Dubca and HER14-Vec 
(Figure 8, top panel and top graph) and remained so after EGF stimulation, although the EGFR was 
eventually degraded in all cell lines. Moreover, MAPK activation was markedly increased in wild type 
Dub expressing cells even after six hours of stimulation compared to HER14-Vec and HER14-Dubca 
(Figures 8, middle panel & bottom graph). Collectively, these findings demonstrate that the C-terminal 
part of UBPY containing the Dub domain coprecipitates with the EGFR in an SB-C-independent and 
Cys748-dependent manner with the EGFR. Overexpression of the catalytically active UBPY Dub 
domain leads to activation of the EGFR under steady state conditions which is associated with 
enhanced MAPK activation, moderately enhanced EGFR expression levels and disappearance of 
intermediate EGFR degradation products. 
 
 Overexpression of the UBPY N-terminal regulatory domain controls EGFR ubiquitination, EGFR 
degradation and downstream MAPK signalling 
We next evaluated whether overexpression of the N-terminal half of UBPY, the Rhod construct, also 
affected EGFR turnover and downstream signaling. Importantly, co-expression of GFP-Rhod or GFP-
Rhod-dSB with the EGFR strongly induced accumulation of ubiquitinated EGFRs, which migrate as a 
smear above the 180 kDa position on the blot (Figure 7, top panel, compare lanes 5-10). Interestingly, 
the smeared ubiquitin-signal also appeared well below the 180 kD position on the blot, which may 
originate from ubiquitinated EGFR-binding proteins. Indeed, overexpression of GFP-Rhod induced 
accumulation of ubiquitinated cellular proteins (Figure 7, 4th panel). Thus, in contrast to 
overexpression of the UBPY Dub domain, overexpression of the UBPY Rhod construct lead to 
significant accumulation of ubiquitinated EGFRs as well as other cellular proteins, suggesting that 
this construct interfered in a dominant negative manner with endogenous UBPY deubiquitinating 
activity. The dominant negative activity of the UBPY rhodanese construct did not require the N- 
terminal SH3 binding sequence but did require the N-terminal 140 amino acids of UBPY. 
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Figure 8: UBPY affects ligand-induced EGFR turnover and downstream signalling to MAPK.  
(A) HER-14 cells that stably express protein-A-tagged wild type Dub domain, Dub-CA (C748A), or control 
vector (Vec) were generated. Serum starved cells were stimulated for various time periods with EGF as 
indicated, lysed and WCL’s used for sequential IB with anti-EGFR, anti-active MAPK, and anti-GAPDH as 
indicated. The expressed protein-A tagged Dub domains were also detected by the IB procedure (top panel) due 
to protA-IgG interaction. Expression levels of EGFR (top panel) and active MAPK (middle panel) were 
quantified and related to the GAPDH expression level (bottom panel) and plotted as a function of time (bottom 
graphs). Representative of 2 experiments. 
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The dominant-negative activity of the GFP-Rhod and GFP-Rhod-dSB constructs correlated (i) with 
their ability to coprecipitate with the EGFR (Figure 7, 3rd panel), (ii) with the disappearance of 
intermediate EGFR degradation products (Figure 7, 2nd panel) and (iii) with the accumulation of the 
180 kDa EGFR (Figure 7, 2nd panel). In addition, as seen previously for the enzymatically active Dub 
domains, overexpression of the dominant negative GFP-Rhod and GFP-Rhod dSB constructs also 
lead to the EGFR mobility shift that is characteristic for activated EGFR (Figure 7, panel 5 and 
Supplementary Figure 1) as well as constitutive upregulation of  EGFR-dependent MAPK activation 
(Figure 7, bottom panel, compare lanes 5-10). Indeed, an EGFR doublet can be clearly observed upon 
coepression of GFP-Rhod but not GFP-Rhod d140 or GFP alone, although the mobility shift is 
somewhat less pronounced when compared to EGF stimulation (Supplementary Figure 2), consistent 
with partial activation of the EGFR. Moreover, as shown in Supplementary Figure 3 (bottom panel), 
the basal MAPK activation observed upon coexpression of EGFR with GFP Rhod but not GFP alone 
(compare lanes 1 and 5) is clearly less than the MAPK activation observed upon EGF stimulation. It 
should be noted that HEK293 cells do contain small numbers of EGFRs leading to significant EGF-
induced MAPK activation in the absence of overexpressed EGFR. Collectively, these findings 
demonstrate that the N-terminal half of UBPY acts as a dominant negative and forms a complex with 
the EGFR in a manner that depends on the N-terminal 140 amino acids but not on the N-terminal Hbp 
SH3 binding motif (SB-N). Overexpression of the dominant negative N-terminal regulatory half of 
UBPY leads to enhanced activation of the EGFR under steady state conditions which is associated 
with enhanced EGFR ubiquitination, enhanced MAPK activation, enhanced EGFR expression levels 
and disappearance of intermediate EGFR degradation products. 
 
DISCUSSION 
 
Here we demonstrate that the UBPY/Usp8 deubiquitinating enzyme is tyrosine phosphorylated in 
response to EGF treatment in an EGFR- and Src-family kinase-dependent manner. Our data 
demonstrate that UBPY constitutively forms a complex with the EGFR and that catalytically inactive 
UBPY exhibits enhanced substrate binding (i.e. substrate-trap characteristics). Furthermore, UBPY 
de-ubiquitinates the EGFR in vitro and in vivo in a Cys748-dependent manner. Non-overlapping N-
terminal and C-terminal deletion constructs of UBPY act as dominant negatives in vivo by modulating 
constitutive and ligand-induced (i) EGFR ubiquitination, (ii) EGFR expression levels, (iii) appearance 
of intermediate EGFR degradation products and (iv) downstream MAPK signaling.   
 
 Post-translational modification of UBPY 
Our findings indicate that UBPY is primarily a substrate for Src-family tyrosine kinases that are 
activated in response to EGFR ligand binding. Given that both UBPY (this study) and Src (31) 
coprecipitate with the EGFR, it is possible that UBPY is phosphorylated by Src in a trimolecular 
UBPY-EGFR-Src complex. Our findings indicate that the N-terminal but not the C-terminal half of 
UBPY is sufficient for Src-mediated tyrosine phosphorylation. However, it is formally possible that 
the Dub domain undergoes tyrosine phosphorylation within the context of the full length UBPY. The 
functional relevance of UBPY tyrosine phosphorylation and the predicted recruitment of SH2 or PTB 
domain-containing proteins to UBPY remains unknown. Mapping of UBPY phosphorylation sites (in 
progress) will be necessary to determine its functional significance on UBPY deubiquitination 
activity, its subcellular distribution, its association with other proteins and/or its substrate specificity 
in vivo. As seen in Figure 2, the GFP-Rhod and GFP-Dub constructs migrate as two separate bands on 
SDS-PAGE. Indeed, both endogenous as well as recombinantly expressed wild-type UBPY can be 
resolved into a doublet on SDS-PAGE. It is possible that this is due to post-translational modification, 
e.g. phosphorylation or ubiquitination. However, we have no reason to assume that the upper band is 
due to tyrosine phosphorylation of UBPY as the GFP-Rhod construct still migrates as a doublet in the 
presence of (i) EGFR kinase inhibitor PD153035 (Fig 3A, panel 2, lane 7-8), or (ii) Src kinase 
inhibitor PP2 (Fig 3B, 2nd panel, lane 7-8). In addition, the GFP-Dub domain is not tyrosine 
phosphorylated but it still migrates as a doublet (Fig 2C). Furthermore, overlay of the blots (Fig 2C, 
1st and 2nd panel; Fig 3A, 1st and 2nd panel; Fig 3B, 1st and 2nd panel) reveals that the prominent 
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tyrosine phosphorylated GFP-Rhod band corresponds to the lower band of the doublet. Prolonged 
exposures reveal that the upper band also contains phosphotyrosine (data not shown). 
 Although we do not have direct evidence for ubiquitination of wild-type or endogenous UBPY in 
vivo, inhibition of in vitro enzymatic activity of Flag-tagged UBPY using the alkylating agent NEM 
not only leads to defects in deubiquitination of immunopurified ubiquitinated EGFR substrate but also 
to a slight increase in the apparent molecular weight of wild-type Flag-Usp8 on SDS-PAGE (data not 
shown), suggesting that immunopurified UBPY is ubiquitinated and is undergoing NEM-sensitive 
auto-deubiquitination (25). 
 
 Complex formation of UBPY with the EGFR in vivo 
Our findings demonstrate that UBPY constitutively forms a complex with the EGFR in a ligand- and 
EGFR kinase-independent manner, which contrasts with the EGF-induced EGFR-UBPY 
coprecipitation reported elsewhere (25). Moreover, the coprecipitation of the non-overlapping rhod 
(amino acids 1-504) and dub constructs (amino acids (640-1080) with the EGFR points to a bivalent 
interaction of UBPY with the EGFR. Coprecipitation of the UBPY Rhod construct is dependent on 
the N-terminal 140 amino acids, while the coprecipitation of the UBPY Dub domain with the EGFR is 
dependent on the catalytic Cys748 residue. A similar bivalent interaction involving the UBPY 
rhodanese-like homology and dub domains has recently been demonstrated between UBPY and its 
substrate Nrdp1, an E3 ubiquitin ligase for ErbB3 and ErbB4 proteins (32). It is possible that the 
interaction between UBPY and the EGFR is indirect as pull down experiments with GST-Rhod and 
GST-Dub domains and whole cell lysates obtained from unstimulated and EGF-stimulated HER-14 
cells did not lead to co-purification of the EGFR (data not shown). Interaction of full length UBPY 
with the EGFR increases profoundly when the catalytic cysteine is mutated, as has been reported by 
others (25). In contrast, the association of the truncated UBPY Dub domain with the EGFR is 
abolished by introduction of the C748A mutation, suggesting that the UBPY Dub domain recognizes 
the EGFR solely via active site binding of ubiquitin. Although the molecular basis for the apparent 
discrepant consequences of the C748A mutation in full length UBPY as opposed to the isolated 
UBPY Dub domain is not known, it is possible that failure to deubiquitinate the EGFR by full length 
UBPY C748A leads to prolonged complex formation through the UBPY N-terminal/rhodanese 
region. Based on the crystal structure of HAUSP/Usp7 in the presence and absence of ubiquitin 
aldehyde (33) it is clear that DUB domains undergo a conformational change upon ubiquitin binding, 
which may prevent spurious binding of DUB enzymes to ubiquitinated cellular proteins. Selection of 
the proper substrate for specific dub enzymes may be mediated by specialized substrate interactions 
domains outside the DUB domain, such as the UBPY rhodanese homology domain or the N-terminal 
140 amino acids of UBPY.  
 
 UBPY affects EGFR ubiquitination 
Overexpression of either the catalytically inactive full length UBPY or the truncated UBPY Rhod 
construct leads to enhanced constitutive and ligand-induced EGFR ubiquitination. In contrast, 
overexpression of the isolated UBPY dub domain did not lead to obvious accumulation of 
ubiquitinated EGFRs. We currently favour the model that the isolated enzymatically active UBPY 
dub domain prematurely de-ubiquitinates the EGFR at the plasma-membrane or in an early endosomal 
compartment, thereby limiting ubiquitin-dependent EGFR sorting to the lysosomal pathway which, in 
turn, could lead to enhanced MAPK signaling and reduced EGFR degradation (Supplementary Figure 
4). In contrast, overexpression of the full length UBPY C748A or C-terminally truncated Rhod 
construct leads to profound accumulation of ubiquitinated EGFRs as well as enhanced EGFR 
expression levels and MAPK activation. It is important to note that the effects of the dominant 
negative constructs on EGFR ubiquitination were still retained when the Hbp SH3 binding motifs 
were deleted (data not shown), indicating that the observed effects were not artefacts due to 
competition of these dominant negative UBPY constructs and AMSH for binding to the Hbp-Hrs 
complex. Although it seems counter-intuitive that enhanced EGFR ubiquitination is correlated with 
enhanced EGFR expression levels, it seems possible that the full length UBPY C748A and the UBPY 
Rhod construct are recruited to late endosomal membranes where they associate with evolutionary 
conserved ESCRT-III and/or Vps31/Alix proteins thereby preventing recruitment of endogenous 
UBPY to late endosomal membranes. The failure to de-ubiquitinate EGFR cargo on late endosomal 
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membranes may lead to reduced incorporation into internal vesicles of MVBs and consequent 
enhanced EGFR expression and downstream signalling (Supplementary Figure 4) (34). Consistent 
with our conclusions, Row and colleagues (26) recently reported prolonged retention times of the 
EGFR on late endosomes, enhanced endosomal ubiquitin staining, the appearance of MVBs with 
sparse internal vesicles and large numbers of MVBs that were “stitched” together in UBPY knock 
down cells. They speculated that these “stitched MVBs” could represent cargo proteins on the limiting 
membrane of MVBs that associate in trans with ubiquitin binding motifs on partner MVBs, and 
concluded that UBPY is essential for EGFR degradation (26). As mentioned earlier, Mizuno and 
colleagues reached the conclusion that UBPY inhibits EGFR degradation (25). Although the 
underlying reason for the apparently conflicting data is presently unclear, we believe it is important to 
note that inhibition of UBPY function (using either RNAi or dominant negative constructs) leads to 
enhanced EGFR ubiquitination and thus a shift to higher apparent molecular weights on western blots, 
which confounds and thus limits the use of the 180 kDa EGFR band on Western blots as a 
quantitative measure for EGFR degradation. 
 Although we cannot formally exclude the possibility that the enhanced EGFR ubiquitination seen 
following overexpression of catalytically inactive full length UBPY or the truncated Rhod construct is 
the result of enhanced recruitment of an E3 ligase, we favor the simplest model that enhanced EGFR 
ubiquitination is the result of impaired EGFR deubiquitination for a variety of reasons. First, we 
previously demonstrated that the EGFR undergoes deubiquitination (4). Second, enhanced EGFR 
ubiquitination induced by these dominant negative constructs correlates with their ability to 
coprecipitate with the EGFR. Third, it is not clear why the full length UBPY C748A mutation would 
lead to a gain-of-function such as enhanced E3 ligase recruitment. The UBPY Rhod constructs shows 
a very similar phenotype as the UBPY C748A mutant. Fourth, we (unpublished data) and others (32) 
have not been able to coprecipitate UBPY and the E3 ligase Cbl. Fifth, although it has previously 
been reported that UBPY can physically interact with Nrdp1, an E3 ligase for ErbB3 and ErbB4 
proteins, disruption of UBPY enzymatic activity destabilizes the Nrdp1 protein by enhancing Nrdp1 
ubiquitination and degradation (32). Sixth, a recent crystal structure of the UBPY N-terminal region 
(PDB code 2A9U) shows that this region can dimerize. The requirement for the N-terminal region for 
the dominant negative activity of the UBPY Rhod construct may therefore be due to its ability to 
dimerize with endogenous UBPY proteins. 
 Given that overexpression of the UBPY rhod construct leads to accumulation of ubiquitinated 
cellular proteins even in the absence of co-transfected EGFRs (Figure 7), it is clear that the EGFR is 
not the only substrate for the deubiquitinating enzyme activity of UBPY (30,32). We hypothesize that 
additional endosomal ubiquitinated cargo and/or endosomal adaptor proteins (e.g. Eps15, CIN85) may 
be substrates for UBPY. In yeast, the Doa4 ortholog has been shown to dynamically associate with 
proteasomes in sub-stoichiometric amounts (35). So far, UBPY has not been detected in mammalian 
proteasome preparations. However, if mammalian UBPY (transiently) associates with proteasomes, a 
model that is consistent with our previous findings of proteasome-dependent deubiquitination of the 
EGFR (4), then the number of potential substrates for UBPY may obviously be very large.  
 Our finding that dominant negative UBPY constructs dramatically enhance EGFR ubiquitination 
even in the absence of ligand provides novel and compelling evidence that steady state EGFR 
ubiquitination is determined by the balance between ubiquitination and deubiquitination under our 
assay conditions. Even more striking is our finding that dominant negative UBPY constructs enhance 
ubiquitination of EGFR wild-type and Y1045F constructs, which is in line with the finding by Huang 
et al., (12) that lysine residues within the kinase domain of EGFR Y1045 mutants still undergo 
ubiquitination. Given the role of Doa4/Ubp4 in yeast, we hypothesize that such cycles of 
ubiquitination and deubiquitination occur at the plasma-membrane or in an endosomal compartment. 
The dramatic ligand-independent EGFR ubiquitination seen in the presence of dominant negative 
UBPY rhod constructs also raises the question which E3 ubiquitin ligase is responsible for 
constitutive EGFR ubiquitination. Clearly, such ubiquitination is not mediated by Cbl recruitment to 
EGFR pTyr1045, although Cbl may also be recruited to the EGFR indirectly (6,12,15). Recently, 
SOCS proteins have been implicated in constitutive EGFR ubiquitination (36,37) although the 
mechanism of SOCS recruitment to the EGFR is currently unclear. It is also possible that UBPY is 
not the only DUB enzyme that controls the ubiquitination status of the EGFR and other ErbB family 
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members. Indeed, AMSH has recently been suggested to play a role in EGFR deubiquitination based 
on in vitro data (38).  
 In general, DUB enzymes may be involved in different biological processes such as (i) processing 
of tandem ubiquitin precursor chains, (i) recycling of ubiquitin from proteins that are targeted for 
proteasomal degradation, (iii) recycling of ubiquitin from proteins that are destined for 
vacuolar/lysosomal degradation, or (iv) trimming of poly-ubiquitin chains to mono/oligo-ubiquitin 
adducts (39). Recently,  two groups reported that the EGFR is modified mostly by mono-ubiquitin 
adducts on multiple lysines rather than poly-ubiquitin chains (10,11). More recently, using mass 
spectrometry, Huang and colleagues reported that the EGFR is ubiquitinated on multiple lysines in the 
kinase domain and that a significant fraction of ubiquitin was present in the form of K63-linked poly-
ubiquitin chains (12). The mechanism underlying Cbl-mediated mono- rather than poly-ubiquitination 
is, however, not clear. To reconcile these apparently conflicting data, we suggest the possibility that 
UBPY is involved in trimming Cbl-induced poly-ubiquitin chains to mono-ubiquitin adducts. Such a 
model would predict that the EGFR contains a mixture of mono- and poly-ubiquitin chains. Although 
it was originally reported that UBPY mediated deubiquitination is specific for K48- as opposed to 
K63-linked polyubiquitin chains (38), more recent data from the same group suggest that UBPY can 
hydrolyse both K48- as well as K63-linked polyubiquitin linkages (26), which would be consistent 
with the model we propose. 
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Supplementary Figure 1. EGFR mobility shift induced by coexpression of EGFR with GFP-Rhod and GFP-
Dub  
HEK293 cells were co-transfected with EGFR and GFP-tagged UBPY deletion constructs or as indicated. Serum 
starved cells were lysed, and WCL’s were used for immunoblotting with anti-EGFR (Ab12). 
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Supplementary Figure 2. EGFR mobility shift induced by GFP-Rhod in the presence and absence of EGF.  
HEK293 cells were transfected with EGFR, and EGFP-tagged UBPY deletion constructs as indicated. Serum 
starved cells were EGF-stimulated, and WCLs used for immunoblotting with anti-EGFR (Ab12), anti-GFP and 
anti-GAPDH as indicated. 
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Supplementary Figure 3. Basal MAPK activation upon coexpression of EGFR and GFP Rhod. 
HEK293 cells were co-transfected with GFP-Rhod and EGFR. Serum starved cells were EGF stimulated and 
WCL’s were used for immunoblotting with anti-EGFR, anti-GFP, anti-GAPDH (top panel) and anti-active 
MAPK (bottom panel) as indicated. 
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Supplementary Figure 4. Hypothetical model explaining the effect of UBPY dominant negative constructs on 
EGFR signalling and endosomal transport. 
Following internalisation and transport of the EGFR to early sorting endosomes, ubiquitin serves as a sorting 
signal to incorporate the EGFR into internal vesicles of multivesicular bodies. Similar to the action of 
Doa4/Ubp4 in budding yeast, UBPY may serve to recycle ubiquitin from lysosomal cargo proteins thereby 
promoting incorporation of the EGFR into internal vesicles of MVBs, after which downstream signalling to the 
cytoplasmic MAPK pathway is effectively blocked. Dominant negative UBPYC748A and UBPY Rhod 
constructs may prevent deubiquitination of EGFR cargo, delaying incorporation of the EGFR into internal 
vesicles of MVBs, and allowing prolonged MAPK signalling. The isolated UBPY Dub domain may remove 
ubiquitin from the EGFR in an early endosomal compartment before the ubiquitin-dependent sorting towards 
MVBs has taken place, resulting in prolonged MAPK signaling. 
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ABSTRACT 
 
 Tandem affinity purification (TAP) is widely used as a tool for (genome wide) purification of 
specific protein complexes prior to tandem mass spectrometry (MS) analysis. Here, we report on a 
novel strategy that greatly facilitates the TAP tagging technique. The Usp8 deubiquitinating enzyme 
was N-terminally tagged with a Protein A-TEV-8xHis sequence. Following IgG affinity precipitation, 
His-tagged TEV protease cleavage and metal chelation chromatography, we used a novel elution 
strategy that depends on 8M urea to elute Usp8-interacting proteins which conveniently leaves the 
His-tagged TEV and His-tagged Usp8 proteins bound to the Ni-NTA matrix. Eluted Usp8-interacting 
proteins were identified directly after in solution trypsin digestion by LC-MS/MS analysis. We 
identified 14-3-3 proteins as in vivo Usp8 interacting partners and confirmed this interaction in vitro. 
Phosphorylation of the Usp8 14-3-3 binding motif was confirmed by MS2 and neutral loss directed 
MS3 analysis while interaction between Usp8 and 14-3-3 was abolished by mutation of the Usp8 14-3-
3 binding motif.  
 
INTRODUCTION 
 
 Tandem affinity purification (TAP) (1,2) is widely used as a tool for (genome wide (3-5)) 
purification of specific protein complexes prior to tandem mass spectrometry (MS) analysis (6). The 
TAP tagging technique makes use of two different affinity tags that are separated by a protease 
cleavage site and fused in frame (at either N- or C-terminal end) to the protein-of-interest. In general, 
the S.aureus protein A sequence (sometimes used in tandem) is used as the 1st most distal tag and used 
for IgG affinity precipitation of protein complexes containing the protein-of-interest. The protA tag is 
usually followed (in case of N-terminal TAP-tagging) by a Tobacco Etch Virus (TEV) protease 
cleavage site, a highly unique amino-acid consensus sequence. TEV protease cleavage of IgG affinity 
purified protein-of-interest complexes then leads to release of the protein complexes into the 
supernatant. The second affinity tag can then be used to re-purify released protein complexes 
containing the protein-of-interest. Various tags in combination with various elution strategies have 
been used during the 2nd affinity precipitation step. Originally, calmodulin binding peptide (CBP) was 
used in combination with elution with divalent cation chelators for genome-wide TAP-tagging studies 
in yeast (3,5). However, as calmodulin is associated with many mammalian proteins, various research 
groups who applied the TAP technique to mammalian protein complexes instead have used immuno-
affinity epitope tags (e.g. Flag- or Myc-peptides) followed by elution with excess immuno-affinity 
peptide (7). However, such a strategy leads to the presence of large amounts of uninformative peptide 
in the final eluted purified protein mixture. Moreover, these epitope tags contain an internal trypsin 
cleavage site making further protein purification steps (e.g. gel-filtration, SDS-PAGE) prior to trypsin 
digestion and mass spectrometry necessary. The 6xHis-tag has also been used in combination with 
metal chelation affinity chromatography (MCAC) during the 2nd purification step which is then 
followed by elution with the histidine analog imidazole (8,9). As is true for the other strategies 
described above, this procedure leads to the presence of the protein-of-interest itself in the final 
purified protein mixture. In addition, when using His-tagged TEV protease for cleavage, the His-
tagged TEV protease will be co-purified with the protein complexes following Ni-NTA MCAC and 
imidazole elution. We therefore designed a novel elution strategy after MCAC in combination with the 
ProtA-TEV-8xHis TAP tag that conveniently leaves the His-tagged protein-of-interest and the His-
tagged TEV protease bound to the Ni-NTA matrix. 
 We applied this novel TAP strategy to mouse Usp8 (also called UBPY) (10), a member of the 
ubiquitin specific protease (Usp) family of deubiquitinating enzymes (11). It is the mammalian 
ortholog of yeast Ubp4/Doa4 which is involved in deubiquitination of substrate proteins that are 
targeted through the multi-vesicular body (MVB) pathway to yeast vacuoles (the equivalent of 
mammalian lysosomes) (12-14). Using RNAi techniques against human USP8, Mizuno et al., (15) as 
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well as Row et al., (16)  recently provided the first evidence that Usp8 is involved in deubiquitination, 
degradation and downstream signaling of the EGFR, although these studies reached conflicting 
conclusions. While one study (15) concluded that USP8 mediated EGFR deubiquitination inhibits 
EGFR degradation, the other study (16) concluded that USP8 was essential for EGFR degradation. We 
have previously used a dominant negative approach to study the role of USP8 in EGFR degradation 
(chapter III). Specifically, we found that Usp8 (i) is subject to tyrosine phosphorylation upon EGFR 
activation, (ii) constitutively interacts with the EGFR and (iii) affects EGFR ubiquitination, 
downstream MAPK signal transduction, and EGFR turnover in both ligand-dependent and ligand-
independent model systems. Our findings provided further evidence supporting the model that USP8 
promotes EGFR degradation. Usp8 has also been proposed to be involved in various other pathways 
including G1 to S-phase transition (10), regulation of the Nrdp1 E3 ligase (17), and Ras-GRF1 (18).  
Here, we used the novel TAP tagging strategy to identify 14-3-3 phosphoserine binding proteins as in 
vivo interaction partners for Usp8. Serine phosphorylation of the Usp8 14-3-3 consensus binding motif 
was confirmed by MS2 and neutral loss MS3 analysis and mutation of the Usp8 14-3-3 consensus 
binding motif abolished the association of Usp8 with 14-3-3 proteins.  
 
EXPERIMENTAL PROCEDURES 
 
 Reagents 
The following reagents were used: Tobacco Etch Virus (TEV) protease, Ni-NTA agarose beads, anti-
His antibody and lipofectamine 2000 (Invitrogen), pZome-N1 (CellZome), pEGFP (GE healthcare), 
anti-EGFR 1005 polyclonal Ab, anti-EGFR 528 mAb and anti-GFP mAb (Santa Cruz), anti-EGFR 
Ab-12 (Neomarkers), anti-ubiquitin U537 and anti-flag M2 (Sigma), goat anti-rabbit (GARPO) and 
goat anti-mouse (GAMPO) antibodies linked to horseradish peroxidase (Signal Transduction 
Laboratories), IgG-, protein A- and protein G-sepharose beads (Amersham Biosciences), N-
ethylmaleimide (NEM) (Calbiochem). HEK293 cells, NIH3T3 mouse fibroblasts and ecotrophic 
Phoenix cells were obtained from the American Type Culture Collection. 
 Molecular biology 
The protA-TEV-8xHis TAP-tag sequence was constructed to encode exactly the same TAP sequence 
as reported by Knuesel et al (7), except we used the 8xHis-tag instead of the reported second affinity 
flag epitope-tag. The TAP sequence of pZome-N1 was removed with BamHI and EcoRI digestion. 
The constructed 8xHis TAP-tag was cloned into BamHI and EcoRI site to generate pZTAP-His8 
vector carrying EcoRI and XhoI as multiple cloning sites. The mouse Usp8 cDNA cloned in the 
mammalian expression vector pME18S was kindly provided by Dr. N. Kitamura (19). To construct 
TAP-Usp8, full length Usp8 was amplified by PCR with forward primer: 5`-
AAGAATTCGCTGTAGCTTCAGTTCCTAAAGAACTCTACCTCA-3` and reverse primer: 5`-
AAAACTCGAGCTATGTGGCTACATCAGTTATGCGTGGTC-3`. The resulting fragment was 
digested with EcoRI and XhoI and cloned into pZTAP-His8. Similarly, the Usp8 Dub domain was 
amplified with forward primer: 5`-AAGAATTCCCACCTGAAATGGCTCCTTCGTC-3` and reverse 
primer 5`-AAAACTCGAGCTATGTGGCTACATCAGTTATGCGTGGTC-3` and the resulting Dub 
fragment was cloned into EcoRI and XhoI sites of pZTAP-His8. Construction of EGFP-Usp8 and 
EGFP-Dub is reported elsewhere (chapter III). The EGFP-Usp8 SS->AA and EGFP-Dub SS->AA 
double mutants in which Ser678 and Ser680 (of the RSYSSP motif) were substituted for alanine, were 
generated using the quick-change site directed mutagenesis method (Stratagene) and the forward 
mutant primer 5`-AAACTGAAGCGCGCCTACGCCTCACCAGAT-3` and reverse mutant primer 5`-
GATATCTGGTGAGGCGTAGGCGCGCTTCAG-3`.  GST-14-3-3ζ was a generous gift from Dr. 
Jesse D. Martinez (University of Arizona). 
 Cell culture and generation of stable cell lines: 
HER-14 cells (NIH3T3 cells stably transfected with the human EGFR), NIH3T3 mouse fibroblasts, 
Human Embryonic Kidney Cells (HEK293), and ecotrophic Phoenix cell lines were grown at 37 °C in 
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Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum (NCS). 
Transient transfection was performed using either calcium phosphate precipitation according to 
standard procedure or lipofectamine 2000 according to manufacturer instructions. Retroviral 
transduction was used to generate stable cell lines expressing TAP-tagged mouse Usp8 (amino-acids 
1-1080) and Dub domain (amino-acids 640-1080) according to standard protocols. Briefly, retrovector 
pZTAP-His8 carrying full length mouse Usp8 or Dub domain were transfected into the Phoenix 
ecotrophic retroviral packaging cell line to produce viruses. Viral stock was then used to infect HER-
14 cells. Cells expressing pZTAP-His8 vector, TAP-Usp8 and TAP-Dub proteins were then obtained 
by puromycin selection. 
 Purification of protein complexes, western blotting and Data Quantification: 
HER-14 cells expressing TAP-Usp8 were grown to 90% confluency in ten 15 cm dishes. Cells were 
trypsinized, collected and centrifuged at 4°C, washed once with ice-cold DMEM without serum and 
once with ice-cold PBS. Subsequently, the cell pellet was lysed on ice with 5x pellet volume of lysis 
buffer containing 150 mM NaCl, 25 mM Tris pH 7.5, 1% Triton-X-100, 1 mM Na3VO4, 1 mM NaF, 1 
mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml pepstatin. Whole 
cell lysates (WCLs) were cleared by centrifugation at 4°C, 14000 rpm for 15 minutes. The first affinity 
purification step was carried out by adding 100 μl of 50% slurry IgG sepharose to 1.5 ml of cleared 
cell lysate and incubation for one hour at 4°C in an end-to-end rotor. Beads were washed three times 
with lysis buffer followed by three times with TEV buffer containing 150 mM NaCl, 10 mM Tris-HCl 
pH 8.0, 1mM DTT, 0.1% Triton-X-100. TEV protease was added to the beads in a total volume 150 
μl. TEV cleavage was carried out for one hour at 30°C. Subsequently, the supernatant containing 
protein complexes, which is referred to as the TEV fraction throughout this manuscript, was added to 
Ni-NTA beads to perform the second affinity (metal chelation) purification step for one hour at 4°C. 
Protein complexes purified in the second affinity step were washed 4 times with lysis buffer followed 
by three times with PBS. Finally, Ni-beads were incubated with 8M urea, which denatures proteins 
present in the sample resulting in dissociation of interacting proteins while leaving His-tagged Usp8 
bound to the Ni-beads. Urea supernatant containing the interacting proteins were aliquoted into sterile 
tubes and referred to as the urea elution fraction throughout this manuscript. The remaining Ni-beads 
are referred to as the Ni-beads fraction. Silver staining was carried out according to standard 
procedure. Western blotting was performed as described previously (20,21). Data quantification was 
performed with Photoshop software (Adobe systems). Briefly, mean pixel value (MPV) was calculated 
for a predefined rectangle encompassing signal of interest (SOI) after subtracting the background 
signal. Similar calculation was then carried out for loading control samples as indicated in the figures. 
The data plotted in the graphs represent MPV of SOI divided by the MPV of the loading control. 
 Phosphopeptide and protein identification by LC-MS/MS and MS3 analysis 
Data acquisition 
To identify Usp8 interacting proteins TAP purification of TAP-tagged Usp8 was carried out. The urea 
elution fraction containing interacting proteins was directly used for ‘in solution’ trypsin digestion. For 
phosphopeptide analysis, the Ni-beads fraction containing immobilized Usp8 was reconstituted in 1x 
Laemmli sample buffer and heated at 100 °C for 3 minutes. Sample was then fractionated on SDS-
PAGE gel and coomassie stained. Protein band corresponding to Usp8 was excised from the gel and 
trypsin digestion was carried out according to standard procedure. Prior to nanoLC-MS analysis, all 
trypsin digested samples, from Ni-beads and urea fraction, were purified and desalted using C18 
STAGE tips (21). Peptide identification experiments were performed using a nano-HPLC Agillent 
1100 nanoflow system connected online to a 7-Tesla linear ion trap ion cyclotron resonance Fourier 
transform (LTQ-FT) mass spectrometer (Thermo Electron, Bremen, Germany). Peptides were 
separated on a 15 cm 100 μm ID PicoTip column (New Objective, Woburn, USA) packed with 3 μm 
Reprosil C18 beads (Dr. Maisch GmbH, Ammerbuch, Germany) using a 45 min gradient from 0% 
buffer B to 40% buffer B (buffer B contains 80% acetonitrile in 0.5% acetic acid) with a flow-rate of 
300 nl/min. Peptides eluting from the column tip were electro-sprayed directly into the mass 
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spectrometer with a spray voltage of 2.1 kV. The mass spectrometer was operated in the data-
dependent mode to sequence the four most intense ions per duty cycle. Briefly, full-scan MS spectra of 
intact peptides (m/z 300–2000) with an automated gain control accumulation target value of 1xE6 ions 
were acquired in the Fourier transform ion cyclotron resonance (FT ICR) cell with a resolution of 
50.000. The four most abundant ions were sequentially isolated and fragmented in the linear ion trap 
by applying collisionally induced dissociation using an accumulation target value of 20.000 (capillary 
temperature, 200°C; normalized collision energy, 30%). A dynamic exclusion of ions previously 
sequenced within 180 s was applied. All unassigned charge states were excluded from sequencing. A 
minimum of 500 counts was required for MS2 selection. Data-dependent neutral loss scanning of 
phosphoric acid groups was enabled for each MS2 spectrum among the three most intense fragment 
ions.  
Data analysis 
RAW spectrum files were converted to DTA files and combined into a single Mascot generic peaklist 
by DTA SuperCharge (http://msquant.sourceforge.net/) This software tool also extracts the accurate 
precursor FT-MS mass for data-dependent neutral loss scanning. Peptides and proteins were identified 
using the Mascot 1.2 (Matrix Science) algorithm to search a local version of the NCBI non-redundant 
mammals database (ftp://ftp.ncbi.nih.gov/blast/db/FASTA/  downloaded at 2006-05-02 containing 
3636889 entries) and the UNIProt mammals database 
(ftp://ftp.ebi.ac.uk/pub/databases/uniprot/knowledgebase/ downloaded at 2005-11-29, version 48.0 
containing 199607 entries) . The following search criteria were applied: 10 ppm initial mass tolerance 
for the parental peptide and 0.5 Da for fragmentation spectra, and a fixed carbamidomethyl 
modification for cysteines. Acetylation (lysine and N-terminus), oxidation of methionine, deamidation 
(glutamine and asparagine), phosphorylation (serine and threonine) were searched as variable 
modifications. Stringent criteria for protein identification were applied to eliminate false positive 
protein identifications. These criteria were established previously by us using reverse database 
searches. A minimal Mascot peptide score of 24 was required for the entire dataset in addition to a 
minimal charge state of parent ions of 2 and observed minimal parent ion m/z of 400. An internal mass 
calibration of the peptides was performed using MSQuant (http://msquant.sourceforge.net/) enabling a 
final mass tolerance of 6 ppm. Correct protein identification required at least two non redundant 
peptides fulfilling above-mentioned criteria. For the phosphopeptides, visual inspection of the MS2 
and MS3 spectra was performed to assure correct identification. We only considered phosphopeptides 
identified by both methods. 
 
RESULTS 
 
 To identify novel binding partners for Usp8, we used the tandem affinity purification (TAP) 
technique (1,2) to isolate in vivo protein complexes containing Usp8 (Figure 1). In this procedure, 
Usp8 is N-terminally tagged with the protA-TEV-8xHis linker. The fusion construct was stably 
expressed in HER-14 cells (NIH3T3 cells stably expressing the human EGFR) using retroviral 
infection. The TAP linker did not interfere with the enzymatic activity of the Usp8 proteins (Figure 2). 
The protein A tag was then used for IgG affinity precipitation (Figure 3A). After removal of the 
protein A tag following incubation with His-tagged Tobacco Etch Virus (TEV) protease, His-tagged 
Usp8 was recovered by Ni-NTA metal chelation affinity chromatography (Figure 3B). Rather then 
using the calmodulin binding peptide (CBP) which requires elution with EGTA (3,5), or an immuno-
affinity epitope tag (e.g. flag, myc) which requires elution with high concentrations of epitope tag-
peptide and subsequent gel filtration (7), we used the 8xHis-sequence during the 2nd affinity 
precipitation step. The His-tag has been used previously in the TAP procedure in combination with 
elution with the histidine analog imidazole, which is usually followed by a protein concentration step 
(8,9). Importantly, as a novel strategy we used 8M urea to elute Usp8-interacting proteins from the Ni-
NTA matrix. Urea elution greatly reduces the complexity of the protein mixture for subsequent mass  
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Figure 1: Improvement of TAP-tagging procedure in mammalian cells 
A. The original TAP-tagging procedure as applied to yeast proteomics where a protein of interest is linked to a 
protein A-TEV-calmodulin binding peptide (CBP) sequence (1,3). In the first affinity purification step the 
protein A-tagged protein of interest and its interacting proteins are precipitated by IgG sepharose beads. 
Following removal of unbound material, protein complexes are released into the supernatant after TEV protease 
cleavage. Protein complexes are reprecipitated in the second affinity purification step by recapturing the CBP-
fusion protein complexes on calmodulin-coated beads. Recovered protein complexes are eluted with EGTA and 
proteins are fractionated on SDS-PAGE gel. Protein bands of interests are excised from the gel and ‘in gel’ 
tryptic digestion is usually carried out before protein identification by mass-spectrometry. B. TAP-tagging 
procedure as applied to mammalian cells where the CBP sequence is replaced with a flag epitope-tag.  First step 
purification and TEV protease cleavage is carried out basically as in (A). The second step purification of protein 
complexes requires the preparation of anti-flag affinity matrix. Protein complexes purified by anti-flag affinity 
matrix are subsequently eluted with excess flag peptide. The eluate contains in this case the fusion protein, 
interacting proteins, as well as the flag peptide.  Subsequently, ‘in solution’ trypsin digestion requires prior 
removal of the flag peptide by size exclusion chromatography because the peptide contains a trypsine cleavage 
site, which may decrease the efficiency of trypsin digestion. Therefore, eluates obtained with excess of flag 
peptide are fractionated on SDS-PAGE gel. Coomassie-staining visualizes protein bands, which requires large 
quantities of eluate material. C) Improvement of the TAP-tagging procedure in mammalian cells is achieved by 
using the 8xHis-tag. First affinity purification step and TEV cleavage are carried out as in (A) Protein complexes 
are recovered on Ni-NTA beads. Subsequently, unbound materials are washed away, and elution in 8M urea 
recovers only interacting proteins, while leaving His-tagged proteins bound to the matrix. In Solution trypsin 
digestion is directly carried out in the supernatant prior to identification of interacting proteins by LC-MS/MS. 
On-beads In Solution digestion could also be carried out on the TAP-tagged protein for analysis of post-
translational modifications. 
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Figure 2: The TAP-His tag does not interfere with Usp8 enzymatic activity: 
HER-14 cells stably expressing TAP-His tagged C-terminal Dub domain of Usp8 was used to immobilize TAP-
tagged Dub domain on IgG sepharose beads. As a positive control, flag-tagged Usp8 was transiently expressed 
in NIH3T3 cells and subsequently immobilized on Prot-G sepharose beads coupled to anti-flag antibody. 
Immobilized proteins were either treated with NEM for 60 minutes or mock treated. Serum starved HER-14 
mouse fibroblasts stably expressing human EGFR were stimulated with 100 ng/ml EGF for 15 minutes to allow 
EGFR poly-ubiquitination. Ubiquitinated EGFRs were immunoprecipitated with monoclonal anti-EGFR (528) 
antibodies coupled to Prot-A sepharose beads. After washing of unbound material, the beads were split into four 
fractions. Each of them was combined with immobilized TAP-tagged Dub domain and flag-tagged Usp8 in 1x 
deubiquitination buffer (10 mM Tris-HCl, pH 8.0, 1 mM DTT, 1 mM EDTA). EGFR deubiquitination was 
allowed to proceed for 90 minutes at 37 ˚C. Subsequently, beads were washed three times, resuspended in 2x 
Laemmli sample buffer, and heated for 3 minutes at 100 ˚C. Protein mixtures were then fractionated on SDS-
PAGE gel, transferred to nitrocellulose filter, and subsequently blotted with anti-ubiquitin antibody. The same 
membrane was then reprobed with monoclonal anti-EGFR (clone Ab-12) and monoclonal anti-flag antibody to 
visualize the amount of precipitated EGFR, flag-Usp8, and TAP-Dub. Lane-1 mock-treated TAP-Dub, lane-2 
NEM-treated TAP-Dub, Lane-3 mock-treated flag-Usp8, lane-4 NEM-treated flag-Usp8. Graph represents 
quantification of the ubiquitin signal shown in the middle panel. 
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Figure 3: An improved tandem affinity purification procedure using protein A-TEV-8xHis TAP tagging and urea 
elution prior to in solution trypsin digestion and LC-MS/MS analysis. 
TAP-tagged Usp8 or empty vector was stably expressed by retroviral transduction in HER-14 cells.  A) Whole 
cell lysates (WCLs) were fractionated on SDS-PAGE and transferred to nitrocellulose filter which was incubated 
with GARPO. This conjugated antibody directly binds the protein A sequence in TAP-tagged Usp8. B) HER-14 
cells stably expressing empty vector (lane 1, 3 and 5) or TAP-tagged Usp8 (lane 2, 4 and 6) were used for 
tandem affinity purification. WCLs (lane 1-2), TEV protease-cleavage fraction (lane 3-4) and Ni-bead fraction 
(lane 5-6) were fractionated on SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-His 
antibody. C) HER-14 cells stably expressing TAP-tagged Usp8 were lysed on ice and TAP-tagged Usp8 was 
precipitated with IgG sepharose column (lane 1). His-tagged Usp8 protein complexes were released by TEV 
protease cleavage, purified on Ni-NTA resin and washed extensively to remove unbound material. Ni-beads 
were then reconstituted in 3x beads volume of 8M urea and incubated for 30 minutes at room temperature. The 
urea wash was repeated twice and supernatant from urea washes were combined, which constitute the urea 
elution fraction. Laemmli sample buffer was then added to the remaining Ni-beads (lane 2) and to the urea 
elution fraction (lane 3) in equivalent volumes to ensure comparable protein concentration. Samples were 
incubated at 95˚C for 3 minutes to ensure dissociation of His-tagged Usp8 from the Ni-fraction. Protein mixtures 
were fractionated on SDS-PAGE gel and transferred to nitrocellulose filter, and immuno-blotted with anti-His 
antibody. D) TAP purification procedure was carried out for HER-14 cells stably expressing empty vector (lane 
1 and 3) or TAP-tagged Usp8 (lane 2 and 4). Protein complexes recovered in the Ni-beads purification step were 
subjected to 8M urea elution to separate interacting proteins from Ni-beads bound His-tagged Usp8. Urea elution 
fraction (lanes 1-2) and the Ni-beads fraction (lanes 3-4) were fractionated on SDS-PAGE and used for silver-
staining. The urea fraction in lane-2 shows specific recovery of Usp8 interacting partners that migrate above 
position 25 kD, which are indicated with an asterisk. 
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spectrometry because it does not disrupt the Ni-NTA interaction with (i) the 8xHis-tagged protein-of-
interest and (ii) the His-tagged TEV protease (Figures 3C & 3D). After in solution trypsin digestion of 
the eluted Usp8 interacting proteins, LC-MS/MS analysis was carried out on the urea eluate fractions 
of TAP vector and TAP-Usp8 expressing mouse HER-14 cells, as detailed in the experimental 
procedures section. Apart from contaminating human proteins (mainly keratins) detected in all 
samples, a number of mouse proteins were identified that specifically co-purified with Usp8 proteins 
(Table I). These included various 14-3-3 protein isoforms (14-3-3 -β, -γ, -ε, -η, -τ and ζ) (22) (Table 
II). Indeed, anti-14-3-3ζ immunoblotting of the urea-eluate fraction obtained from serum starved and 
EGF-stimulated HER-14 cells directly confirmed the constitutive in vivo interaction between Usp8 and 
14-3-3ζ proteins (Figure 4A). 
 14-3-3 Proteins are phospho-serine/threonine binding proteins that are known to be involved in the 
regulation of cell cycle progression, apoptosis and mitogenesis (22). Mammalian cells contain seven 
14-3-3 isoforms, i.e.β, γ, ε, η, τ (also called θ), ζ and σ. Except for 14-3-3σ, which preferentially 
forms homo-dimers with unique substrate recognition properties (23),  14-3-3 isoforms form homo- 
and hetero-dimers with similar/overlapping substrate recognition profiles (22), providing an 
explanation for the identification of all 14-3-3 isoforms except 14-3-3σ in purified Usp8 complexes. 
14-3-3 proteins bind short serine phosphorylated consensus motifs in either mode I (RSXpSXP) or 
mode II ([R/K]X[Y/F]XpSXP) (22). Inspection of the amino-acid sequence of (predicted) Usp8 
orthologs in the vertebrate lineage (data not shown) revealed the presence of an absolutely conserved 
KLKRSYSSPD sequence that contains a mode I 14-3-3 binding motif (RSYSSPD, amino-acids 677-
683 of mouse Usp8). This suggests an important function for 14-3-3 association with Usp8 in the 
vertebrate lineage. A similar 14-3-3 binding motif is also present in the predicted Usp8 gene from 
echinoderm and urochordate species but not in various arthropods or fungal Ubp4/Doa4 orthologs 
(data not shown).  
 Indeed, anti-GFP immunoblotting (Figure 4B) and Coomassie brilliant blue (CBB)-staining 
(Figure 4C) revealed that substitution of mouse Usp8 Ser678 and Ser680 for alanine (almost) 
completely abolished GST-14-3-3ζ interaction with both full length GFP-tagged Usp8 (Figure 4B, 
lanes 1-4; Figure 4C, lanes 2-5) as well as a Usp8 construct (denoted GFP-Dub, amino-acids 640-1080 
of mouse Usp8) that lacks the N-terminal half of the protein but retains the 14-3-3 binding motif 
(Figure 4B, lane 5-8; Figure 4C, lanes 6-9). As the EGFR has been reported to interact with 14-3-3 
through an - as yet - unknown mechanism (24), we evaluated whether the 14-3-3 binding motif was 
required for the interaction between EGFR and GFP-Dub. However, co-immunoprecipitation analysis 
did not reveal significant differences in EGFR-Usp8 interaction between Usp8 wild-type and 
Ser678/680Ala mutant proteins (Figure 4D). These findings demonstrate that the 14-3-3 binding motif 
of Usp8 is not required for the interaction of Usp8 with its substrate, the EGFR.  
 To confirm phosphorylation of the Usp8 14-3-3 binding motif in vivo, we performed 
phosphopeptide analysis on purified Usp8 by LC-MS analysis using a linear ion trap - Ion Cyclotron 
Resonance Fourier Transform mass spectrometer. MS2 and neutral loss directed MS3 analysis enables 
identification of phosphopeptides and precise determination of phosphorylation sites (as detailed in the 
Experimental Procedures section). We identified three serine phosphorylation sites (Supplementary 
Figures 1 & 2), one of which is part of the 14-3-3 binding motif (SYpSSPDITQALQEEEK, amino-
acids 678-693) thereby identifying Ser680 of mouse Usp8 as the phosphorylated residue, consistent 
with the phosphorylated consensus 14-3-3 binding motif (22). The other phosphorylated peptides of 
mouse Usp8 were (i) pSVENLLDSK a conserved motif (amino-acids 153-161) in mammals that is 
located in between the Usp8 N-terminal helical domain and the rhodanese-like homology domain (25), 
and (ii) LADVpSPASVSGELNAGK a motif (amino-acids 575-592) in the proline-rich domain of 
Usp8 that does not show obvious sequence conservation among vertebrates (data not shown).  
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Figure 4: Identification of Usp8 interaction with 14-3-3 by TAP tagging and mass spectrometry 
TAP-tagged Usp8 or empty vector was stably expressed by retroviral transduction in HER-14 cells. A) Full 
TAP-purification procedure was carried out to purify Usp8 and interacting proteins from serum starved and 
EGF-stimulated cells expressing TAP-tagged Usp8. Following stimulation with 100 ng/ml EGF for 30 minutes, 
cells were lysed on ice and WCLs (lanes 1-2) used for IgG sepharose purification of TAP-tagged Usp8. Usp8 
and interacting proteins were released into the supernatant by TEV cleavage (lanes 3-4) and 8xHis-Usp8 protein 
complexes purified on Ni-NTA beads (lanes 5-6), and interaction proteins eluted with 8M urea (lanes 7-8). 
Samples were fractionated on SDS-PAGE gel and blotted with anti-Usp8 and anti 14-3-3ζ antibodies. The 
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positions of TAP-Usp8, 8xHis-Usp8, and 14-3-3ζ are indicated with an arrow. B) Wild type EGFP-tagged Usp8, 
EGFP-USP8 S678/680A (mut), c-terminal EGFP-Dub domain (amino-acids 640-1080), and EGFP-Dub 
S678/680A (mut) were transiently transfected into HEK293 cells. WCLs were either incubated with GSH-
immobilized control GST alone or with GST-14-3-3ζ. Unbound material was washed out extensively and protein 
complexes were fractionated on SDS-PAGE gel, along with input whole cell lysates and transferred to 
nitrocellulose filter. Subsequently, the filter was probed with anti-GFP antibody. Position of GFP-Usp8 (150 
kDa), and GFP-Dub (70 kDa) are indicated with an arrow. C) Samples from (B) were also fractionated on SDS-
PAGE followed by coomassie brilliant blue staining. Position of GFP-Usp8, GFP-Dub, GST-14-3-3ζ and control 
GST are indicated with an arrow. D) HEK293 cells were transiently transfected with wild type GFP-Dub or 
GFP-Dub S678/680A) mutant with human EGFR cDNA and control empty vector as indicated. Subsequently, 
cells were lysed on ice and anti-EGFR (528) immuno-precipitates were fractionated on SDS-PAGE and 
immunoblotted with anti-GFP antibody. The same membrane was reprobed with polyclonal anti EGFR antibody 
clone 1005 to show the amount of precipitated EGFR. Whole cell lysates were also fractionated on SDS-PAGE 
gel and blotted with anti-EGFR and anti-GFP antibodies showing the expression of the various constructs used 
in this experiment. To quantify interaction of EGFR/GFP-Dub wild type and mutant, the signal was calculated as 
a function of co-purifying GFP-Dub signals related to the expression level in of these proteins in whole cell 
lysates. 
 
 
DISCUSSION 
 
 14-3-3 proteins are usually involved in the regulation of protein function, acting to (i) modulate 
protein interactions, (ii) inhibit enzymatic activity, (iii) change the sub-cellular localization of its 
interacting partner, or (iv) sequester its interacting partner in a specific compartment (22). So far, we 
have not detected an effect of the 14-3-3 interaction on Usp8 enzymatic activity or on Usp8 interaction 
with its substrate protein, the EGFR tyrosine kinase. Several proteins that function in receptor-
mediated endocytosis and endosomal trafficking are, however, 14-3-3 binding proteins, including the 
EGFR itself (24), the Cbl E3 ubiquitin ligase adapter proteins which is responsible for ligand-induced 
EGFR ubiquitination (26), and the Rab5 guanine nucleotide exchange factor RIN1 (27). The Usp-
family of deubiquitinating enzymes (11) contains >50 family members in a single mammalian species. 
Interestingly, additional Usp enzymes may interact with 14-3-3 proteins as conserved 14-3-3 binding 
motifs are also found in Usp20 (RSSSRP) and Usp42 (RPYMSQP) deubiquitinating enzymes (data 
not shown). Additional studies are required to identify the functional significance of 14-3-3 interaction 
with Usp8 and possibly other deubiquitinating enzymes. 
 The modification of the TAP procedure that we report here may be very useful for genome wide 
proteomics studies. The combined use of 8xHis metal chelation affinity chromatography with urea 
elution during the second affinity precipitation step provides a simple and efficient strategy to purify 
interacting partners of a protein-of-interest without the need for additional SDS-PAGE fractionation, 
gel filtration (e.g. when eluting with high concentrations of flag- or myc-peptides) or protein 
concentration steps (although such steps may be included to improve purity and/or yield). This 
simplified yet powerful approach could be very suitable for automated genome wide proteomics 
screens.    
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Accession  Primary Protein name Mass  TAP-USP8 TAP-Vector 
name accession nr  (Da) no. peptides no. peptides 
ACTN4_MOUSE P57780 *Alpha-actinin 4 (Non-muscle alpha-actinin 4) 105368 10 18 
TERA_RAT P46462 *Transitional endoplasmic reticulum ATPase 89846 7 12 
HSP7C_MOUSE P63017 *Heat shock cognate 71 kDa protein 71055 12 5 
UBP8_MOUSE Q80U87 Ubiquitin carboxyl-terminal hydrolase 8 123447 12 2 
1433Z_MOUSE P63101 14-3-3 protein zeta/delta 27925 13  
1433E_MOUSE P62259 14-3-3 protein epsilon 29326 12  
AKAP2_MOUSE O54931 *A-kinase anchor protein 2 97954 11  
GRP75_MOUSE P38647 *Stress-70 protein, mitochondrial precursor 73768 11  
1433G_MOUSE P61982 14-3-3 protein gamma 28325 10  
GRP78_MOUSE P20029 *78 kDa glucose-regulated protein precursor 72492 9  
1433B_MOUSE Q9CQV8 14-3-3 protein beta/alpha 28052 6  
ACTB_MOUSE P60710 *Actin, cytoplasmic 1 (Beta-actin) 42052 3 3 
RCN3_MOUSE Q8BH97 *Reticulocalbin-3 precursor 37978 4 2 
1433F_MOUSE  P68510 14-3-3 protein eta 28234 5  
1433T_MOUSE P68254 14-3-3 protein theta 28046 4  
ACTN1_MOUSE Q7TPR4 *Alpha-actinin 1 103631 4  
EPLIN_MOUSE Q9ERG0 *Epithelial protein lost in neoplasm 84665  2 
TBA1_MOUSE P68369 *Tubulin alpha-1 chain (Alpha-tubulin 1) 50788  2 
 
Table I:  Proteins identified by mass spectrometry following tandem affinity purification and 8M urea elution of 
TAP-vector and TAP-USP8 expressing mouse HER-14 cells. Data has been searched against the mammals DB of 
NCBI and UNIprot database, resulting in the identification of equal numbers of identified mouse proteins. 
Contaminating proteins are marked with an asteric. Listed are the rodent proteins that were identified by 2 or 
more peptides.   
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 ISOFORM Sequence nr identical nr pept/ 
Seq 
coverage Score Peptide MA 
  peptides protein   delta score (ppm)
epsilon (14-3-3E) DNLTLWTSDMQGDGEEQNK 1 14 52,2 89 89,2 2,1 
epsilon (14-3-3E) EALQDVEDENQ 1 14 52,2 61 60,8 1,7 
epsilon (14-3-3E) HLIPAANTGESK 1 14 52,2 55 42,6 1,5 
epsilon (14-3-3E) IISSIEQK 1 14 52,2 50 31,6 0,1 
epsilon (14-3-3E) IISSIEQKEENK 1 14 52,2 48 38,4 1,8 
epsilon (14-3-3E) LICCDILDVLDK 1 14 52,2 74 65 1,8 
epsilon (14-3-3E) MDDREDLVYQAK 1 14 52,2 43 38,5 2 
epsilon (14-3-3E) QMVETELK 1 14 52,2 54 26,7 0,7 
epsilon (14-3-3E) YDEMVESMKK 1 14 52,2 45 42,6 5,7 
epsilon (14-3-3E) YLAEFATGNDR 1 14 52,2 53 38,4 1,4 
epsilon (14-3-3E) YLAEFATGNDRK 1 14 52,2 40 8,4 2 
epsilon (14-3-3E) DSTLIMQLLR 6 14 52,2 53 23,9 1,3 
epsilon (14-3-3E) LAEQAER 6 14 52,2 34 13,3 0,3 
epsilon (14-3-3E) NLLSVAYK 6 14 52,2 39 22,8 0,1 
gamma ATVVESSEK 1 13 54,9 48 29,6 0,3 
gamma AYSEAHEISK 1 13 54,9 73 63,7 1,5 
gamma DNLTLWTSDQQDDDGGEGNN 1 13 54,9 86 0 1,3 
gamma NCSETQYESK 1 13 54,9 44 43,5 1,3 
gamma NVTELNEPLSNEER 1 13 54,9 71 64,5 2,2 
gamma RATVVESSEK 1 13 54,9 55 37 0,9 
gamma TAFDDAIAELDTLNEDSYK 1 13 54,9 57 56,7 1,7 
gamma VDREQLVQK 1 13 54,9 39 21,8 0,9 
gamma YLAEVATGEK 1 13 54,9 60 38,9 0,9 
gamma VISSIEQK 4 13 54,9 55 0 0,4 
gamma DSTLIMQLLR 6 13 54,9 53 23,9 1,3 
gamma LAEQAER 6 13 54,9 34 13,3 0,3 
gamma NLLSVAYK 6 13 54,9 39 22,8 0,1 
zeta/delta DNLTLWTSDTQGDEAEAGEGGEN 1 13 53,1 94 2,1 4,9 
zeta/delta FLIPNASQPESK 1 13 53,1 57 46,3 1,8 
zeta/delta GIVDQSQQAYQEAFEISK 1 13 53,1 99 91,7 1,9 
zeta/delta KGIVDQSQQAYQEAFEISK 1 13 53,1 52 28,3 0,2 
zeta/delta SVTEQGAELSNEER 1 13 53,1 87 74,2 2,2 
zeta/delta VVSSIEQK 1 13 53,1 50 27,2 0 
zeta/delta YDDMAACMK 1 13 53,1 53 47,6 1,4 
zeta/delta YLAEVAAGDDK 1 13 53,1 57 46,6 1,3 
zeta/delta YLAEVAAGDDKK 1 13 53,1 59 48,7 1,7 
zeta/delta EMQPTHPIR 3 13 53,1 38 26,7 1 
zeta/delta DSTLIMQLLR 6 13 53,1 53 23,9 1,3 
zeta/delta LAEQAER 6 13 53,1 34 13,3 0,3 
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zeta/delta NLLSVAYK 6 13 53,1 39 22,8 0,1 
beta/alpha AVTEQGHELSNEER 1 11 56,7 84 65 2,2 
beta/alpha DNLTLWTSENQGDEGDAGEGEN 1 11 56,7 75 0,9 0 
beta/alpha QTTVSNSQQAYQEAFEISK 1 11 56,7 78 2,1 4 
beta/alpha TAFDEAIAELDTLNEESYK 1 11 56,7 68 64,7 1,6 
beta/alpha YLILNATQAESK 1 11 56,7 77 64,6 1,7 
beta/alpha YLSEVASGENK 1 11 56,7 60 48,2 1 
beta/alpha EMQPTHPIR 3 11 56,7 38 26,7 1 
beta/alpha VISSIEQK 4 11 56,7 55 0 0,4 
beta/alpha DSTLIMQLLR 6 11 56,7 53 23,9 1,3 
beta/alpha LAEQAER 6 11 56,7 34 13,3 0,3 
beta/alpha NLLSVAYK 6 11 56,7 39 22,8 0,1 
eta EAFEISK 1 9 38,4 26 15,7 0,2 
eta ELETVCNDVLALLDK 1 9 38,4 72 64,8 2,1 
eta NCNDFQYESK 1 9 38,4 39 38,8 1,3 
eta QAFDDAIAELDTLNEDSYK 1 9 38,4 111 109 1,9 
eta YLAEVASGEK 1 9 38,4 54 41,9 1 
eta VISSIEQK 4 9 38,4 55 0 0,4 
eta DSTLIMQLLR 6 9 38,4 53 23,9 1,3 
eta LAEQAER 6 9 38,4 34 13,3 0,3 
eta NLLSVAYK 6 9 38,4 39 22,8 0,1 
theta (  tau) SICTTVLELLDK 1 9 34,7 61 51,5 1,7 
theta (  tau) TAFDEAIAELDTLNEDSYK 1 9 34,7 122 118,9 1,1 
theta (  tau) YLAEVACGDDR 1 9 34,7 62 52,1 3,5 
theta (  tau) YLAEVACGDDRK 1 9 34,7 60 51,4 1,8 
theta (  tau) EMQPTHPIR 3 9 34,7 38 26,7 1 
theta (  tau) VISSIEQK 4 9 34,7 55 0 0,4 
theta (  tau) DSTLIMQLLR 6 9 34,7 53 23,9 1,3 
theta (  tau) LAEQAER 6 9 34,7 34 13,3 0,3 
theta (  tau) NLLSVAYK 6 9 34,7 39 22,8 0,1 
 
 
Table II: 14-3-3 peptides identified by LC-FTMS (Fourier Transform Mass Spectrometry) obtained from TAP-
tagged Usp8 expressing mouse HER-14 cells.  
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>M.musculus_USP8_gi|31981044|ref|NP_062703.2|ubiquitinspecificprotease8;put
ativedeubiquitinatingenzyme[Musmusculus] 
MPAVASVPKELYLSSSLKDLNKKTEVKPEKTSTKNYIHSAQKIFKTAEECRLDRDEERAYVLYMKYVAVYNLIKK
RPDFKQQQDYYLSILGPANIKKAIEEAERLSESLKLRYEEAEVRKQLEEKDRREEEQLQQQKRQEMGREDSGAAA
KRSVENLLDSKTKTQRINGEKSEGAAAAERGAITAKELYTMMMDKNTSLIIMDARKIQDYQHSCILDSLSVPEEA
ISPGVTASWIEANLSDDSKDTWKKRGSVDYVVLLDWFSSAKDLLLGTTLRSLKDALFKWESKTVLRHEPLVLEGG
YENWLLCYPQFTTNAKVTPPPRSRAEEVSVSLDFTYPSLEEPVPSKLPTQMPPPPIETNEKALLVTDQDEKLRLS
TQPALAGPGAAPRAEASPIIQPAPATKSVPQVDRTKKPSVKLPEDHRIKSENTDQSGRVLSDRSTKPVFPSPTTM
LTDEEKARIHQETALLMEKNKQEKELWDKQQKEQKEKLRREEQERKAGKTQDADERDSTENQHKAKDGQEKKDSK
QTKTEDRELSADGAQEATGTQRQSKSEHEASDAKVPVEGKRCPTSEAQKRPADVSPASVSGELNAGKAQREPLTR
ARSEEMGRIVPGLPLGWAKFLDPITGTFRYYHSPTNTVHMYPPEMAPSSAPPSTPPTHKVKPQVPAERDREPSKL
KRSYSSPDITQALQEEEKRRPAVTPMVNRENKPPCYPKAEISRLSASQIRNLNPVFGGSGPALTGLRNLGNTCYM
NSILQCLCNAPHLADYFNRNCYQDDINRSNLLGHKGEVAEEFGIIMKALWTGQYRYISPKDFKVTIGKINDQFAG
SSQQDSQELLLFLMDGLHEDLNKADNRKRHKEENNEHLDDLQAAEHAWQKHKQLNESIIVALFQGQFKSTVQCLT
CRRRSRTFEAFMYLSLPLASTSKCTLQDCLRLFSKEEKLTDNNRFYCSHCRARRDSLKKIEIWKLPPVLLVHLKR
FSYDGRWKQKLQTSVDFPLENLDLSQYVIGPKNSLKKYNLFSVSNHYGGLDGGHYTAYCKNAARQRWFKFDDHEV
SDISVSSVRSSAAYILFYTSLGPRITDVAT 
 
Supplementary Figure 1: Aminoacid sequence of mouse Usp8 with N-terminal region (light blue), serine 
phosphorylated peptides (green, phosphoserine residue is in bold & underlined), rhodanese-like domain (yellow), 
Hbp/STAM SH3 binding sites (red), and the catalytic Dub domain (pink) 
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Precursor m/z 952.9127, 2+, mass accuracy 1.1 ppm MS2 Mascot score 91 MS3 Mascot score 87 
 
 
 
Precursor m/z 542.74913, 2+, mass accuracy 1.1 ppm MS2 Mascot score 31 MS3 Mascot score 75 
 
 
Precursor m/z 847.9079, 2+, mass accuracy 5.3 ppm MS2 Mascot score 35 MS3 Mascot score 58 
 
Supplementary Figure 2: m/z plots of UBPY phosphopeptides 
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Chapter V 
 
 
 
General Discussion 
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Mitogenic signalling cascades downstream active growth factor receptors constitute an important 
mechanism for cellular transformation in human cancers where members of the ErbB family of 
receptor tyrosine kinases are over expressed like head and neck, breast and prostate cancers. Receptor 
activation in addition, regulates other cellular processes like cell migration, differentiation and 
suppression of apoptosis. These processes have to be tightly regulated to prevent abnormal cell 
behaviour. The cells regulate the magnitude and temporal aspects of receptor-dependent signalling 
through internalisation and subsequent lysosomal degradation of activated receptors. This ensures the 
clearance of the receptors from the cell surface leading for instance to attenuation of mitogenic 
signalling. Importantly, various ligands of the EGFR induce differential routing of internalised 
receptors within the endocytic pathway. Stimulation of EGFR with EGF leads to efficient receptor 
degradation, while its activation by TGF-α or the chimera E4T leads to decreased receptor degradation 
relative to EGF and significantly enhanced receptor recycling. Therefore, identification of key factors 
that regulate receptor breakdown is crucial for understanding the mechanism of receptor degradation. 
This may provide opportunities for novel therapeutic approaches aimed at controlling the signalling of 
receptor tyrosine kinases.  
 
A key event in receptor degradation is its ligand-dependent ubiquitination following receptor 
activation. Deubiquitination enzymes counteract the ubiquitination machinery, and therefore, they are 
expected to play important roles in receptor breakdown. Indeed, in yeast cells, the deubiquitination 
enzyme DOA4 plays an important regulatory role in trafficking of activated membrane-bound 
receptors within the endocytic pathway. However, little is known about receptor deubiquitination in 
animal cells, and the role of deubiquitination enzymes in receptor degradation remained largely 
unknown.  
 
In chapter II, the degradation mechanism of activated EGF-receptors following stimulation with 
various ligands has been analysed. In chapter III, we analysed the role of the mammalian 
deubiquitination enzyme UBPY/USP8, which is an orthologue of the yeast deubiquitination enzyme 
DOA4, in EGFR deubiquitination, degradation, and downstream signalling. In chapter IV, we report 
the purification of the endogenous protein complex of UBPY, which was carried out by virtue of 
Tandem Affinity Purification (TAP-tagging) method. 
 
Based on biochemical analysis, the data presented in this thesis funnel into a mechanistic model, 
which signifies a novel regulatory layer in EGFR degradation and mitogenic signalling. 
 
 100
5.1) EGF-receptor recycling and mitogenic signalling 
 
Previous studies have shown that binding of EGF and TGF-α to the EGFR results in differential 
routing of internalised receptors (1, 2). Experiments with 125I-labeled ligands revealed that EGF 
treatment induces enhanced receptor degradation compared to TGF-α and E4T. Like E4T, TGF-α 
induces enhanced receptor recycling when compared to EGF. These findings led to the conclusion that 
internalised receptors might be subject to active molecular sorting machinery that is able to 
discriminate between receptors that are destined for degradation from those who must be transported 
back to the cell surface. Indeed, studies in yeast demonstrated unambiguously that ubiquitination of 
membrane-bound receptors serves, at least in part, as a sorting signal within the endocytic pathway 
(3). Many membrane-bound receptors are rapidly ubiquitinated following activation by their cognate 
ligands. Consequently, ubiquitinated species of activated receptors are efficiently targeted for 
vacuolar/lysosomal degradation (4, 5). In the case of the EGFR, trafficking of internalised receptors 
strongly depends on the identity of the ligand. Stimulation of the EGFR with EGF leads to its 
clearance from the cell surface due to its lysosomal degradation. In contrast to EGF, stimulation with 
either TGF-α or E4T shows reduced targeting of activated receptors to the lysosomes, which has been 
shown to be a consequence of enhanced recycling as revealed by monensin treatment that blocks the 
recycling pathway (1). Given that the EGFR is known to undergo EGF-induced Cbl-mediated 
ubiquitination, it is therefore possible that both TGF-α and E4T fail to induce recruitment of Cbl 
ubiquitin ligase to activated EGFR, which may lead to a reduction or complete failure of EGFR 
ubiquitination. To directly test this possibility, biochemical analysis of EGFR/Cbl interaction and 
EGFR ubiquitination following ligand stimulation has been performed. Our findings, as presented in 
chapter II, demonstrate that TGF-α and E4T induce weak EGFR ubiquitination compared to EGF 
(chapter II, figure-1). We found that decreased EGFR ubiquitination in response to TGF-α and E4T 
correlated with decreased binding of the ubiquitin ligase Cbl protein to the EGFR as shown in (chapter 
II, figure-2). Consistent with these data, we also found that the kinetics of receptor degradation in 
response to TGF-α and E4T treatment is slower when compared to stimulation with EGF. This is 
probably partially caused by the binding characteristics of these ligands. Binding of TGF-α and E4T to 
the EGFR is sensitive to low pH environment in acidifying endosomes, which may cause these ligands 
to dissociate prematurely, prior to entering of the receptor-ligand complex into the degradative 
pathway. This may lead to increased receptor recycling due to disassembly of activated EGFR protein 
complexes. The low level of EGFR ubiquitination observed upon TGF-α and E4T stimulation may 
result from reduced recruitment of Cbl ubiquitin ligase to activated EGFR. Indeed, we consistently 
observed that Cbl binding to the EGFR is significantly lower in TGF-α and E4T than in EGF 
stimulated receptors. In support of our model, Longva et. al. (6) reported previously that translocation 
of Cbl protein to the plasma membrane in response to EGF and TGF-α is comparable. More 
importantly, they also reported that TGF-α failed to induce Cbl recruitment to endosomes, which may 
explain the low level of EGFR ubiquitination upon TGF-α treatment (6). Alternatively, disassembly of 
EGFR protein complex under these conditions might render the EGFR susceptible for attack by 
deubiquitination enzymes.  
Differential ubiquitination of the EGFR by the tested ligands correlates strongly with the differential 
degradation profile of the EGFR, which may account for the observed recycling of the EGFR after 
TGF-α and E4T stimulation (6). Importantly, stimulation of cells expressing the EGFR leads to 
enhanced cellular proliferation and cell survival when compared to EGF. The decreased EGFR 
ubiquitination and degradation induced by TGF-α and E4T correlates inversely with their mitogenic 
potency. We therefore propose that TGF-α and E4T-induced receptor recycling is caused by reduced 
EGFR ubiquitination leading to enhanced receptor stabilization and sustained mitogenic signalling.  
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5.2) Proteasome-dependent deubiquitination of activated EGF-receptors 
 
As K48-poly-ubiquitination of cellular proteins targets them for proteasomal degradation, the 
proteasome was hypothesized to participate in the degradation of ubiquitinated EGFR following 
receptor activation (7). Specifically, based on treatment with the proteasomal inhibitor peptide 
aldehyde MG132 it has been reported that not only degradation of the EGFR could be blocked but also 
the degradation of other signalling proteins downstream of the EGFR (6, 7). Therefore, the relative 
contribution of the lysosomes and proteasomes in the process of EGFR degradation remained an issue 
of debate. In addition to blocking the proteasomes, MG132 efficiently blocks the lysosomal protease 
cathepsin B, which was reported to selectively mediate the degradation of the EGFR (8). Therefore, in 
order to analyse the degradation mechanism of the EGFR in a detailed manner, we blocked the 
proteasomes with potent and specific inhibitor called lactacystin, and monitored ligand-induced EGFR 
degradation.  
 
By blocking acidification of endosomes and lysosomes with the specific v-ATPase proton pump 
inhibitor bafilomycin AI and comparison of EGFR ubiquitination and degradation to proteasomal 
inhibition with lactacystin, we consistently observed that ubiquitinated species of activated EGFRs are 
degraded by the lysosomes. Importantly, we also found that the EGFR is deubiquitinated prior to its 
incorporation into the late endosomes MVBs. Deubiquitination of the bafilomycin AI stabilized 
EGFRs was blocked in the presence of lactacystin, demonstrating that deubiquitination is proteasome 
dependent. These data demonstrate for the first time that proteasomal function is needed along the 
endocytic pathway to deubiquitinate cargo proteins. Moreover, our data were the first to demonstrate 
that the EGFR is undergoing deubiquitination. Consistent with our findings, recent reports suggested 
that proteasomes associate with late endosomes through specific interaction of the proteasome α-
subunit XAPC7 with Rab7 (9). Proteasome associated proteins like Ecm29 were also detected on 
membrane vesicles of early and late endosomes (10). It remains unknown whether these molecular 
interactions are relevant for proteasome-mediated deubiquitination of cargo proteins.  
Based on our own data and data from other laboratories, it is possible that recruitment of the 
proteasomes to endosomal vesicles is required to eliminate EGFR complexes by two compatible 
actions: first, deubiquitination of activated EGFR within the endocytic pathway in order to facilitate its 
entry into the MVB’s/late endosomes. Second, proteasomal degradation of EGFR associated proteins 
like c-Cbl and other signalling molecules. Based on electron microscopic studies, it has been 
hypothesized that Cbl proteins undergo ligand-induced degradation in lysosomes (11). This implies 
that Cbl proteins are translocated from the cytosol to the lumen of lysosomes through the MVB 
pathway. Our data consistently show that while blocking the lysosomes prevents EGFR degradation it 
fails to rescue Cbl proteins from degradation. Under the experimental conditions we used in this work, 
Cbl protein appears to undergo proteasome-dependent degradation following receptor activation. In 
support of this model it has been previously reported that Cbl proteins undergo ubiquitination 
following receptor engagement (7). 
 
The EGFR escapes proteasomal degradation probably due to its ubiquitination profile. It is well 
known that poly-ubiquitination with at least four K48-linked ubiquitin moieties is required for 
efficient recognition of ubiquitinated substrates by the regulatory cap of proteasomes. It has been 
found that following receptor engagement, the EGFR undergoes multiple mono-ubiquitination as well 
as K63-linked poly-ubiquitination (12, 13), which explains why the EGFR is not degraded by the 
proteasomes. Ubiquitination of the EGFR is essential for trafficking of internalised receptors within 
the endocytic pathway since mutation of all lysine ubiquitination sites to arginines leads to severe (but 
still incomplete) defects in EGFR translocation to the lysosomes (13). Ubiquitination of the EGFR 
also function as a platform for recruitment of key ubiquitin interacting proteins that regulate 
vesicular/cargo trafficking in the endosomal system.  
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5.3) Deubiquitination within the endocytic pathway: A conserved process 
 
Our findings funnel into the model that EGFR deubiquitination takes place prior to its lysosomal 
degradation. Interestingly, the ubiquitination/deubiquitination profile of the EGFR in our model 
system HER-14 cells strongly resembles the ubiquitination/deubiquitination events of the yeast 
membrane-bound receptors (14). Following activation, the yeast uracil permease Fur4 cell surface 
receptor is targeted to the MVB degradative pathway in an ubiquitin dependent manner. Prior to its 
vacuolar degradation, Doa4 deubiquitination enzyme mediates the removal of the ubiquitin tag from 
Fur4. Interestingly, Doa4 was found associated with the proteasomes in yeast (in a substoichiometric 
and therefore probably dynamic (on/off) manner) and was implicated in maintaining the level of 
cellular free ubiquitin (15).  
Recruitment of Doa4 to ubiquitinated endosomal cargo is strongly regulated by the class E AAA-
ATPase Vps4 protein (16). Vps4 plays a central role in controlling the dynamic association of ESCRT 
protein complexes with endosomal membranes by inducing their dissociation from late endosomal 
membranes an event that allow the formation of internal vesicles of MVBs. Consistently, Doa4 
interacts genetically with members of the ESCRT machinery, which is responsible for regulating 
trafficking of cargo proteins within the endocytic pathway at the level of MVB/late endosomes. 
Furthermore, Doa4 is widely implicated in removal of ubiquitin from cargo proteins prior to their 
entry into the internal vesicles of MVB/late endosomes (14, 16, 17, 18, 19). This led to the hypothesis 
that Doa4 functions at the level of late endosomes to recover ubiquitin from ubiquitinated cargo 
proteins, an event that allows recycling of ubiquitin monomers (17). Given the fact that trafficking of 
internalised EGFR to the MVB pathway is regulated by members of the ESCRT machinery, it is 
therefore possible that UBPY/USP8 the mammalian orthologue of Doa4 may play important role in 
deubiquitination of the EGFR and its translocation to the MVB pathway. 
 
5.4) UBPY-dependent EGFR deubiquitination 
 
5.4.1) Tyrosine phosphorylation of UBPY following EGFR activation 
 
Doa4 is structurally related to the mammalian deubiquitination enzyme UBPY/USP8. We therefore 
hypothesized that UBPY, like Doa4, might play an important role in deubiquitination of membrane-
bound receptors within the endocytic pathway. Our biochemical analysis of UBPY function in the 
EGFR pathway clearly indicates that UBPY is involved in the EGFR signalling pathway as it 
undergoes tyrosine phosphorylation in response to EGFR activation. Serial deletion mutants of UBPY 
protein shows that this phosphorylation event takes place primarily on the N-terminal part of UBPY 
sequence encompassing the Rhodanese construct. Although we did not detect phosphorylation with 
the C-terminal part mutant, it is formally possible that its phosphorylation may depend on the N-
terminal part of UBPY. Importantly, endogenous UBPY undergoes tyrosine phosphorylation reaching 
maximum detectable levels after 60 minutes of EGFR activation. UBPY phosphorylation in addition 
strongly depends on Src kinases. Treating the cells with Src family kinase inhibitor PP2 prevents 
UBPY phosphorylation in a PP2 concentration dependent manner. Under these conditions, the EGF-
induced phosphorylation of the EGFR is slightly reduced. This is probably caused by PP2-dependent 
inhibition of EGFR tyrosine phosphorylation by Src-family kinases (20, 21). These findings strongly 
suggest that UBPY is linked to the EGFR pathway. Phosphorylation of UBPY is not essential for its 
deubiquitination activity because bacterially expressed UBPY is competent in disassembly of 
polyubiquitin chain in vitro (22). Importantly, N-terminal truncation of UBPY, which retains the Dub 
domain and does not show tyrosine phosphorylation following EGFR activation, is competent in 
deubiquitination of the EGFR (see below). Therefore, UBPY phosphorylation might be relevant for 
interaction with so far unknown proteins that act in the UBPY pathway. Elucidating the functional 
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significance of UBPY tyrosine phosphorylation in vivo requires the identification of the 
phosphorylated tyrosine residues and subsequent analysis of tyrosine phosphorylation mutants of 
UBPY.  
 
5.4.2) Interaction of UBPY with EGFR complex 
 
UBPY copurifies with the EGFR in co-immunoprecipitation experiments. In addition, this interaction 
seems to be bivalent since both the Rhodanese construct (N-terminal part) of UBPY and the Dub 
domain (C-terminal part) independently associate with the EGFR. Furthermore, binding of the 
Rhodanese construct depends on the first 140 amino acids (N-terminal box), while binding of the Dub 
domain critically depends on its active site cystein at amino acid position 748 of mouse UBPY. 
Mutation of the active site in the Dub domain truncation mutant abolishes its binding almost 
completely. It has been recently reported that EGF treatment induces UBPY/EGFR complex formation 
(23). However, our data clearly show that UBPY/EGFR complex formation does not depend on the 
activation status of the EGFR. Given the fact that tyrosine phosphorylation of the deletion mutants of 
UBPY does not correlate with their binding capacity, it allows us to infer that UBPY phosphorylation 
is not required for interaction with the EGFR, which further supports the finding that association of 
full length UBPY with the EGFR is constitutive. These findings are consistent with previously 
reported bivalent interaction of UBPY with the ubiquitin ligase Nrdp1, which plays an important role 
in ubiquitination of ErbB-3 and ErbB-4 receptors (24). Our analysis shows that the efficiency of full 
length UBPY interaction with the EGFR critically depends on its active site. Mutation of the active 
site cystein of UBPY to alanine increases UBPY association with the EGFR approximately four times 
in agreement with the findings presented by Komada and co-workers (23). This enhanced interaction 
depends on the N-terminal part of UBPY since a catalytically deficient Dub domain fails to bind the 
EGFR and exhibits loss of function compared to catalytically deficient full length UBPY. 
 
Within the proline rich central domain of UBPY N-terminal and C-terminal SH3 binding motifs are 
located (i.e. N-SH3 amino acid position in mouse UBPY 405-413 and C-SH3 amino acid position in 
mouse UBPY 699-708) (12). It has been found that UBPY associates with Hrs-binding protein Hbp 
through these motifs (12). As Hrs and Hbp are known to play an important role in trafficking of 
endosomal vesicles (25, 26, 27, 28, 29, 30), this leads to the hypothesis that UBPY might be recruited 
to cargo proteins on endosomes through Hbp. To evaluate this possibility, UBPY mutants lacking N-
SH3 and C-SH3 sequences were tested in binding to the EGFR. In contrast to what Komada and co-
workers have reported (23), our biochemical data show that UBPY mutant lacking these motifs bind to 
the EGFR as efficiently as wild type UBPY. Consistently, the Rhodanese construct and the dub 
domain deletions lacking the SH3 binding motif do not show reduced binding to the EGFR compared 
to the deletion mutants who retain the SH3 binding motif. Apparently, UBPY binding to the EGFR 
protein complex seems to be indirect since GST-UBPY affinity precipitation experiments failed to 
recover the EGFR from serum-starved or from EGF-stimulated cells (data not shown). 
 
5.4.3) UBPY deubiquitinates the EGFR in vivo 
 
Cotransfection of the EGFR with catalytic defective UBPY-C748A leads to strong accumulation of 
ubiquitinated EGFRs compared to cotransfection with wild type UBPY. This suggests the possibility 
that the EGFR might be subject to ubiquitination/deubiquitination cycles constitutively. In addition, 
UBPY-C748A strongly enhanced ubiquitination of the EGFR Y1045A mutant, which is profoundly 
defective in Cbl binding. Therefore, we speculate that additional ubiquitin ligases may participate in 
constitutive, basal EGFR ubiquitination, which is counteracted by constitutive UBPY-mediated EGFR 
deubiquitination. In view of this hypothesis, it has been reported recently that SOCS proteins may 
regulate recruitment of E3 ubiquitin ligases to the EGFR in a Cbl independent manner (19, 31). 
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Alternatively, Cbl might ubiquitinate the EGFR through interaction with EGFR-bound Grb2 (32). 
Whether these mechanisms are involved in constitutive EGFR ubiquitination remains to be 
investigated. In addition to transient transfection approach, stable HER-14 cell lines expressing either 
wild type or catalytic defective UBPY show enhanced EGFR ubiquitination in cells expressing 
UBPY-C748A following receptor activation. Based on these findings we therefore conclude that 
UBPY is involved in deubiquitination of the EGFR in vivo under steady-state and ligand-induced 
conditions.  
 
5.5) The consequence of UBPY-mediated EGFR deubiquitination 
 
The deubiquitination activity of the C-terminal Dub domain as well as the Dub domain lacking the 
SH3-binding motif induced inhibition of EGFR degradation and accumulation of activated EGFRs. 
Consequently, EGFR-dependent activation of MAPK was significantly increased. Mutation of the 
active site cystein of the Dub in the presence and absence of the C-terminal SH3-binding motif caused 
loss of its ability to bind the EGFR and therefore it did not affect EGFR degradation nor did it affect 
MAPK activation. 
Expression of the C-terminally truncated UBPY Rhodanese construct resulted in severe accumulation 
of ubiquitinated EGFR, increased EGFR expression and enhanced MAPK activation. This phenotype 
depends on the first 140 amino acids N-terminal box of UBPY. Examination of the amino acid 
sequence of this region revealed that it shows 'reasonable' homology/similarity to the N-terminal 
region of the deubiquitination enzyme AMSH (data not shown). Given that AMSH has recently been 
implicated in EGFR deubiquitination (22, and data not shown), it raises the possibility that the N-
terminal box of both AMSH and UBPY may play important roles in their function. Indeed, deletion of 
the N-terminal box leads to loss of function of UBPY Rhodanese construct due to failure to associate 
with EGFR protein complex, thereby allowing the EGFR to be deubiquitinated and subsequently 
delivered for degradation as judged by the appearance of EGFR proteolytic products. These findings 
clearly demonstrate a dominant negative effect of the Rhodanese construct on EGFR deubiquitination, 
degradation and downstream signalling. The N-terminal box could serve as a platform for substrate 
recognition or for interaction with ubiquitin. However, GST-Ubq pull down experiments failed to 
show that the N-terminal box could bind ubiquitin in vitro (data not shown). Importantly, the N-
terminal box is essential for interaction of the Rhodanese construct with the EGFR thereby 
demonstrating that the effect of UBPY on EGFR ubiquitination status is direct. Interestingly, Dhe-
Paganon and co-workers from the structural genomics consortium recently solved the crystal structure 
of the N-terminal box (33). The structure of this box exists as a homodimer with each monomer 
pointing to opposite directions. These data point to two possible mechanisms that may explain the 
dominant negative effect of the Rhodanese construct: First, it is possible that endogenous UBPY may 
oligomerize through the N-terminal box region. This raises the possibility that the Rhodanese 
construct may block the function of endogenous UBPY by virtue of binding to its N-terminal box 
thereby preventing the oligomerization of endogenous UBPY. Second, overexpression of the N-
terminal part of UBPY may compete with endogenous UBPY for binding to the EGFR. Once bound to 
the EGFR, endogenous UBPY can no longer be recruited to the EGFR, which is critical for EGFR 
deubiquitination. Third, the N-terminal box may be required for recruitment of UBPY to endosomal 
membranes (e.g. interaction with Vps class E proteins), which in turn is required for interaction with 
cargo molecules. Consequently, Rhodanese construct-dependent stabilization of the EGFR leads to 
sustained EGFR signalling as judged by accumulation of activated MAPK. Activation of MAPK 
correlates in our experiments with inhibition of both EGFR deubiquitination and degradation. 
Inversely, the Rhodanese domain lacking the N-terminal 140 amino acids showed loss of function 
because it failed to stabilize the EGFR and no MAPK activation could be observed due to failure to 
bind the EGFR. 
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Previous studies in yeast reported association of Doa4 with the proteasomes through its Rhodanese-
domain containing N-terminal part (15). This interaction was found in substoichiometric amounts and 
it was therefore hypothesized to be a dynamic, transient interaction. Whether UBPY associates with 
proteasomes in mammalian cells remains unknown. Several studies analysed the protein composition 
of proteasomes from several organisms other than yeast. None of them detected UBPY orthologs in 
purified proteasomes. It is possible that UBPY associates with the mammalian proteasomes only 
transiently, which might explain the failure to isolate UBPY as a complex with proteasomes.  
 
5.6) Novel link between UBPY and 14-3-3 proteins 
 
Application of the tandem affinity purification strategy allowed us to uncover a physical link between 
UBPY and 14-3-3 proteins. It is formally possible that pull down of UBPY proteins with GST-14-3-3 
fusion proteins is mediated by intermediate proteins present in the cell lysate. However, we strongly 
support the model that interaction of UBPY with 14-3-3 is direct as 14-3-3 proteins directly bind to 
their consensus motif. UBPY encodes 14-3-3 binding motif (RSYSSP, amino acid position 677-680), 
which is in full compliance with the mode I consensus sequence RSXSXP known to be recognized 
directly by 14-3-3 proteins. 14-3-3 binding to this motif in UBPY is critically dependent on 
phosphorylation of serine at position 680. Moreover, our analysis shown in chapter III also identified 
additional phosphorylation sites in UBPY sequence including serine 153, threonine 318, and serine 
580. It has been reported that 14-3-3 proteins interact with the EGFR (5). Therefore, we hypothesized 
that UBPY might be recruited to the EGFR through 14-3-3 proteins. Co-immunoprecipitation 
experiments demonstrated clearly that UBPY binding to the EGFR does not depend on 14-3-3 
proteins. 14-3-3 proteins are known, among others, to regulate the subcellular localization of their 
client proteins leading to spatial segregation of the client protein and its binding proteins in vivo. 
Given that bacterially expressed UBPY is competent in its deubiquitination activity in vitro (in the 
absence of 14-3-3 proteins), it is therefore possible that 14-3-3 binding to UBPY might block its 
activity in vivo by sequestration of UBPY into another subcellular compartment. Alternatively, 
binding of 14-3-3 to UBPY might prevent access of ubiquitin to the active site of UBPY. This notion 
is supported by the fact the 14-3-3 binding motif is very close to the active site of UBPY. Therefore, 
performing in vitro deubiquitination assays, as shown in chapter III, in the presence of purified 14-3-3 
proteins will clarify this issue. 
14-3-3 proteins were previously linked to the EGFR and its downstream signalling pathway (3, 34). 
As mentioned above, it has been suggested that 14-3-3 interact with the EGFR and also with Cbl 
ubiquitin ligase (5, 35). The role of 14-3-3 proteins in the regulation of UBPY remains unknown. 
 
5.7) Multi-ubiquitination and -deubiquitination, problem and solution 
 
Our findings favour the model whereby the Rhod domain inhibits EGFR deubiquitination at a late step 
in the endocytic pathway, i.e. prior to incorporation of internalised EGFR into the MVBs. This model 
is in agreement with our findings reported in chapter II, which clearly demonstrate that inhibition of 
the lysosome with Bafilomycin A treatment, which is thought to block transport to late endosomes, 
leads to significant accumulation of poly-ubiquitinated EGFR. According to our model, Rhodanese 
construct-mediated stabilization of ubiquitinated EGFRs maintain their signalling potency which leads 
to enhanced MAPK activation. Interestingly, this model also predicts that challenging the EGFR with 
increased deubiquitination activity along the endocytic route would lead to rescue of the EGFR from 
the degradative pathway since overexpression of the Dub domain prevents EGFR degradation. 
Consequently, Dub-mediated stabilization of the EGFR leads to enhanced MAPK activation (figure-
1). 
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Deubiquitination activity along the endocytic route might be required to recover ubiquitin from 
ubiquitinated substrates in order to maintain the level of free ubiquitin monomers. Specific to the 
EGFR, its deubiquitination might be essential to facilitate its entrance into the internal vesicles of 
MVBs. Moreover, removal of the ubiquitin moiety from the EGFRs could lead to disassembly of 
proteins that interact with ubiquitinated EGFRs, such as Hrs, TSG101 and Vps25. This could facilitate 
recycling of these proteins in order to allow rapid multiple rounds of cargo recognition and sorting to 
the MVBs. Alternatively, it is possible that deubiquitination activity might be involved in fine-tune or 
trimming of the ubiquitin chain following receptor ubiquitination by Cbl ubiquitin ligase. Such 
trimming function might be required to optimise the length of the chain in order to facilitate 
recognition of ubiquitinated receptors by the ESCRT complexes and other UIM-containing proteins 
that are involved in substrate recognition and sorting to the MVB pathway.  
It has been reported that Doa4 exhibits specificity towards K63-linked polyubiquitin chains. However, 
UBPY is able to disassemble both K63 and K48 linked ubiquitin chains (36). AMSH shows specificity 
towards K63 linked chains and it is unable to disassemble di-ubiquitins. This differential specificity of 
the deubiquitination activity of UBPY and AMSH raises the hypothesis that both proteins might co-
operate in deubiquitination of the EGFR. Under physiological conditions, the EGFR is undergoing 
both mono- as well as K63-linked poly-ubiquitination. UBPY might deubiquitinate EGFR-associated 
signalling molecules that are ubiquitinated by K48-linked poly-ubiquitin chains to target them for 
proteasomal destruction. Furthermore, UBPY and AMSH might co-operate to remove K63-linked 
poly-ubiquitin chains. Thus, AMSH may be involved in trimming extensive K63-linked poly-ubiquitin 
chains. When AMSH fails to deubiquitinate di- and mono-ubiquitin moieties, UBPY may continue to 
remove these remnants of the poly-ubiquitin chains. 
 
 
 
 
 
 
Figure-1: 
Integrative hypothetical model summerizing the role of UBPY and possible involvement of 14-3-3 proteins in 
EGFR pathway. See text for further explanation. 
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Finally, AMSH and UBPY may be involved in deubiquitination of the EGFR in different 
compartments. Deubiquitination of the EGFR by AMSH prior to lysosomal sorting may lead to 
decreased EGFR degradation and enhanced EGFR recycling. Deubiquitination of the EGFR by UBPY 
following lysosomal targeting may not be sufficient for EGFR recycling, but may increase the 
efficiency of cargo incorporation into internal vesicles of MVBs, leading to termination of MAPK 
signalling. This model does not explain, however, why both AMSH and UBPY use similar strategies 
for recruitment to cargo proteins (i.e. binding to Hbp/STAM SH3 domains and recruitment to ESCRT-
III complexes). 
UBPY might be linked to regulation of signalling cascades downstream activated EGFR through 
interaction with 14-3-3 proteins (figure-1). 14-3-3 proteins are known to participate in 
phosphorylation-dependent protein-protein interaction that regulate various processes like MAPK 
activation, progression through the cell cycle, and inhibition of apoptosis. For instance, Raf and 
MAPK are two known examples of being 14-3-3 client proteins. Interestingly, several proteins 
involved in mitogenic signalling are subject to ubiquitination like Ras, Raf, and MAPK. If cells indeed 
rely on UBPY/14-3-3 axis to regulate their function, then the implications of UBPY binding to 14-3-3 
are staggering given the multitude of human cancers that are, at least in part, caused by mutations in 
these proteins.  
 
5.8) Future directions 
 
Future studies will be essential to decipher the role of 14-3-3 proteins in UBPY function, not only in 
relation to EGFR pathway but also within the context of endosomal trafficking of cargo proteins. One 
issue that needs to be clarified is whether UBPY is functionally or physically coupled to oncogenic 
kinases downstream the EGFR in a 14-3-3-dependent manner. UBPY’s post-translational 
modifications like phosphorylation and ubiquitination could be an important area of focus for future 
experiments. Ubiquitination of UBPY might affect its stability. Tyrosine phosphorylation is unlikely 
to affect UBPY catalytic activity; therefore future experiments should focus on the role of UBPY 
tyrosine phosphorylation in regulation of substrate specificity or subcellular localization of UBPY.  
Since the endocytic pathway and its key components are conserved from yeast to human, it would be 
crucial to uncover the mechanism that is responsible for UBPY recruitment to endocytosed 
ubiquitinated cargo proteins in order to test the universality of the relationship between 
deubiquitination enzymes and the endocytic pathway. If such universal relationships exist then UBPY, 
either alone or together with AMSH, might act on many other membrane-bound receptors thereby 
functioning as a molecular regulator of trafficking of endocytosed cargo proteins.  
 
 
5.9) References 
 
[1]  Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, 
Waterman H, Sela M, van Zoelen EJ, Yarden Y. EMBO J  (1998)  17  3385-97. 
[2]  Lenferink AE, Kramer RH, van Vugt MJ, Konigswieser M, Di Fiore PP, van Zoelen EJ, van de 
Poll ML. Biochem J  (1997)  327  859-65. 
[3]  Tzivion G, Luo Z, Avruch J. Nature  (1998)  394  88-92. 
[4]  Hicke L. Trends Cell Biol  (1999)  9  107-12. 
[5]  Oksvold MP, Huitfeldt HS, Langdon WY. FEBS Lett  (2004)  569  207-10. 
[6]  Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. J Cell Biol  (2002)  
156  843-54. 
[7]  Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, 
Lipkowitz S. J Biol Chem  (2001)  276  27677-84. 
[8]  Authier F, Metioui M, Bell AW, Mort JS. J Biol Chem  (1999)  274  33723-31. 
 108
[9]  Dong J, Chen W, Welford A, Wandinger-Ness A. J Biol Chem  (2004)  279  21334-42. 
[10]  Gorbea C, Goellner GM, Teter K, Holmes RK, Rechsteiner M. J Biol Chem  (2004)  279  54849-
61. 
[11]  de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J. J Cell Sci  (2001)  114  2167-78. 
[12]  Kato M, Miyazawa K, Kitamura N. J Biol Chem  (2000)  275  37481-7. 
[13]  Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. Mol Cell  (2006)  21  737-48. 
[14]  Dupre S, Haguenauer-Tsapis R. Mol Cell Biol  (2001)  21  4482-94. 
[15]  Papa FR, Amerik AY, Hochstrasser M. Mol Biol Cell  (1999)  10  741-56. 
[16]  Amerik AY, Nowak J, Swaminathan S, Hochstrasser M. Mol Biol Cell  (2000)  11  3365-80. 
[17]  Losko S, Kopp F, Kranz A, Kolling R. Mol Biol Cell  (2001)  12  1047-59. 
[18]  Luhtala N, Odorizzi G. J Cell Biol  (2004)  166  717-29. 
[19]  Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y. J Biol 
Chem  (2005)  280  7038-48. 
[20]  Muthuswamy SK, Muller WJ. Oncogene  (1995)  11  271-9. 
[21]  Stover DR, Becker M, Liebetanz J, Lydon NB. J Biol Chem  (1995)  270  15591-7. 
[22]  McCullough J, Clague MJ, Urbe S. J Cell Biol  (2004)  166  487-92. 
[23]  Mizuno E, Iura T, Mukai A, Yoshimori T, Kitamura N, Komada M. Mol Biol Cell  (2005)  16  
5163-74. 
[24]  Wu X, Yen L, Irwin L, Sweeney C, Carraway KL 3rd. Mol Cell Biol  (2004)  24  7748-57. 
[25]  Bache KG, Raiborg C, Mehlum A, Stenmark H. J Biol Chem  (2003)  278  12513-21. 
[26]  Mizuno E, Kawahata K, Kato M, Kitamura N, Komada M. Mol Biol Cell  (2003)  14  3675-89. 
[27]  Lu Q, Hope LW, Brasch M, Reinhard C, Cohen SN. Proc Natl Acad Sci U S A  (2003)  100  
7626-31. 
[28]  Lloyd TE, Atkinson R, Wu MN, Zhou Y, Pennetta G, Bellen HJ. Cell  (2002)  108  261-9. 
[29]  Kanazawa C, Morita E, Yamada M, Ishii N, Miura S, Asao H, Yoshimori T, Sugamura K. 
Biochem Biophys Res Commun  (2003)  309  848-56. 
[30]  Zheng Q, Yin G, Yan C, Cavet M, Berk BC. J Biol Chem  (2004)  279  8787-91. 
[31]  Nicholson SE, Metcalf D, Sprigg NS, Columbus R, Walker F, Silva A, Cary D, Willson TA, 
Zhang JG, Hilton DJ, Alexander WS, Nicola NA. Proc Natl Acad Sci U S A  (2005)  102  2328-33. 
[32]  Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y. EMBO J  
(2002)  21  303-13. 
[33]  Avvakumov GV, Walker JR, Xue S, Finerty PJ Jr, Mackenzie F, Newman EM, Dhe-Paganon S. 
J Biol Chem  (2006)  0  . 
[34]  Huang D, Liu X, Plymate SR, Idowu M, Grimes M, Best AM, McKinney JL, Ware JL. 
Oncogene  (2004)  23  6881-9. 
[35]  Liu YC, Elly C, Yoshida H, Bonnefoy-Berard N, Altman A. J Biol Chem  (1996)  271  14591-5. 
[36]  Urbe S, McCullough J, Row P, Prior IA, Welchman R, Clague MJ. Biochem Soc Trans  (2006)  
34  754-6. 
 109
Summary 
 
Members of the membrane-bound ErbB receptor tyrosine kinase family, such as the EGF-receptor, 
and their ligands are widely implicated in human carcinomas. Under normal conditions, ErbB-
mediated signaling is crucial for proper development and normal growth. Therefore, activated ErbB 
receptors are subject to tight control to restrict their signaling time-window, since continuous 
mitogenic signaling will lead to sustained mitotic activity, a property that  constitutes one of the major 
hall-marks of cancer cells.  
Control of receptor tyrosine kinase signaling is primarily mediated by endocytosis of the ligand-
receptor complex and subsequent delivery to the lysosomes for degradation, a process that is often 
referred to as receptor downregulation. This leads to clearance of the receptors from the cell surface, 
which is expected to attenuate downstream signaling. Earlier studies in human cells and other 
organisms have shown that  internalized receptors undergo active sorting and trafficking within the 
endocytic pathway prior to their delivery to the lysosmes. Moreover, internalization and subsequent 
delivery to the lysosomes is often orchestrated by ubiquitination of activated receptors. This led to the 
plausible hypothesis that ubiquitin can act as a sorting signal within the endocytic route. As 
ubiquitination is a reversible process, it inevitably raises the possibility that deubiquitination enzymes 
might be linked to the EGFR and possibly to downstream mitotic signaling. However, the role of 
deubiquitination enzymes in the EGFR pathway remaines poorly understood in mammalian cells. 
Therefore, this study focused on analyzing the role of UBPY/USP8, a mammalian deubiquitination 
enzyme that shows structural similarities with the yeast deubiquitination enzyme Doa4, in trafficking 
of internalized membrane-bound receptors. 
Our initial analysis reported in chapter II showed that different ligands induce different degradation 
kinetics of the EGFR. Enhanced EGFR degradation induced by EGF, when compared to TGF-α 
correlated strongly with enhanced ubiquitination of activated receptors.  However, prior to lysosomal 
degradation the EGFR underwent deubiquitination. This process was sensitive to proteasome 
inhibitors, but the exact mechanism responsible for EGFR deubiquitination remained unknown.  
Subsequent studies reported in chapter III demonstrated that UBPY is responsible, at least in part, for 
deubiquitination of the EGFR in vivo. Prevention of EGFR deubiquitination by overexpression of the 
N-terminal part of UBPY, which lacks the catalytic deubiquitination domain, prevented EGFR 
lysosomal degradation. Consequently, EGFR-dependent mitogenic signaling was enhanced.  
As UBPY interacting proteins might constitute an additional regulatory layer in EGFR pathway, the 
study reported in chapter IV was aimed at identifying the endogenous protein complex of UBPY.  This 
study revealed that UBPY interacts with 14-3-3 proteins but that UBPY binding to the EGFR complex 
does not depend on 14-3-3 proteins.  
Collectively, the findings presented in this thesis funnel into the model that ubiquitinated EGFRs are 
subject to a deubiquitination activity that requires at least the deubiquitination enzyme UBPY and 
proteasomal activity. Removal of ubiquitin and/or polyubiquitin tags from internalized receptors might 
facilitate their incorporation into late endosome and lysosomes for degradation. This event will 
consequently lead to termination of mitogenic signaling. UBPY/14-3-3 interaction might link UBPY 
to mitogenic kinases downstream the EGFR, such as MAPK and Raf. Alternatively, 14-3-3 might 
affect UBPY localization in order to spatially segregate UBPY from its substrates, including the 
EGFR. Future studies will be essential to decipher the physical and functional coupling of UBPY and 
14-3-3 proteins. 
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Samenvatting 
 
Leden van de membraan-gebonden ErbB receptor tyrosine kinase familie, waaronder de EGF-receptor 
(EGFR), en hun bijbehorende groeifactor-liganden zijn vaak gekoppeld aan carcinogenese. Onder 
normale omstandigheden is gecontroleerde activering van ErbB-receptoren en de daaruit volgende 
cascade van intracellulaire signalen cruciaal voor de ontwikkeling en normale groei van meercellige 
organismen. Deze door ErbB-receptoren gegenereerde signalen moeten daarom onderworpen zijn aan 
strikte regulatie. Wanneer dit reguleringmechanisme wegvalt of onvoldoende functioneert, kan dit 
leiden tot voortdurende mitogene signalering, hetgeen een belangrijke eigenschap is van  carcinogene 
cellen. 
Regulatie van ErbB-activiteit wordt mede gereguleerd door internalisering van het groeifactor-receptor 
complex en het daaropvolgende transport naar het lysosome voor afbraak. Dit proces, dat vaak 
receptor-downregulatie wordt genoemd, leidt tot het verwijderen van de actieve receptoren van het 
cellulaire oppervlak en de vermindering van hun mitogene signalering. Eerdere studies met humane 
cellen en cellen uit andere organismen toonden aan dat voor het uiteindelijke afleveren van de 
receptoren bij de lysosomen, geïnternaliseerde receptoren onderhevig zijn aan actieve sortering binnen 
het endosomale systeem. Internalisering en transport naar het lysosoom gaan vaak gepaard met  
ubiquitinatie van de actieve receptoren. Dit heeft aanleiding gegeven tot de veronderstelling dat 
ubiquitine kan fungeren als een sorteringsignaal binnen het endosomale systeem. Aangezien 
ubiquitinatie een omkeerbaar proces is, hebben wij gepostuleerd dat deubiquitineringsenzymen 
mogelijk betrokken zijn bij regulatie van door de EGF-receptor geactiveerde mitogene 
signaleringcascade. Betrokkenheid van deubiquitineringsenzymen bij de EGF-receptor pathway was 
experimenteel echter nog niet aangetoond. Daarom hebben  wij in deze studie de rol van UBPY in het 
afbraakproces van de EGF-receptor geanalyseerd. Het zoogdiereiwit UBPY is een enzym dat 
structurele homologie vertoont met het gist deubiquitineringsenzym Doa4. Van Doa4 was al eerder 
bekend dat het betrokken is bij de regulering van geïnternaliseerde receptoren in gistcellen. Dit 
betekent dat deubiquitineringsenzymen in het endosomale systeem een evolutionair geconserveerde 
functie kunnen hebben.  
In hoofdstuk II tonen wij aan dat de kinetiek van EGFR-afbraak sterk bepaald wordt door de identiteit 
van de gebonden groeifactor. EGF induceert relatief snelle EGFR-afbraak in vergelijking met de 
potente groeifactor TGF-α. Deze versnelde degradatie correleerde sterk met verhoogde EGFR-
ubiquitinatie. Onze gegevens tonen aan dat EGFR gedeubiquitineerd wordt voor de uiteindelijke 
afbraak in het lysosoom, en dat deze deubiquitineringsactiviteit gevoelig is voor proteosomale 
inhibitors.  
De bevindingen vermeld in hoofdstuk III tonen aan dat EGFR-deubiquitinatie mogelijk gemedieerd 
wordt door het deubiquitineringsenzym UBPY. Overexpressie van het N-terminale gedeelte van 
UBPY, dat het katalytisch domein mist, resulteerde in het verhinderen van de EGFR lysosomale 
afbraak. Het gevolg is dat de door EGFR ontstane mitogene signalering verhoogd wordt door de 
stabilisatie van actieve receptoren.  
UBPY bindt aan verschillende isoformen van een familie van eiwitten die ‘14-3-3 eiwitten’ genoemd 
worden, zoals gerapporteerd in hoofdstuk IV. Experimenten met een puntmutatie in UBPY-sequentie 
hebben aangetoond dat UBPY-binding aan het EGFR-complex onafhankelijk is van 14-3-3/UBPY 
interactie. 
De bevindingen gepresenteerd in deze thesis leiden tot de conclusie dat geactiveerde EGF-receptoren 
gedeubiquitineerd worden door ten minste UBPY en proteasoom-afhankelijke activiteit. Het 
verwijderen van ubiquitine bij geïnternaliseerde actieve receptoren kan de opname van deze 
receptoren in late endosomen en lysosomen bevorderen, hetgeen nodig is om ze vervolgens volledig af 
te breken. Dit proces kan uiteindelijk de mitogene signalering afremmen. UBPY/14-3-3 interactie kan 
UBPY koppelen aan mitogene kinases die downstream van actieve receptoren functioneren zoals Raf 
en MAPK. De 14-3-3 binding aan UBPY kan ook de subcellulaire lokalisatie van UBPY beïnvloeden, 
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waardoor deze kan fungeren als mechanisme om UBPY-functies te reguleren. Verdere studies zullen 
nodig zijn om de functionele betekenis van UBPY/14-3-3 interactie nader te ontrafelen. 
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